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The patents of several best-selling biologic therapeutic products are expiring soon. 
Consequently, the interest of developing biosimilar products is growing. A biosimilar product is 
developed if there are no clinically meaningful differences in terms of safety, efficacy, and purity 
after evaluating side-by-side with the originator. Biosimilar products are anticipated to be 
accessible to healthcare providers and patients at a lower cost compared to the originators. 
Unlike small-molecule generic drug products, which are structurally replicable and well-defined, 
that guarantee the safety and efficacy, biologic products are structurally complex, larger in size 
and often contain mixtures of various posttranslational modifications. Consequently, 
demonstrating the similarity of a biosimilar molecule with the reference product requires 
extensive characterization to ensure safety and efficay.  
One of the challenges in developing a biosimilar product is the lack of knowledge about 
the reference product’s  manufacturing process, which is not accessible to the public because it 
is a proprietary knowledge. Therefore, the biosimilar sponsor needs to develop a process by 
extensive characterization of a biosimilar candidate side-by-side with a reference product. This is 
an iterative process aimed at developing a biosimilar molecule similar to the reference product. 
The first step in biosimilarity assessment is to establish structural similarity by extensive 
characterization using several analytical techniques. Therefore, analytical tools play a vital role in 
demonstrating structural similarity as well as process development of a biosimilar candidate. In 
addition, the level of similarity established by the analytical tools guides the type of non-clinical 
and clinical data packages required for regulatory approval.  If a high degree of similarity is 
demonstrated using analytical techniques, then phase II clinical trials are not required for 
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registration of a biosimilar candidate. Consequently, this will lower the cost of developing a 
biosimilar product. Hence, developing sensitive and robust analytical techniques is vital in a 
biosimilar development process. 
In this dissertation, four homogeneous glycoforms of IgG1 Fc (HM-Fc, GlcNAc-Fc, Man5-
Fc, and N297Q-Fc) were produced using recombinant protein expression combined with in-vitro 
enzymatic reactions to be utilized as a model for biosimilar comparability analysis. These 
glycoforms were characterized by mass spectrometry, SEC, SDS-PAGE, and cIEF. The main focus 
of the project was to produce homogeneous glycoforms of IgG1 Fc and to utilize them to develop 
new biolayer interferometry (BLItz) assay methods. Two biolayer interferometry methods with 
different immobilization techniques were developed to measure the binding affinity of IgG1 Fc 
glycoforms to FcRIIIa and FcRIIb.  In addition, these four glycoforms were mixed in pre-defined 
composition to examine the characteristics of mixtures of glycoforms and to study important 
biological and physicochemical features of protein drugs in a biosimilar analysis. For the mixture 
samples, differences in binding were observed when the two immobilization formats were 
employed. Furthermore, these glycoforms were incubated at low and elevated temperatures for 
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1.1 Impact of Glycosylation on Antibody Structure and Activity    
Immunoglobulin G (IgG) contains two heavy chains and light chains that form the 
fragment crystallizable (Fc)  and fragment antigen binding (Fab) regions. The Fc is a homodimer 
containing, a conserved glycosylation site within the CH2 at Asparagine-297 (Figure 1). This 
glycosylation site is known to play a critical role in the structural integrity, functional activity, and 
stability of therapeutic monoclonal antibodies (mAbs).1  For example, a significant number of 
publications reported that non-fucosylated mAbs bind to FcRIIIa about 50- to 100-fold more 
tightly than their fucosylated counterparts. This increase in binding affinity correlated with a 
higher antibody-dependent cytotoxicity (ADCC) response.2-9  Similarly, the presence of sialic acid 
in the Fc glycans (e.g., G2F+ NANA in Figure 1) was proposed to be necessary for the anti-
inflammatory activity of Intravenous Immunoglobulin (IVIG). Interestingly, it has been shown that 
the removal of sialic acid abrogates the anti-inflammatory effect and turns the activity to  pro-
inflammatory.10-12 Additionally, glycans influence the pharmacokinetics of therapeutic mAbs. 
One such example is the systemic clearance of antibodies containing 100% of high-mannose 
which is found to be faster than antibodies that contain complex glycans. This faster clearance is 
presumably due to mannose binding receptors in the liver.13-14 As shown in Figure 1 Man8 and 
G2F+NANA are examples of high-mannose and complex glycans, respectively. In addition, 
differentially sialylated glycoprotein therapeutics may also display decreased pharmacokinetic 
and pharmacodynamic (PK/PD) properties due to carbohydrate binding to asialoglycoprotein 
receptor expressed in the liver. This desialylated glycoprotein is selectively taken and rapidly 
degraded in the liver.15-16 Immunogenicity is another important clinical factor that can be affected 
by glycans. For instance, it has been reported that murine cells can potentially produce non-
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human immunogenic glycoforms, such as a terminal N-glycosyl-sialic acid (NeuSGc) and gal-1,3 
gal linkage.17 As a result, close monitoring of the glycan profile is required during the production 
and development of therapeutics mAbs. 
1.2 Glycosylation Heterogeneity and its Effect on Product Development 
Glycosylation is heterogeneous by nature that includes the differential addition of fucose, 
alternative mannose branching linkages, presence or absence of galactose, and terminal 
sialylation as shown in Figure 1. Furthermore, there could be site-occupancy heterogeneity in 
which one of the heavy chains is non-glycosylated, resulting in asymmetric glycosylation.17 This 
heterogeneity in glycosylation pattern could be due to several factors such as culture media 
composition, growth condition, cultivation procedure, and type of cell line used.18-22 One typical 
example is a significant difference in sialylation observed when the same mAb was produced in 
myeloma cell line (NSO) vs. Chinese hamster ovary (CHO).23 In another study, it has been reported 
that a significant variability was observed in galactosylation among therapeutic mAbs produced 
by different manufacturers. Therapeutic mAbs expressed in CHO cells showed a higher level of 
G0 glycans when compared with mAbs expressed in mouse myeloma cell lines.24 The variability 
in glycosylation profile indicates that the production of therapeutic antibodies with a 
homogeneous glycosylation profile for a particular functional activity remains a significant 
challenge.1 In contrast to the primary amino acid sequence of proteins which is a template-driven 
process, glycosylation of recombinant proteins is not a guided synthesis. As a result, glycosylation 
is subject to a high degree of heterogeneity.25-26 X-ray crystallographic studies have shown that 
the pair of carbohydrate chains are buried inside the hydrophobic core of the two CH2 domains.27 
The Man α-1,6 arm makes contact with an inner surface of the CH2 domain, whereas the Man α-
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1,3 arm protrudes into the space between the CH2 domains (Figure 2). This structural 
environment creates steric hindrance that restricts access to the glycan processing enzymes, such 
as glycosyltransferases and glycosyl hydrolases in the endoplasmic reticulum and Golgi 
complex.26-28  
1.3  Recombinant Protein Expression in Yeast  
Mammalian cell cultures have been commonly used for the production of monoclonal 
antibodies. However, compared to mammalian cells, glycoengineered P. pastoris provides many 
advantages, such as easy genetic manipulation, reduced cultivation time, high-yield, low-cost 
fermentation, and no risk of human pathogenic viral contamination.29-30 The Pichia expression 
system has more considerable flexibility in producing glycoengineered IgGs compared to 
mammalian expression system.31 As a result, a particular focus was given to the production of 
mammalian complex-type structures in P.pastoris by engineering the N-glycosylation pathway. 
Recently, an advance has been made in improving glycosylation site occupancy at Asn297 to 
greater than 99%, which is comparable to the site occupancy expected from mammalian cell line 
expression.32 It has been reported that Pichia produces stable IgGs with comparable aggregation, 
charge variant, and oxidation profile compared to the same IgGs produced from mammalian cell 
line.31 Thus, glycoengineered Pichia offers a promising platform for the production of IgGs. 
1.4 Demonstrating Biosimilarity of Protein Therapeutics  
 Several top-selling commercialized biologics are coming off patent; as a result, biosimilars 
are expected to be accessible to patients and healthcare providers at a lower cost in the near 
future. Biosimilars are biological products that are approved because they are “highly similar” to 
an already-approved biological product, known as the reference product (originator). Food and 
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Drug Administration (FDA) defines biosimilarity to mean “That the biological product is highly 
similar to the reference product notwithstanding minor differences in clinically inactive 
components” and that “there are no clinically meaningful differences between the biological 
product and the reference product in terms of the safety, purity, and potency of the product”.33 
Biosimilars should demonstrate no clinically meaningful differences in terms of safety and 
effectiveness when they are compared with the reference product. Likewise, biosimilars should 
have the same mechanism of action and use for the same indication as for the reference 
product.34   
The processes of developing a biosimilar heavily depend on the depth of knowledge 
collected from the reference product, which will aid in getting faster regulatory approval (Figures 
3 and 4).34  The first step in biosimilarity assessment is an extensive characterization of the 
reference product to identify critical quality attributes (Figure 3). After studying the reference 
product, in the early phase of the development processes, analytical techniques are employed to 
establish structural and functional similarity.34-35  Technically, a biosimilar candidate is compared 
head-to-head with the reference product at each stage of the development processes to ensure 
safety and efficacy.34   
The type of additional test required for regulatory approval is determined on a case-by-
case basis and by the level of similarity demonstrated during the analytical assessment. In other 
words, the degree of similarity demonstrated by the analytical methods ultimately guides the 
type of next steps required for approval.34  For instance, if “highly similar” is confirmed by the 
analytical data then, a reduced clinical test may be required which ultimately resulting in time 
and cost savings.34, 36-37 In addition, the discovery phase as well dose-finding studies (phase II) are 
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not required in the development process because biosimilar development uses the same dosing 
as the reference product and this may contribute to the reduction of time and cost of 
development (Figure 4). Filgrastim-sndz, a biosimilar to Neupogen, was the first biosimilar 
product approved by the Food and Drug Administration (FDA) in 2015.38 One additional example 
was  Inflectra (infliximab-dyyb), a biosimilar to Remicade which was approved in 2016.39 
1.4.1 Biological Evaluation in Biosimilarity Study 
Protein molecules are complex in structure and possess a dynamic three-dimensional 
structure. The folded conformation of a protein can be altered by process and storage conditions, 
such as pH, temperature, and pressure. Functional activity is dependent on the conformation of 
the protein, which is a higher-order structure. Therefore, testing the primary structure without 
the tertiary structure does not necessarily guarantee the biological activity.23  In a biosimilar 
assessment,  extensive functional characterization of both the proposed product and the 
originator is required to establish similarity. Therapeutic mAbs mediate their effector function by 
the Fc region (Figure 1). Thus, biological characterizations for examination of the Fc effector 
function are used in similarity exercise. Such tests are necessary even if the mechanism of action 
is not related to the Fc because a change in glycosylation profile can have a negative impact on 
the safety of therapeutic mAbs.  As a result, the Fc region is important for the safety, structure, 
and function of the mAbs.40 Moreover, monitoring glycosylation of mAbs during a biosimilar 
development process is essential because differential glycosylation can alter the functional 
activity (ADCC and CDC),19, 41 immunogenicity,21, 37, 42-45 pharmacokinetics,15-16, 46-48  and the 
stability of therapeutic mAbs.49 
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Biological tests (e.g., potency assay) are routinely used in quality control setting to 
monitor the potency of a product during manufacturing.  These assay methods should be 
sensitive enough to detect structural changes with a potential impact on the safety as well as 
efficacy of the product. Although such techniques can provide relevant information, the 
correlation between potency assay and the mechanism of action of the treatment cannot be 
established with a high degree of certainty. Nevertheless, biological assays can be used to 
establish functional equivalence in a biosimilar comparability assessment.  In addition, functional 
assays can be employed together with biophysical assays to confirm higher-order structural 
similarity.40 overall, a biological assay provides critical information about the characteristics of a 
biosimilar candidate related to its function and thereby demonstrates the similarity with the 
originator. Furthermore, a biological assay complements the physicochemical analysis by 
demonstrating potential effects of structural difference between a reference product and the 
biosimilar candidate.34, 50 
1.4.1.1 Fc Receptor Binding Assays  
Monoclonal antibodies are composed of two Fab regions and one Fc region. These regions 
regulate the functional activity and may need to be tested for their capacity to interact with their 
specific targets.51  For instance, the Fc region specific targets include but are not limited to 
FcRIIIa, FcRIIb, FcRIIa, and FcRI. Several mAbs exert their activity by binding their Fc region 
with Fc receptors. Therefore, Fc receptor binding is part of the functional characterization in the 
comparative assessment during a biosimilar product development. This binding interaction is 
substantially affected by the N-linked glycans in the Fc region of the mAbs.  As a result, 
characterization of glycosylation is one of the main characteristics of mAbs that received 
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significant attention by the regularity agencies.42  Determining the binding activity of monoclonal 
antibody drugs is performed using a series of in-vitro binding assays, such as bioLayer 
Interferometry (BLI), surface plasmon resonance (SPR), and enzyme-linked immunosorbent 
assays (ELISA).52 
For instance, the binding interactions of Remicade (originator) and Remsima (a biosimilar 
product)  with FcRIIIa were compared using a biolayer interferometry technique. The result 
showed that Remicade binds with a two-fold higher affinity when compared with Remsima. This 
higher binding affinity was attributed to the substantial proportion of non-fucosylation level in 
Remicade when compared to Remsima. This difference in fucosylation level was due to the 
differences in cell line (subtle genetic variants) used for production.39 In general, binding assays 
can provide information to predict how a biosimilar may behave in-vivo, although not as much 
regarding safety. Thus, such tests together with other analytical data may provide evidence of 
clinical testing.34, 50 If a higher level of similarity was established using physicochemical and in-





1.5 Binding Interaction Models and Equations  
1.5.1 1:1 Binding Model 
The ideal model of interaction, in which one ligand molecule binds with one analyte 
molecule assumes all interaction sites on the ligand are equivalent and independent of one 
another. Additionally, the 1:1 binding model assumes the interaction between ligand and analyte 
follows the pseudo-first-order kinetics. The association and dissociation phases display a time-
resolved signal that is described by a single exponential function. Furthermore, analyte molecules 
bind and dissociate at the same rate to every ligand binding site. The association curve follows a 
hyperbolic binding profile, with the exponential increase in signal followed by a leveling off to 
plateau as the binding reaches equilibrium.53,54  The dissociation curve follows single exponential 
decay with signal eventually returning to baseline. 
Kinetic analysis of 1:1 binding model is based on the concept that the interaction between 
a monovalent analyte, A, and immobilized component, B, on the sensor surface is described by 
the reaction scheme as follows.53 
A +  B ⇌  AB 
The interaction between the two components is assumed to be reversible complex.54 
The rate of formation of the product AB at a time t can be written as follows:            
𝑑[𝐴𝐵]
𝑑𝑡
= 𝑘𝑜𝑛[𝐴][𝐵] − 𝑘𝑜𝑓𝑓[𝐴𝐵] ⋯ ⋯ ⋯ ⋯ ⋯ ⋯ ⋯ ⋯ ⋯ ⋯ (1) 
Where 𝑘𝑜𝑛  and 𝑘𝑜𝑓𝑓 are the respective association and dissociation rate constants.
55 The 
term 𝑘𝑜𝑓𝑓   measures the stability of the complex, or the fraction of complexes that decay per 
second, and is expressed in units of sec–1.  The association rate constant, 𝑘𝑜𝑛, represents the 
number of AB complexes formed per second in a 1 molar solution of A and B. The  𝑘𝑜𝑛 is 
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expressed in M–1sec–1. KD is the affinity constant, or equilibrium dissociation constant, which 
measures how tightly the ligand binds to its analyte. It represents the ratio of the on-rate to the 
off-rate and can be calculated using  𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓. KD is expressed in molar units (M). 
After some time, t, the concentration of unbound immobilized ligand is expressed as: 
[𝐵] = [𝐴𝐵]𝑚𝑎𝑥 − [𝐴𝐵] 
  [AB]max is the maximum complex formed when all ligand binding sites are occupied, which is 
theoretical binding capacity. Substituting into equation 1 gives.54 
𝑑[𝐴𝐵]
𝑑𝑡
= 𝑘𝑜𝑛[𝐴]([𝐴𝐵]𝑚𝑎𝑥 − [𝐴𝐵]) − 𝑘𝑜𝑓𝑓[𝐴𝐵] ⋯ ⋯ ⋯ ⋯ ⋯ ⋯ ⋯ ⋯ ⋯ ⋯ (2) 
This equation describes the interaction between the analyte in solution, and the free 
binding sites on the surface, minus the simultaneously occurring dissociation of the complex 
formed.56 The signal observed R is proportional to the formation of AB complex at the surface of 
the biosensor, and the maximum signal Rmax is proportional to the maximum complex formation 
[AB]max. Rmax is the maximum response that would be obtained if all ligand binding sites were 
saturated.56 Therefore, equation two can be written as shown below.56 
𝑑[𝑅]
𝑑𝑡
= 𝑘𝑜𝑛𝐶(𝑅𝑚𝑎𝑥 − 𝑅) − 𝑘𝑜𝑓𝑓𝑅 … … … … … … . . (3) 
         Where dR/dt is the rate of formation of the complexes on the surface of the biosensor, ( i.e., 
the derivative of the observed response curve), C is the concentration of the analyte in solution; 
Rmax is the maximum capacity of the immobilized ligand surface expressed in resonance units, 
and Rmax -R represents the number of unoccupied surface binding sites at the time t.54 The above 
equation was rearranged and integrated to give the final equation as shown below.  
𝑅 =
𝑘𝑜𝑛𝐶𝑅𝑚𝑎𝑥
𝑘𝑜𝑛𝐶 + 𝑘𝑜𝑓𝑓 
(1 − 𝑒− (𝑘𝑜𝑛𝐶+𝑘𝑜𝑓𝑓 )(𝑡−𝑡0)) … … … … … … . . (4) 
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The above equation describes 1:1 binding where a single analyte molecule interacts with 
one ligand molecule. The assumption in the above equation is that all binding sites are equivalent 
and independent of one another. In addition, it is assumed that all binding events are governed 
by the same free energy of binding. This is a reasonable assumption if all immobilized antigens 
are equally accessible, and only monovalent complexes are involved. This assumption many not 
be valid when bivalent binding occurs, since bridging complexes of different geometries will be 
obtained, leading to a range of on rates and off-rates.56 One additional assumption is that the 
analyte concentration maintains its initial value, C due to the presence of the excess analyte in 
the cuvette. Hence the interaction is pseudo first order.53 
The dissociation phase is described by the equation as follows: 
𝑅 = 𝑅𝑑𝑒
−(𝑡−𝑡𝑐)𝑘𝑜𝑓𝑓  + 𝑅∞ … … … … … … … … … … … . (5) 
 Where 𝑅𝑑  is the initial response before the dissociation starts 𝑅∞  is the response at the 
end of the dissociation phase. To account for the fact that even after complete dissociation of 
the complex, AB, from the surface of the sensor chip the instrument response is not zero.54 
The final equation that combines the association and dissociation phases is given below  
𝑅 =
𝑘𝑜𝑛𝐶𝑅𝑚𝑎𝑥
𝑘𝑜𝑛𝐶 + 𝑘𝑜𝑓𝑓 
(1 − 𝑒− (𝑘𝑜𝑛𝐶+𝑘𝑜𝑓𝑓 )(𝑡−𝑡0)) + 𝑅0𝑒
−(𝑡−𝑡𝑐)𝑘𝑜𝑓𝑓  + 𝑅∞ … … … … … … … … . . (6) 
𝑅𝑒𝑞 =
𝑘𝑜𝑛𝐶𝑅𝑚𝑎𝑥
𝑘𝑜𝑛𝐶 + 𝑘𝑜𝑓𝑓 
 
 𝑅𝑒𝑞   is the equilibrium response for a given concentration. 
The final equation can be further modified to as shown below.  
𝑅 = 𝑅𝑒𝑞 (1 − 𝑒
− (𝑘𝑜𝑛𝐶+𝑘𝑜𝑓𝑓 )(𝑡−𝑡0)) + 𝑅0𝑒





1.5.2 Heterogeneous Ligand Binding Model 
The 2:1 heterogeneous ligand model assumes one analyte binding at two independent 
ligand sites. Each ligand site binds the analyte independently and with a different rate constant. 
Mathematically, the equation used to fit a 2:1 binding interaction is a combination of two 1:1 
curve fits. Two sets of rate constants are given, one for each interaction: where A represents the 
analyte and B represents the immobilized ligand. 
The binding interaction is the sum of two independent reactions. 
A +  B1  ⇌  AB1,    A +  B2   ⇌  AB2 
Let [𝐴𝐵1] = 𝑅1is the complex formed between the analyte and ligand one and [𝐴𝐵1]𝑚𝑎𝑥  is the 
maximum available sites for binding site B1   or maximum binding capacity of ligand one and 
[𝐴𝐵2] = 𝑅2  is the complex formed between the analyte and ligand one and [𝐴𝐵2]𝑚𝑎𝑥 is the 
maximum available sites for binding site B2, maximum binding capacity of ligand two,   A= is the 
analyte concentration expressed as C. 
 [𝐵1] = [𝐴𝐵1]𝑚𝑎𝑥 − [𝐴𝐵1] = 𝑅𝑚𝑎𝑥1 − 𝑅1,                         [𝐵2] = [𝐴𝐵2]𝑚𝑎𝑥 − [𝐴𝐵2] = 𝑅𝑚𝑎𝑥2 − 𝑅2 
𝑑[𝐴𝐵1]
𝑑𝑡
= 𝑘𝑜𝑛1[𝐴][𝐵1] − 𝑘𝑜𝑓𝑓1[𝐴𝐵1]                                   
𝑑[𝐴𝐵2]
𝑑𝑡
= 𝑘𝑜𝑛2[𝐴][𝐵2] − 𝑘𝑜𝑓𝑓2[𝐴𝐵2] 
After integration, the response for the association phase is expressed by the equation  
𝑅 =
𝑘𝑜𝑛1𝐶𝑅𝑚𝑎𝑥1
𝑘𝑜𝑛1𝐶 + 𝑘𝑜𝑓𝑓1 
(1 − 𝑒− (𝑘𝑜𝑛1𝐶+𝑘𝑜𝑓𝑓1 )(𝑡−𝑡0)) +
𝑘𝑜𝑛2𝐶𝑅𝑚𝑎𝑥2
𝑘𝑜𝑛2𝐶 + 𝑘𝑜𝑓𝑓2 
(1 − 𝑒− (𝑘𝑜𝑛2𝐶+𝑘𝑜𝑓𝑓2 )(𝑡−𝑡0)) … … … … … … (8) 
The dissociation phase is given as a biphasic model as shown below let 𝑅𝑑1  is the initial response 
before dissociation phase 1 and 𝑅𝑑2  is the initial response before dissociation phase 2. 
Where 𝑘𝑜𝑛1 and 𝑘𝑜𝑓𝑓1   are the rate constants describing one interaction with a maximal 
response of 𝑅𝑚𝑎𝑥1 , and 𝑘𝑜𝑛2 and 𝑘𝑜𝑓𝑓2  are the rate constants describing the second interaction 




𝑦 = 𝑅𝑑1 𝑒
−(𝑡−𝑡𝑐)𝑘𝑜𝑓𝑓1  + 𝑅𝑑2 𝑒
−(𝑡−𝑡𝑐)𝑘𝑜𝑓𝑓2  + 𝑅∞ … … … . . (9) 
The final equation for the heterogeneous binding model is shown below.  
𝑅 =
𝑘𝑜𝑛1𝐶𝑅𝑚𝑎𝑥1
𝑘𝑜𝑛1𝐶 + 𝑘𝑜𝑓𝑓1 
(1 − 𝑒− (𝑘𝑜𝑛1𝐶+𝑘𝑜𝑓𝑓1 )(𝑡−𝑡0)) +
𝑘𝑜𝑛2𝐶𝑅𝑚𝑎𝑥2
𝑘𝑜𝑛2𝐶 + 𝑘𝑜𝑓𝑓2 
(1 − 𝑒− (𝑘𝑜𝑛2𝐶+𝑘𝑜𝑓𝑓2 )(𝑡−𝑡0)) + 𝑅𝑑1 𝑒
−(𝑡−𝑡𝑐)𝑘𝑜𝑓𝑓1  + 𝑅𝑑2 𝑒
−(𝑡−𝑡𝑐)𝑘𝑜𝑓𝑓2  + 𝑅∞ 
Equation (10) 
The above equation can be rewritten in more simplified form as follows: 
𝑅 = 𝑅𝑒𝑞1(1 − 𝑒
− (𝑘𝑜𝑛1𝐶+𝑘𝑜𝑓𝑓1 )(𝑡−𝑡0)) + 𝑅𝑒𝑞2(1 − 𝑒
− (𝑘𝑜𝑛2𝐶+𝑘𝑜𝑓𝑓2 )(𝑡−𝑡0)) + 𝑅𝑑1 𝑒
−(𝑡−𝑡𝑐)𝑘𝑜𝑓𝑓1  + 𝑅𝑑2 𝑒
−(𝑡−𝑡𝑐)𝑘𝑜𝑓𝑓2  + 𝑅∞ … … … . (11) 
1.5.3  Heterogeneous Analyte Competing for a Single Ligand Binding Site Model 
Two analytes in solution are competing for a sing ligand immobilized onto the biosensor 
surface.57 The concentration and molecular weight of the two components should be known 
before analysis. A1 and A2 are two analytes competing for a single binding site B and the equation 
can be described as follows: 
     A1 + B ⇌ A1B               A1B=𝑅1                                                                 A2 + B ⇌ A2B        A2B=𝑅2         Let A=C 
[𝐵1] = [𝐴1𝐵]𝑚𝑎𝑥 − [𝐴1𝐵] = 𝑅𝑚𝑎𝑥1 − 𝑅1                                      [𝐵2] = [𝐴2𝐵]𝑚𝑎𝑥 − [𝐴2𝐵] = 𝑅𝑚𝑎𝑥2 − 𝑅2 
R1 and R2 correspond to the concentration of the molecular complexes formed. 𝐶1 and 𝐶2  are 
the concentrations of the analytes A1 and A2. 58 
𝑑𝑅1
𝑑𝑡









− 𝑅2) − 𝑘𝑜𝑓𝑓2𝑅2 
𝑅𝑚𝑎𝑥  corresponds to the total concentration of the immobilized partner. For competing reactions, 
p is a normalizing factor. This parameter is introduced since specific responses are different for 
analytes of different molecular weight.58 After integration, the above differential equations is 
described as follows:   
𝑅 =
𝑘𝑜𝑛1𝐶1𝑅𝑚𝑎𝑥
2𝑘𝑜𝑛1𝐶1 + 𝑘𝑜𝑓𝑓1 





2𝑘𝑜𝑛2𝐶2 + 𝑘𝑜𝑓𝑓2 
(1 − 𝑒− (2𝑘𝑜𝑛2𝐶2+𝑘𝑜𝑓𝑓2)(𝑡−𝑡0)) … … … . . (12) 
The dissociation phase is given as a biphasic model as shown below let 𝑅𝑑1  is the initial response 
before dissociation phase 1 and 𝑅𝑑2  is the initial response before dissociation phase 2. 
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𝑦 = 𝑅𝑑1 𝑒
−(𝑡−𝑡𝑐)𝑘𝑜𝑓𝑓1  + 𝑅𝑑2 𝑒
−(𝑡−𝑡𝑐)𝑘𝑜𝑓𝑓2  + 𝑅∞ 
Moreover, the final that includes the association and dissociation phases is as described below. 
𝑅 =
𝑘𝑜𝑛1𝐶1𝑅𝑚𝑎𝑥
2𝑘𝑜𝑛1𝐶1 + 𝑘𝑜𝑓𝑓1 





2𝑘𝑜𝑛2𝐶2 + 𝑘𝑜𝑓𝑓2 
(1 − 𝑒− (2𝑘𝑜𝑛2𝐶2+𝑘𝑜𝑓𝑓2)(𝑡−𝑡0)) + 𝑅𝑑1 𝑒
−(𝑡−𝑡𝑐)𝑘𝑜𝑓𝑓1  + 𝑅𝑑2 𝑒
−(𝑡−𝑡𝑐)𝑘𝑜𝑓𝑓2  







1.6 Challenges in Developing a Biosimilar Product 
Small molecules are defined by their chemical structure, while protein molecules are not 
completely defined by their amino acid sequences and are mixtures of different variants due to 
posttranslational modifications. The challenge of developing biosimilar products is that they are 
not generic products, and for biologics, the operative paradigm is that the bioprocesses define 
the product.52 Moreover, even minor changes in the manufacturing protocol can lead to a 
significant change in post-translational modifications (PTMs) and product variations.52, 59  Since 
the manufacturing process of the originator is undisclosed, a biosimilar product has to be 
produced with a different process. It is well known that minor changes in the manufacturing 
process can have a significant effect on the products quality.34, 50 For instance, glycosylation is 
relevant for the biological activity; however, a change in glycosylation profile can have a negative 
impact on the safety and efficacy of a mAb therapeutic.60   Thus, the biosimilar sponsor is required 
to demonstrate specific quality attributes of the originator and biosimilar using appropriate 
techniques.20 Similarly, chemical modifications, such as deamidation, isomerization, and oxidized 
forms, can affect the structure. Likewise, non-native structures, such as aggregates generated 
during production, can have a detrimental effect on the product’s quality.37  Because of these 
challenges, development timeline for a biosimilar product is longer and expensive compared to 
small-molecule  generic drugs.61  
1.7 Demonstrating Comparability of Protein Therapeutics 
The implementation of changes in process or changes related to the product (e.g., 
formulation), during development as well as after commercialization, needs an assessment of 
their effect on the safety and efficacy of the product. This exercise to demonstrate the similarity 
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between the post-change and pre-change is known as a comparability study.23  Manufacturers of 
biological products (e.g., mAbs) often make changes to the manufacturing process of products 
during development phase as well as after commercialization. Any change made that can 
potentially affect the product quality, such as manufacturing protocol, formulation condition, 
and cell-line clone, requires a comparability study. The main reasons behind such changes include 
the following: improving the bioprocess protocol, scale up, improving product stability, and 
complying with new regulatory requirements. When changes are made to the bioprocess 
protocol, the manufacturer examines the critical quality attributes of the product to show that 
modifications did not occur that would negatively affect the safety and efficacy of the biological 
product.62  For example, oligosaccharide moieties in monoclonal antibodies (mAbs) were known 
to be affected by the bioprocess parameters, duration of expression, and cell-line type. In 
addition, the protein can undergo physicochemical changes during production, which may lead 
to more structural heterogeneity. Certainly, the effect of the posttranslational modifications on 
the safety and efficacy of a post-change product needs to be examined.23 
Physicochemical characterizations using a vast array of analytical techniques are 
examined in all comparability studies. In a similar fashion, the extensive biological 
characterization in combination with pharmacokinetic and pharmacodynamic data can be used 
to demonstrate functional equivalence. If the results of these characterizations suggest “highly 
similar,” then other clinical studies are not necessary. However, if the comparison of the pre-
change and post-change product is found to be either inconclusive or showed differences, then 




1.8 Differences Between Comparability and Biosimilarity Assessments   
A comparability study is aimed at demonstrating that the post-change has no negative 
effect on the safety, efficacy, and quality of the biological product. The primary goal of 
biosimilarity assessment is to demonstrate the similarity of a biosimilar candidate with the 
reference product in terms of physicochemical and biological quality attributes as well as safety 
and efficacy. Therefore, a biosimilar assessment is more deferent than a comparability 
assessment, which requires extensive characterization of a biologic product. Moreover, 
development of a biosimilar product by demonstrating similarity with the originator is a more 
challenging task than comparability assessment of the pre-change and post-change of an 
originator product.63-64  
A comparability assessment involves extensive characterization of several lots of the 
originator’s pre- and post-process changes. This characterization data can provide enough 
evidence to confirm that the safety and efficacy of the post-change remained within the pre-
change range. This comparability claim can be supported by the pre-change clinical data, 
manufacturing history, analytical methods, and a post-approval history.  It is worth noting that 
these historical data are not accessible to a biosimilar sponsor. Therefore, the manufacturing 
processes of a biosimilar candidate have to be developed by reverse engineering. Manufacturing 
process development is one of the challenging tasks in biosimilar product development as 
described below.63-64 
1.8.1 Manufacturing Processes 
Manufacturing biologic products is a complex process because of their large size and 
structural complexity, coupled with variability in expression system and cell lines.65-66 Biosimilar 
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sponsors have to develop a new cell line, cell culture condition, analytical methods, purification, 
and formulation of the biosimilar candidate with a limited knowledge of a reference product. 
Developing a new cell line for a biosimilar candidate can potentially lead to differences in 
glycosylation, aggregation, oxidation, and 3-D structures. This is in contrast to comparability 
assessment, which is a minor change in manufacturing processes and the post-change is with the 
available historical data of the pre-change. However, even a minor change in processes change 
can have a detrimental effect on the product safety and efficacy. For instance, the 
immunogenicity of epoteins has been attributed to an aggregation that arises after processes 
change.67-68 Manufacturing processes are continuously changed during product development as 
well as after commercialization. Some of the reasons for manufacturing changes are to improve 
operation, yield, and safety profile, as well as to change raw materials. The manufacturing 
processes could be minor or major, which depends on the type of change introduced. An example 
of major manufacturing change would be an alteration of the cell line, culture media 
composition, and purification processes. All of these changes can potentially affect the safety and 
efficacy of the biologic product.63-64  
In a comparability assessment, expression parameters, such as pH, temperature, and 
shear forces, can have a significant effect on the product safety and efficacy. As a result, 
heterogeneity between the different batches needs to be assessed on a routine basis. Most of 
the heterogeneity of the biologic product is attributed to glycosylation and to some extent, 
additional post-translational modifications, such as oxidation, deamidation, fragmentation, and 
aggregation. For instance, monoclonal antibodies are glycosylated and controlling glycosylation 
within a defined range to confirm safety and efficacy is required.69-70 Moreover, during product 
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development, the condition of expression can affect the glycosylation profile of a biological 
product. For instance, a biologic product with α-gal glycans can potentially induce 
immunogenicity.63-64  
As described above, the process development, controls, and methods not accessible to a 
biosimilar sponsor. Thus,  biosimilar manufacturing faces a “knowledge gap” and should develop 
a new cell line, manufacturing protocol, and purification processes aimed at producing a product 
highly similar to the originator.71 Furthermore, to address the knowledge gap, the biosimilar 
sponsor uses an approach of “reverse-engineering” of the manufacturing processes with the 
main focus being on the critical quality attribute of the biosimilar product. In other words, 
process development of a biosimilar candidate is an iterative process, in which the manufacturing 
processes are adjusted until the critical quality attributes of the biosimilar are highly similar to 
the originator. Therefore, the objective is to reverse-engineer the biosimilar candidate aimed at 
producing highly similar to the reference product. Again, all the development process is 
performed with limited knowledge of the reference product manufacturing processes.63-64  
1.8.2 Regulatory Approval Requirments  
In a comparability assessment, a minor change in manufacturing processes can be 
approved without clinical trials. However, high-risk manufacturing changes require clinical trials 
to demonstrate the pre-change is similar to the post-change. Unlike comparability, biosimilar 
development is more than high-risk manufacturing changes because of the knowledge gap as 
well as the lack of accessible historical data of the reference product. Therefore, as outlined in  
ICHQSE “more data and information will be needed to establish biosimilarity than would be 
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needed to establish that a manufacturer’s post-manufacturing change product is comparable to 
the pre-manufacturing change product”.63-64  
Biosimilar sponsors must establish analytical and pre-clinical biosimilarity assessments as 
well as clinical data for regulatory approval. This is in contrast to comparability that requires a 
limited data package for regulatory approval. However, if substantial process changes have been 
implemented during comparability assessment, then clinical and non-clinical tests may be 
required. For instance, the production scale-up of  Lumizyme® within the same manufacturing 
facility showed significant differences in glycosylation and PK profiles between the pre-change 
and post-change. Thus, additional clinical data were required for regulatory approval of 
Lumizyme®. Similarly, after scaling up the fermentation, analytical and PK data failed to 
demonstrate comparability of alglucosidase Alfa. Therefore, the level of data required for 
approval in comparability exercise depends on the type of change introduced and its impact on 
the critical quality attributes. Nevertheless, the approval processes for a biosimilar is different 
from the processes needed for approval of a comparability process. Moreover, there are clear 
differences between the data package and approval processes required for a biosimilar product 
and assessment of comparability (manufacturing changes).63-64 
In the biosimilarity assessment, the totality of the data is considered for regulatory 
approval, such as structural and functional characterization, immunogenicity, pharmacodynamic, 
and comparative clinical study. The first biosimilar to be approved by this regulatory pathway 
was ZarxioTM, which was a recombinant granulocytes colony-stimulator factor. For regulatory 
approval after the process change (i.e., in comparability assessment), the historical data 
generated pre-change can be used to compare with the post-change to predict no adverse effect 
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on the safety and efficacy of the product is anticipated. However, if the analytical test cannot 
demonstrate comparability, then a non-clinical test of the post-change product should be 
conducted to ensure safety and efficacy. This is in contrast to the biosimilarity assessment’s 
comprehensive side-by-side testing showing similarity to the reference product is performed. 
Demonstrating a high degree of similarity is the basis for reduced clinical trials. Unlike 
comparability, side-by-side non-clinical and clinical safety data as well as immunogenicity 
assessment are required to support a claim of biosimilarity. In addition,  pharmacokinetics and 
pharmacodynamics profiles as well as efficacy trials are also necessary to gain regulatory 
approval.63 
1.9 Stability of Protein Therapeutics  
1.9.1 Physical Stability of Proteins  
The number of mAbs approved for treatment of various diseases has increased 
significantly over the last decade, and this trend continues today.72 There are many advantages 
of antibodies compared to other proteins, such as specificity, fewer side effects, and less 
immunogenicity. Also, antibodies can be conjugated with other small-molecule drugs for efficient 
delivery to their target site. Immunoglobulin G structure comprises the Fab and the Fc. The Fab 
region contains heavy and light chains. The Fc and the Fab are connected at the hinge region (via 
disulfide bonds) and form the Y-shaped structure.73-74 The Fc portion of IgG contains two identical 
heavy chains, and each comprises CH2 and CH3 domain. The CH2 domains are connected by a 
disulfide bond, whereas a detailed study indicates that the two CH3 domains are stabilized by 
non-covalent interaction (Figures 1 and 2).75  
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Antibodies are heterogeneous in their structure because of the variation in glycosylation 
pattern and physicochemical changes during production. The chemical modification includes the 
following: C-terminal variability, oxidation, deamidation, and fragmentation.76 For instance, in 
one study that used capillary isoelectric focusing (cIEF), five charge isoforms were isolated 
indicating the level of heterogeneity generated.77 Similarly, physical degradation of antibodies 
was observed in liquid, frozen, and lyophilized states. In most cases, various degradation 
pathways can occur simultaneously, depending on the type of stress applied and the solution 
condition.78 This creates an immense challenge in developing therapeutic protein products.72 
Antibodies can denature upon exposure to high temperature, shear, and extreme pH, 
which ultimately leads to loss of potency. For instance, a recombinant scFv antibody fragment 
functional activity was decreased after a shear, likely due to denaturation.72, 79-80 Several reports 
indicate that thermal treatment produces noncovalent linked aggregated, dimers, and 
monomers.72 81Antibody aggregation is usually observed after physical instability and, to some 
extent, chemical instability. Protein aggregation is known to increase as concentration increases 
and creates significant challenges in high concentration formulation development.82 However, 
one advantage of high-protein concentration formulation is its stability during freeze-thaw. 
Protein at a high concentration is more resistant to freeze-thaw-induced aggregations, as the 
interface-induced protein denatures can quickly reach a saturation point.72 Besides heating, low-
temperature storage can induce aggregation. For instance, it has been reported that Igm 
cryoglobulin precipitated at storage temperature below 10°C.  
Other studies indicate that the aggregation of IgG1 at a low temperature and surprisingly 
the processes are reversible upon increasing the storage temperature.83 One plausible theory as 
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to how low temperature causes aggregation and precipitations is that a decrease in temperature 
reduces the hydrophobic interaction, and consequently, leads to exposure of hydrophobic 
surfaces. This exposure leads to an increase in protein-protein interaction and results in 
aggregation.72 
Glycosylation can affect the physical stability and solubility of antibodies, as shown in 
many studies.84 For example, the physical stability of IgG1 Fc glycoforms with a different site 
occupancy (expressed in P.pastoris) was studied in detail. The diglycosylated showed the highest 
physical stability. The non-glycosylated IgG1 Fc (N297Q-Fc) showed the lowest stability indicating 
the effect of glycosylation on the stability. The mono-glycosylated IgG1 Fc (glycosylated in one 
site) showed the least physical stabilities. Furthermore, non-native structure from circular 
dichroism (CD) and intrinsic fluorescence was observed, which was reversible upon the removal 
of the glycan (i.e., treatment with PNGase F). Functional activity studies showed that the mono-
glycosylated Fc binds two-fold less than the diglycosylated in agreement with other reports.49 
These studies indicated the role of glycosylation on the higher-order structure of IgG, which 
impacts the stability and functional activity.  
In a similar study, the solubility and physical stabilities of four glycoforms (HM-Fc, Man5-
Fc. GlcNAc-Fc, and N297Q-Fc) were studied in detail. The results indicated that the diglycosylated 
HM-Fc (Man8GlcNAc2) and Man5-Fc (Man5GlcNAc2) have higher solubility and physical stabilities. 
Comparatively, the GlcNAc-Fc has lower physical stability and solubility. The solubility and 
physical stability of N297Q-Fc significantly decreased compared to the other glycoforms, 
indicating the effect of the glycans. Other studies suggested that removal of glycan exposes the 
hydrophobic pocket, which ultimately leads to structural alteration and aggregation.85 
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1.9.2 Chemical Degradation of Proteins 
Chemical degradation of proteins is one of the common degradation pathways that 
occurs at all stages of product development. The most common types of chemical degradation 
include the following: oxidation, fragmentation, glycation, and deamidation.86 The chemical 
degradation that alters the higher-order structure of an IgG can lead to aggregation and 
immunogenicity. Furthermore, alteration in higher-order structure may lead to physical 
degradation, which consequently, can alter the biological activity of therapeutic antibodies. 
Therefore, chemical stability is one of the critical quality attributes that needs to be monitored 
during protein therapeutic development.86  For instance, oxidation of Trp in antibodies was 
shown to cause loss of functional activity as well as change in color of a high concentration 
formulation.87 Also, the rate of Trp oxidation was pH-dependent processes and at basic 
conditions, can result in the formation of aggregates.87 In one study, mAbs MED-493 has reported 
a loss of binding and biological activity due to Trp oxidation.88 In another study, antibodies were 
exposed to 254 nm, and resulted in increased percentage of aggregation over the time of 
exposure.89 Other studies showed that photoionization of Trp could reduce disulfide bonds by 
electron transfer, which led to both chemical and physical degradation of the protein.90-93 
Oxidation of therapeutic mAbs can occur at any stage of production, purification, storage, 
and transportation.94-97  Oxidation hot spots in the Fc region of IgG are Met252 and Met428, which 
are known to affect the conformational stability of the CH2 domain. The impact of oxidation on 
the CH2 domain stability of antibodies has been observed in several studies.96, 98-99 Unlike other 
chemical modifications, Met oxidation increased for samples stored at a low temperature 
(refrigerator) compared to samples stored at high temperature (room). This increase in oxidation 
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at low temperature was because of the concentration of oxygen at low-temperature increases 
(solubility of oxygen increases at a low temperature). There are many potential sources of free 
radicals, such as excipient and container.100-101  
Besides Met and Trp, there are other sites prone to oxidation, such as His, Cys, and Tyr 
amino acids. Oxidation of these reactive sites can occur by reaction with a number of reactive 
oxygen species (ROS).102-105 The residue that is solvent exposed and accessible to ROS exhibits a 
high oxidation rate.97-98, 106-107 Oxidation of protein can be categorized as metal-catalyzed 
oxidation (site-specific) and photo-oxidation reaction (non-site-specific). For instance, light can 
lead to oxidation of Met and Trp sites in protein.86 Another possible oxidation is metal-catalyzed 
oxidation (MCO), which occurs when redox-active metals, such as iron and copper, bind with the 
antibody. Metals are known to bind to histidine and cysteine, and  these sites are sensitive to 
oxidation due to the proximity of the ROS generated.108 
 Deamidation is another chemical modification that requires monitoring during 
therapeutic product developments. Asparagine sites followed by serine, asparagine, and aspartic 
acid residues appear to exhibit higher deamidation rate.86 Therefore, sequence plays a critical 
role in the rate of deamidation.108-109 In addition to sequence, high order structure can play a 
significant role in the rate of deamidation.86, 110-112 Additionally, deamidation of mAbs can be 
affected by temperature, buffer, and pH condition.86 For instance, in one study after an extended 
storage of antibody, chemical degradations, such as deamidation (Asn and Gln), fragment, and 
oxidation, were observed.76, 113-114   
The correlation between deamidation rate and glycosylation was not studied extensively. 
A recent report examined the effect of glycan nature on the chemical stability of well-defined 
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IgG1 Fc glycoforms. After incubation at 40°C for three months, the results indicated that the 
deamidation of Asn315 and transformation of Trp into glycine-hydroperoxide were glycan-
dependent. The non-glycosylated N297Q-Fc showed higher deamidation followed by GlcNAc-Fc. 
The Man5-Fc and HM-Fc showed similar deamidation profiles. Furthermore, the data showed 
different glycoforms lead to different impurity profiles. Therefore, these results are significant in 
biosimilar development, in which impurity profile difference can have a significant effect on the 
chemical degradation. The chemical degradation studies of the four well-defined IgG1 Fc 
glycoforms showed a significant difference in their degradation profile, influenced by the type of 
glycan at Asn297.115 Glycation is another modification that can occur when antibodies are 
incubated in a solution containing a reducing sugar.86 Some results indicate glycation affects the 
function,116 while other results suggest no effect on the binding affinity.117 Glycation can affect 
the stability and, consequently, may lead to loss of potency. Glycation can occur in the presence 
of reducing sugars commonly used as excipients, such as glucose, lactose, and fructose.86 The 
common sites of glycation are lysine and arginine, which ultimately results in loss of charge and 
increase in hydrophobicity.118 Similarly, formulation of diketopiperazine (DKP) was observed 
during extended storage.86 Although forced degradation is essential for formulation screening, 
the degradation profile may not be the same when compared with the long-term storage.96 
Hence, care must be exercised with analysis degradation profiles generated from forced 
degradations. 
1.9.2.1 Chemical Modification of Proteins During Storage 
 
Chemical degradation is one of the most common degradations of proteins, which include 
cross-linking, deamidation, isomerization, oxidation, disulfide bond exchange, and 
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fragmentation.86 Disulfide bond exchange is typical chemical degradation and may lead to 
protein aggregation.119 The disulfide bond exchange is initiated by thiolate ions generated at 
higher pH; hence, increasing pH leads to more degradation.120 In a study of lyophilized IgG1 Fc, 
Storage (1 year at 30°C), it has been demonstrated that the disulfide exchange caused the 
formation of dimers and trimers. Similarly, other studies indicate non-reduced dimers of IgG1  Fc 
after storage at elevated temperature and basic pH for several weeks.94, 121-122 Storage at a high-
temperature > 4°C can easily generate a range of dimer products as indicated in several reports.78, 
123  
Besides disulfide bond, isomerization is a common degradation pathway in therapeutic 
mAbs. For example, a recombinant monoclonal antibody HER2 (Herceptin) showed isomerization 
and decrease in potency.124 Similarly, anti-IgE antibody (E25) isomerization reduced the binding 
activity to 15%.125 Oxidation is another degradation route for antibodies stored at a low 
temperature. For example, oxidation was shown in IgG2a during solution stored at 5°C. Similarly, 
oxidation was observed in rhu mAb anti CD20 after incubation at 4°C for about two months.126 
Light exposure can increase oxidation as indicated in HER2 at 30°C and 40°C. Other degradation 
pathways during storage are the formation of basic and acidic species. Deamidation is the most 
common pathway that leads to acid species, and such degradation was observed after incubation 
at 25°C for twelve weeks.127 On the other hand, basic species in antibodies were observed after 
removal of sialic acid as well as after pyroglutamate and succinimide formation. Such a basic 
species was observed after incubation of a human monoclonal antibody at 37°C for two weeks.72 
Fragmentation is another major degradation pathway of antibodies that can occur after acidic or 
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basic treatment,122 thermal stress, freeze-thaw,78 and storage.121 There are fragmentation prone 
sequences in IgG1 Fc, such as Asp-Gly and Asp-pro.128  
1.9.3 Accelerated and Long-Term Stability Study of Proteins 
 
Stability testing is required to establish shelf-life of therapeutic products. It is well known 
that environmental factors, such as pH, temperature, ionic strength, and the presence of 
stabilizers, can impact the conformational stability of the product. Therefore, the stability of the 
biosimilar in the formulation should be studied.52 Accelerated stability studies are performed 
based on the underlying assumption that the degradation profile follows Arrhenius behavior. This 
is true in small molecules where studies conducted at a higher temperature can predict stability 
during longer and lower temperatures.129 A non-Arrhenius behavior was introduced to account 
for protein aggregation, in which the rate depends on equilibrium (for the formation of 
aggregation-prone state) and the rate of irreversible aggregation.130 However, using Arrhenius 
equation to fit protein stability data can be very difficult,131 because there are potentially multiple 
degradation pathways  involved.52 
Forced degradation study include a set of analytical tests applied to examine 
physicochemical mechanisms of degradation. On the other hand, accelerated stability study 
measures the rate of a given degradation process over time at a different temperature in specific 
formulation conditions. Examining the effect of storage time, excipients on the accelerated and 
long-term stabilities of biologic drug products is an important part of formulation development 
as well as comparability evaluation. Biological drug products may encounter many environmental 
stresses during expression, purification, processing, storage, and shipment. Therefore, forced 
degradation and accelerated stability studies are required to study the degradation profile of a 
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biologic drug by applying various stress conditions, such as elevated temperature, freeze-thaw, 
agitation, oxidation environment, light, and the presence of different interfaces as well as pH 
changes. The design and outcome of successfully forced degradation and accelerated stability 
studies depends on the analytical techniques employed to identify and characterize the 
degradants generated. 
Temperature-induced unfolding is widely used to predict long-term protein stability at 
low temperature ( storage). For instance, a good correlation between the measured Tm  value and 
aggregation propensity during storage at 40oC has been obtained for mAbs.132 This study suggests 
that the closer the Tm value is to the thermal stress,  the higher the probability the protein starts 
to unfold. Consequently, there is a  loss of its native structures to form aggregates. However, this 
mechanism of thermal induced aggregation at an elevated temperature may not help to predict 
long-term stability at a lower temperature. Moreover, most proteins are conformationally stable 
at low storage temperature (2 and 8 oC). The mechanism of aggregation at low temperature is 
driven by native self-association (colloidal stability) rather than on non-native protein-protein 
interaction (conformational stability). Although some progress has been achieved,  the prediction 









1.10 Chapter Overview 
1.10.1 Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc 
Glycoforms as a Model System for Biosimilarity Analysis (Chapter 2) 
 
Four different well-defined IgG1 Fc glycoforms are proposed as a model system to 
examine important biological and physicochemical features for protein drug biosimilar analysis. 
The IgG1 Fc glycoforms were produced by yeast expression combined with in-vitro enzymatic 
synthesis as a series of sequentially truncated, high-mannose IgG1 Fc glycoforms with an 
anticipated range of biological activity and structural stability. Initial characterization with mass 
spectrometry, SDS-PAGE, SEC, and cIEF confirmed the glycoproteins are overall highly similar 
with the only major difference being glycosylation state. Binding to the activating Fc receptor 
FcRIIIa was used to evaluate the potential biological activity of the IgG1 Fc glycoproteins. Two 
complementary methods utilizing biolayer interferometry (BLI), one with protein G immobilized 
IgG1 Fc and the other with streptavidin immobilized FcRIIIa, were developed to assess FcRIIIa 
affinity in kinetic binding studies. The HM-Fc and Man5-Fc were highly similar to one another 
with high affinity for FcRIIIa, while GlcNAc-Fc had a weak affinity, and the non-glycosylated 




1.10.2 Comparative Evaluation of Well-Defined Mixtures of IgG1 Fc Glycoforms as a 
Model for Biosimilar Comparability Analysis (Chapter 3) 
Four well-defined IgG1 Fc glycoforms (HM-Fc, Man5-Fc, GlcNAc-Fc, and N297Q-Fc) were 
prepared and blended to produce well-defined mixtures with evident and subtle differences in 
physical and functional properties. The mixtures were prepared by mixing HM-Fc with the three 
glycoforms in pre-defined proportion to make two sets of mixtures (90%HM:10%X, 
50%HM:50%X, in which X was N297Q-Fc, Man5-Fc, and GlcNAc-Fc). In addition, a more complex 
system was prepared by blending the four glycoforms (25% each) to model heterogeneous 
systems typically encountered in monoclonal antibodies. Seven mixtures of glycoforms were 
prepared and utilized a model system for biosimilar comparability assessment. Also, the four 
glycoforms were used as a control in each characterization technique. The focus of this study is 
to evaluate the functional and physical characteristics of the mixtures as a model system for 
biosimilar comparability analysis. Two complimentary BioLayer Interferometry (BLI) methods, Fc-
immobilized (receptor in solution), and receptor-immobilized (Fc in solution), were employed to 
examine the functional activity of the mixture of glycoforms. Although both immobilization 
techniques showed similar KD (equilibrium dissociation constant) values for the control 
glycoforms as expected, differences in KD values were observed for the mixture of glycoforms. 
These differences in KD values depended on the type of immobilization technique used, the 
percentage of composition of the mixtures, and the type of mixtures. Therefore, the result 
demonstrated that the binding interactions were influenced not only by the type of mixtures, but 
also by the immobilization technique employed. Response measurements were performed using 
the Fc-immobilization technique; a trend was observed, which depended on the type and 
composition of the mixtures. Mixtures containing Man5-Fc and HM-Fc showed higher responses, 
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followed by a mixture of GlcNAc-Fc and HM-Fc. Meanwhile, combinations of N297Q-Fc and HM-
Fc showed the lowest responses.  
1.10.3  Characterization of IgG1 Fc Glycoforms After Prolonged Storage at Low and 
Elevated Temperatures: A Model System for Biosimilar Comparability Analysis 
(Chapter 4) 
Stabilities of therapeutic monoclonal antibodies are routinely tested under accelerated 
conditions, such as exposure to chemicals and incubation at a high temperature. IgG1 Fc 
glycoforms were characterized after incubation at -80˚C, 4˚C, and 40˚C for time points at two, 
four, and twelve weeks. The data indicated that samples stored at 40˚C showed significantly 
lower binding affinities to FcRIIIa, while the samples stored at 4˚C and -80˚C showed a moderate 
change in binding affinities when tested using the Fc-immobilized format. Additionally, a 
reduction in binding response was observed when the Fc-immobilized technique was used. In 
addition, the samples stored at 40˚C showed significant chemical modifications, presumably 
oxidation, whereas a modest change in chemical modification was observed for samples stored 
at low temperatures (4˚C and -80˚C) at all the time points examined. Furthermore, HM-Fc, Man5-
Fc, and GlcNAc-Fc showed significantly lower binding affinities when the measurements were 
performed using the receptor-immobilized format compared to the measurement conducted 
using the Fc-immobilized. These data illustrated differences between the two immobilization 
techniques in detecting a reduction in binding affinities for the samples incubated at low and 




1.10.4 Summary, Conclusions, and Future Work (Chapter 5) 
This chapter summarizes the concepts developed from chapters two to four with the 
focus being the utility of homogenous well-defined IgG1 Fc glycoforms as a model for biosimilar 
comparability analysis. The application of the concepts and methods developed in biosimilar and 
comparability assessments as well as in new-product development was discussed. Finally, areas 




1.11 Figures  
Figure 1.  Schematic representation of IgG1 containing two Fab regions and a homodimer 
Fc region. The domains are marked with variable (V) or constant (C) with a subscription 
for light (L) and heavy chain (H). The heavy chain is numbered 1, 2, and 3, starting from 
the N-terminus. The glycosylation site for IgG1 is located at Asn297 (EU numbering).  The 
two heavy chains are connected  by  the disulfide bonds in the hinge region (marked red). 
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 Figure 2. Crystal structure of IgG1 Fc which contains glycosylation at Asn297 (PDB ID: 1H3Y).  









Figure 3.  The amount of data required for a biosimilar product compared to a new product.  Extensive 
physicochemical and functional characterizations (analytics) are required in a biosimilar development 







Figure 4. Steps required for developing a biosimilar, small-molecule generic, and new biologic 
products. In a biosimilar product, the discovery phase and phase II (i.e., dose finding), are not 









1. Zheng, K.; Bantog, C.; Bayer, R., The impact of glycosylation on monoclonal antibody 
conformation and stability. mAbs 2011, 3 (6), 568-576. 
2. Shinkawa, T.; Nakamura, K.; Yamane, N.; Shoji-Hosaka, E.; Kanda, Y.; Sakurada, M.; 
Uchida, K.; Anazawa, H.; Satoh, M.; Yamasaki, M.; Hanai, N.; Shitara, K., The Absence of Fucose 
but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-
type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular 
Cytotoxicity. Journal of Biological Chemistry 2003, 278 (5), 3466-3473. 
3. Raju, T. S., Terminal sugars of Fc glycans influence antibody effector functions of IgGs. 
Current Opinion in Immunology 2008, 20 (4), 471-478. 
4. Okazaki, A.; Shoji-Hosaka, E.; Nakamura, K.; Wakitani, M.; Uchida, K.; Kakita, S.; 
Tsumoto, K.; Kumagai, I.; Shitara, K., Fucose Depletion from Human IgG1 Oligosaccharide 
Enhances Binding Enthalpy and Association Rate Between IgG1 and FcγRIIIa. Journal of 
Molecular Biology 2004, 336 (5), 1239-1249. 
39 
 
5. Yamane-Ohnuki, N.; Kinoshita, S.; Inoue-Urakubo, M.; Kusunoki, M.; Iida, S.; Nakano, R.; 
Wakitani, M.; Niwa, R.; Sakurada, M.; Uchida, K.; Shitara, K.; Satoh, M., Establishment of FUT8 
knockout Chinese hamster ovary cells: An ideal host cell line for producing completely 
defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. 
Biotechnology and Bioengineering 2004, 87 (5), 614-622. 
6. Mori, K.; Kuni-Kamochi, R.; Yamane-Ohnuki, N.; Wakitani, M.; Yamano, K.; Imai, H.; 
Kanda, Y.; Niwa, R.; Iida, S.; Uchida, K.; Shitara, K.; Satoh, M., Engineering Chinese hamster 
ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. 
Biotechnology and Bioengineering 2004, 88 (7), 901-908. 
7. Schuster, M.; Umana, P.; Ferrara, C.; Brünker, P.; Gerdes, C.; Waxenecker, G.; 
Wiederkum, S.; Schwager, C.; Loibner, H.; Himmler, G.; Mudde, G. C., Improved Effector 
Functions of a Therapeutic Monoclonal Lewis Y-Specific Antibody by Glycoform Engineering. 
Cancer Research 2005, 65 (17), 7934-7941. 
8. Niwa, R.; Natsume, A.; Uehara, A.; Wakitani, M.; Iida, S.; Uchida, K.; Satoh, M.; Shitara, 
K., IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by 
fucose removal from Asn297-linked oligosaccharides. Journal of Immunological Methods 2005, 
306 (1–2), 151-160. 
9. Shields, R. L.; Lai, J.; Keck, R.; O'Connell, L. Y.; Hong, K.; Meng, Y. G.; Weikert, S. H. A.; 
Presta, L. G., Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to 
40 
 
Human FcγRIII and Antibody-dependent Cellular Toxicity. Journal of Biological Chemistry 2002, 
277 (30), 26733-26740. 
10. Kaneko, Y.; Nimmerjahn, F.; Ravetch, J. V., Anti-Inflammatory Activity of 
Immunoglobulin G Resulting from Fc Sialylation. Science 2006, 313 (5787), 670-673. 
11. Anthony, R. M.; Nimmerjahn, F.; Ashline, D. J.; Reinhold, V. N.; Paulson, J. C.; Ravetch, J. 
V., Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc. Science 2008, 
320 (5874), 373-376. 
12. Anthony, R. M.; Kobayashi, T.; Wermeling, F.; Ravetch, J. V., Intravenous gammaglobulin 
suppresses inflammation through a novel TH2 pathway. Nature 2011, 475 (7354), 110-113. 
13. Maiorella, B. L.; Ferris, R.; Thomson, J.; White, C.; Brannon, M.; Hora, M.; Henriksson, T.; 
Triglia, R.; Kunitani, M.; Kresin, L.; Dollinger, G.; Jones, R.; Senyk, G.; Young, J.; Moyer, B.; 
McEntire, J.; Dougherty, J.; Monica, T.; Goochee, C., Evaluation of Product Equivalence During 
Process Optimization for Manufacture of a Human IgM Monoclonal Antibody. Biologicals 1993, 
21 (3), 197-205. 
14. Kálmán-Szekeres, Z.; Olajos, M.; Ganzler, K., Analytical aspects of biosimilarity issues of 
protein drugs. Journal of Pharmaceutical and Biomedical Analysis 2012, 69 (0), 185-195. 
41 
 
15. Schmelzer, A. E.; Miller, W. M., Hyperosmotic Stress and Elevated pCO2 Alter 
Monoclonal Antibody Charge Distribution and Monosaccharide Content. Biotechnology 
Progress 2002, 18 (2), 346-353. 
16. Stockert, R. J., The asialoglycoprotein receptor: relationships between structure, 
function, and expression. Physiological Reviews 1995, 75 (3), 591-609. 
17. Lubiniecki, A.; Volkin, D. B.; Federici, M.; Bond, M. D.; Nedved, M. L.; Hendricks, L.; 
Mehndiratta, P.; Bruner, M.; Burman, S.; DalMonte, P.; Kline, J.; Ni, A.; Panek, M. E.; Pikounis, 
B.; Powers, G.; Vafa, O.; Siegel, R., Comparability assessments of process and product changes 
made during development of two different monoclonal antibodies. Biologicals 2011, 39 (1), 9-
22. 
18. Chirino, A. J.; Mire-Sluis, A., Characterizing biological products and assessing 
comparability following manufacturing changes. Nat Biotech 2004, 22 (11), 1383-1391. 
19. Putnam, W. S.; Prabhu, S.; Zheng, Y.; Subramanyam, M.; Wang, Y.-M. C., 
Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies 
for monoclonal antibodies. Trends in Biotechnology 2010, 28 (10), 509-516. 
20. Berkowitz, S. A.; Engen, J. R.; Mazzeo, J. R.; Jones, G. B., Analytical tools for 
characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 
2012, 11 (7), 527-540. 
42 
 
21. Kilgore, B. R.; Kilgore, B. R., Comparability and Monitoring Immunogenic N-linked 
Oligosaccharides from Recombinant Monoclonal Antibodies from Two Different Cell Lines using 
HPLC with Fluorescence Detection and Mass Spectrometry. 2008; Vol. 446, pp 333-346. 
22. Gawlitzek, M.; Valley, U.; Nimtz, M.; Wagner, R.; Conradt, H. S., Characterization of 
changes in the glycosylation pattern of recombinant proteins from BHK-21 cells due to different 
culture conditions. Journal of Biotechnology 1995, 42 (2), 117-131. 
23. Federici, M.; Lubiniecki, A.; Manikwar, P.; Volkin, D. B., Analytical lessons learned from 
selected therapeutic protein drug comparability studies. Biologicals 2013, 41 (3), 131-147. 
24. Raju, T. S.; Jordan, R. E., Galactosylation variations in marketed therapeutic antibodies. 
mAbs 2012, 4 (3), 385-391. 
25. Wacker, C.; Berger, C. N.; Girard, P.; Meier, R., Glycosylation profiles of therapeutic 
antibody pharmaceuticals. European Journal of Pharmaceutics and Biopharmaceutics 2011, 79 
(3), 503-507. 
26. Hanson, Q. M.; Barb, A. W., A Perspective on the Structure and Receptor Binding 
Properties of Immunoglobulin G Fc. Biochemistry 2015, 54 (19), 2931-2942. 
27. Sondermann, P.; Oosthuizen, V., X-ray crystallographic studies of IgG-Fcγ receptor 
interactions. Biochemical Society Transactions 2002, 30 (4), 481-486. 
43 
 
28. Liu, L., Antibody Glycosylation and Its Impact on the Pharmacokinetics and 
Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins. Journal of 
Pharmaceutical Sciences 2015, n/a-n/a. 
29. Zhang, N.; Liu, L.; Dumitru, C. D.; Cummings, N. R. H.; Cukan, M.; Jiang, Y.; Li, Y.; Li, F.; 
Mitchell, T.; Mallem, M. R.; Ou, Y.; Patel, R. N.; Vo, K.; Wang, H.; Burnina, I.; Choi, B.-K.; Huber, 
H.; Stadheim, T. A.; Zha, D., Glycoengineered Pichia produced anti-HER2 is comparable to 
trastuzumab in preclinical study. mAbs 2011, 3 (3), 289-298. 
30. Potgieter, T. I.; Cukan, M.; Drummond, J. E.; Houston-Cummings, N. R.; Jiang, Y.; Li, F.; 
Lynaugh, H.; Mallem, M.; McKelvey, T. W.; Mitchell, T.; Nylen, A.; Rittenhour, A.; Stadheim, T. 
A.; Zha, D.; d’Anjou, M., Production of monoclonal antibodies by glycoengineered Pichia 
pastoris. Journal of Biotechnology 2009, 139 (4), 318-325. 
31. Ha, S.; Wang, Y.; Rustandi, R. R., Biochemical and biophysical characterization of 
humanized IgG1 produced in Pichia pastoris. mAbs 2011, 3 (5), 453-460. 
32. Choi, B.-K.; Warburton, S.; Lin, H.; Patel, R.; Boldogh, I.; Meehl, M.; d’Anjou, M.; Pon, L.; 
Stadheim, T.; Sethuraman, N., Improvement of N-glycan site occupancy of therapeutic 
glycoproteins produced in Pichia pastoris. Appl Microbiol Biotechnol 2012, 95 (3), 671-682. 




34. Al-Sabbagh, A.; Olech, E.; McClellan, J. E.; Kirchhoff, C. F., Development of biosimilars. 
Seminars in Arthritis and Rheumatism 2016, 45 (5, Supplement), S11-S18. 
35. Beck, A.; Debaene, F.; Diemer, H.; Wagner-Rousset, E.; Colas, O.; Dorsselaer, A. V.; 
Cianférani, S., Cutting-edge mass spectrometry characterization of originator, biosimilar and 
biobetter antibodies. Journal of Mass Spectrometry 2015, 50 (2), 285-297. 
36. Schneider, C. K.; Vleminckx, C.; Gravanis, I.; Ehmann, F.; Trouvin, J.-H.; Weise, M.; 
Thirstrup, S., Setting the stage for biosimilar monoclonal antibodies. Nat Biotech 2012, 30 (12), 
1179-1185. 
37. Xie, H.; Chakraborty, A.; Ahn, J.; Yu, Y. Q.; Dakshinamoorthy, D. P.; Gilar, M.; Chen, W.; 
Skilton, S. J.; Mazzeo, J. R., Rapid comparison of a candidate biosimilar to an innovator 
monoclonal antibody with advanced liquid chromatography and mass spectrometry 
technologies. mAbs 2010, 2 (4), 379-394. 
38. Raedler, L. A., Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States. 
American Health & Drug Benefits 2016, 9 (Spec Feature), 150-154. 
39. Pisupati, K.; Tian, Y.; Okbazghi, S.; Benet, A.; Ackermann, R.; Ford, M.; Saveliev, S. V.; 
Hosfield, C. M.; Urh, M.; Carlson, E.; Becker, C.; Tolbert, T. J.; Schwendeman, S. P.; Ruotolo, B. 
T.; Schwendeman, A., A Multidimensional Analytical Comparison of Remicade and the 
Biosimilar Remsima. Analytical Chemistry 2017. 
45 
 
40. Jiang, X.-R.; Song, A.; Bergelson, S.; Arroll, T.; Parekh, B.; May, K.; Chung, S.; Strouse, R.; 
Mire-Sluis, A.; Schenerman, M., Advances in the assessment and control of the effector 
functions of therapeutic antibodies. Nat Rev Drug Discov 2011, 10 (2), 101-111. 
41. Jones, A. J. S.; Papac, D. I.; Chin, E. H.; Keck, R.; Baughman, S. A.; Lin, Y. S.; Kneer, J.; 
Battersby, J. E., Selective clearance of glycoforms of a complex glycoprotein pharmaceutical 
caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. 
Glycobiology 2007, 17 (5), 529-540. 
42. Jefferis, R., Glycosylation of Recombinant IgG Antibodies and Its Relevance for 
Therapeutic Applications. In Cell Engineering, Al-Rubeai, M., Ed. Springer Netherlands: 2002; 
Vol. 3, pp 93-107. 
43. Chung, C. H., Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-
Galactose. The New England journal of medicine 2008, 358 (11), 1109-1117. 
44. Hokke, C. H.; Bergwerff, A. A.; van Dedem, G. W. K.; van Oostrum, J.; Kamerling, J. P.; 
Vliegenthart, J. F. G., Sialylated carbohydrate chains of recombinant human glycoproteins 
expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid. FEBS 
Letters 1990, 275 (1–2), 9-14. 
46 
 
45. Borys, M. C.; Dalal, N. G.; Abu-Absi, N. R.; Khattak, S. F.; Jing, Y.; Xing, Z.; Li, Z. J., Effects 
of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion 
protein produced in CHO cells. Biotechnology and Bioengineering 2010, 105 (6), 1048-1057. 
46. Wright, A.; Sato, Y.; Okada, T.; Chang, K. H.; Endo, T.; Morrison, S. L., In vivo trafficking 
and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. 
Glycobiology 2000, 10 (12), 1347-1355. 
47. Wright, A.; Morrison, S. L., Effect of glycosylation on antibody function: implications for 
genetic engineering. Trends in Biotechnology 1997, 15 (1), 26-32. 
48. Kálmán-Szekeres, Z.; Olajos, M.; Ganzler, K., Analytical aspects of biosimilarity issues of 
protein drugs. Journal of Pharmaceutical and Biomedical Analysis 2012, 69, 185-195. 
49. Alsenaidy, M. A.; Okbazghi, S. Z.; Kim, J. H.; Joshi, S. B.; Middaugh, C. R.; Tolbert, T. J.; 
Volkin, D. B., Physical Stability Comparisons of IgG1-Fc Variants: Effects of N-Glycosylation Site 
Occupancy and Asp/Gln Residues at Site Asn 297. Journal of Pharmaceutical Sciences 2014, 103 
(6), 1613-1627. 
50. Tsuruta, L. R.; Lopes dos Santos, M.; Moro, A. M., Biosimilars advancements: Moving on 
to the future. Biotechnology Progress 2015, 31 (5), 1139-1149. 
47 
 
51. Alsenaidy, M.; Jain, N. K.; Kim, J.; Middaugh, C.; Volkin, D., Protein comparability 
assessments and potential applicability of high throughput biophysical methods and data 
visualization tools to compare physical stability profiles. Frontiers in Pharmacology 2014, 5 (39). 
52. Falconer, R. J.; Jackson-Matthews, D.; Mahler, S. M., Analytical strategies for assessing 
comparability of biosimilars. Journal of Chemical Technology & Biotechnology 2011, 86 (7), 915-
922. 
53. O'Shannessy, D. J.; Winzor, D. J., Interpretation of Deviations from Pseudo-First-Order 
Kinetic Behavior in the Characterization of Ligand Binding by Biosensor Technology. Analytical 
Biochemistry 1996, 236 (2), 275-283. 
54. Oshannessy, D. J.; Brighamburke, M.; Soneson, K. K.; Hensley, P.; Brooks, I., 
Determination of Rate and Equilibrium Binding Constants for Macromolecular Interactions 
Using Surface Plasmon Resonance: Use of Nonlinear Least Squares Analysis Methods. Analytical 
Biochemistry 1993, 212 (2), 457-468. 
55. Roden, L. D.; Myszka, D. G., Global Analysis of a Macromolecular Interaction Measured 
on BIAcore. Biochemical and Biophysical Research Communications 1996, 225 (3), 1073-1077. 
56. Nieba, L.; Krebber, A.; Plückthun, A., Competition BIAcore for Measuring True Affinities: 
Large Differences from Values Determined from Binding Kinetics. Analytical Biochemistry 1996, 
234 (2), 155-165. 
48 
 
57. Fischer, N. J. d. M. a. M. J. E., Kinetic and Thermodynamic Analysis of Ligand–Receptor 
Interactions: SPR Applications in Drug Development. 10 Mar 2008. 
58. Karlsson, R.; Fält, A., Experimental design for kinetic analysis of protein-protein 
interactions with surface plasmon resonance biosensors. Journal of Immunological Methods 
1997, 200 (1), 121-133. 
59. Wang, Y.-M. C.; Chow, A. T., Development of Biosimilars—Pharmacokinetic and 
Pharmacodynamic Considerations. Journal of Biopharmaceutical Statistics 2009, 20 (1), 46-61. 
60. Jefferis, R., Recombinant antibody therapeutics: the impact of glycosylation on 
mechanisms of action. Trends in Pharmacological Sciences 2009, 30 (7), 356-362. 
61. Blackstone, E. A.; Joseph, P. F., The Economics of Biosimilars. American Health & Drug 
Benefits 2013, 6 (8), 469-478. 
62. ICH Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in 
Their Manufacturing Process www.fda.gov/ohrms/dockets/98fr/2004d-0118-gdl0001.pdf. 
63. Azevedo, V.; Hassett, B.; Fonseca, J. E.; Atsumi, T.; Coindreau, J.; Jacobs, I.; Mahgoub, E.; 
O’Brien, J.; Singh, E.; Vicik, S.; Fitzpatrick, B., Differentiating biosimilarity and comparability in 
biotherapeutics. Clinical Rheumatology 2016, 35 (12), 2877-2886. 
49 
 
64. Declerck, P.; Farouk-Rezk, M.; Rudd, P. M., Biosimilarity Versus Manufacturing Change: 
Two Distinct Concepts. Pharm Res 2016, 33 (2), 261-268. 
65. Morrow, T.; Felcone, L. H., Defining the difference: What Makes Biologics Unique. 
Biotechnology Healthcare 2004, 1 (4), 24-29. 
66. Kuhlmann, M.; Covic, A., The protein science of biosimilars. Nephrology Dialysis 
Transplantation 2006, 21 (suppl 5), v4-v8. 
67. Carpenter, J. F.; Randolph, T. W.; Jiskoot, W.; Crommelin, D. J. A.; Russell Middaugh, C.; 
Winter, G.; Fan, Y.-X.; Kirshner, S.; Verthelyi, D.; Kozlowski, S.; Clouse, K. A.; Swann, P. G.; 
Rosenberg, A.; Cherney, B., Overlooking Subvisible Particles in Therapeutic Protein Products: 
Gaps That May Compromise Product Quality. Journal of Pharmaceutical Sciences 2009, 98 (4), 
1201-1205. 
68. JS, P., A critical review of methods for size characterization of non-particulate protein 
aggregates. Curr Pharm Biotechnol 2009 10 (4), 359-72. 
69. Sarpatwari, A.; Avorn, J.; Kesselheim, A. S., Progress and Hurdles for Follow-on Biologics. 
New England Journal of Medicine 2015, 372 (25), 2380-2382. 




71. Lee, J. F.; Litten, J. B.; Grampp, G., Comparability and biosimilarity: considerations for 
the healthcare provider. Current Medical Research and Opinion 2012, 28 (6), 1053-1058. 
72. Wang, W.; Singh, S.; Zeng, D. L.; King, K.; Nema, S., Antibody structure, instability, and 
formulation. Journal of Pharmaceutical Sciences 2007, 96 (1), 1-26. 
73. Furtado, P. B.; Whitty, P. W.; Robertson, A.; Eaton, J. T.; Almogren, A.; Kerr, M. A.; Woof, 
J. M.; Perkins, S. J., Solution Structure Determination of Monomeric Human IgA2 by X-ray and 
Neutron Scattering, Analytical Ultracentrifugation and Constrained Modelling: A Comparison 
with Monomeric Human IgA1. Journal of Molecular Biology 2004, 338 (5), 921-941. 
74. Wörn, A.; Plückthun, A., Mutual Stabilization of VL and VH in Single-Chain Antibody 
Fragments, Investigated with Mutants Engineered for Stability. Biochemistry 1998, 37 (38), 
13120-13127. 
75. Dall'Acqua, W.; Simon, A. L.; Mulkerrin, M. G.; Carter, P., Contribution of Domain 
Interface Residues to the Stability of Antibody CH3 Domain Homodimers. Biochemistry 1998, 37 
(26), 9266-9273. 
76. Harris, R. J.; Shire, S. J.; Winter, C., Commercial manufacturing scale formulation and 
analytical characterization of therapeutic recombinant antibodies. Drug Development Research 
2004, 61 (3), 137-154. 
51 
 
77. Hunt, G.; Moorhouse, K. G.; Chen, A. B., Capillary isoelectric focusing and sodium 
dodecyl sulfate-capillary gel electrophoresis of recombinant humanized monoclonal antibody 
HER2. Journal of Chromatography A 1996, 744 (1), 295-301. 
78. P.K. Tsai, M. W. B., J.I. Irwin, C.C. Ip, C.N. Oliver, R.W. Nelson,; D.B. Volkin, C. R. M., 
Chemical and physical stability of chimeric L6, a mouse-human monoclonal antibody. Pharm. Res 
1993,  (10), 1580. 
79. Chen, B.; Bautista, R.; Yu, K.; Zapata, G. A.; Mulkerrin, M. G.; Chamow, S. M., Influence of 
Histidine on the Stability and Physical Properties of a Fully Human Antibody in Aqueous and 
Solid Forms. Pharm Res 2003, 20 (12), 1952-1960. 
80. Welfle, K.; Misselwitz, R.; Hausdorf, G.; Höhne, W.; Welfle, H., Conformation, pH-
induced conformational changes, and thermal unfolding of anti-p24 (HIV-1) monoclonal 
antibody CB4-1 and its Fab and Fc fragments. Biochimica et Biophysica Acta (BBA) - Protein 
Structure and Molecular Enzymology 1999, 1431 (1), 120-131. 
81. Alexander, A. J.; Hughes, D. E., Monitoring of IgG Antibody Thermal Stability by Micellar 
Electrokinetic Capillary Chromatography and Matrix-Assisted Laser Desorption/Ionization Mass 
Spectrometry. Analytical Chemistry 1995, 67 (20), 3626-3632. 
82. Shire, S. J.; Shahrokh, Z.; Liu, J., Challenges in the development of high protein 
concentration formulations. Journal of Pharmaceutical Sciences 93 (6), 1390-1402. 
52 
 
83. Ramsland, P. A.; Farrugia, W., Crystal structures of human antibodies: a detailed and 
unfinished tapestry of immunoglobulin gene products. Journal of Molecular Recognition 2002, 
15 (5), 248-259. 
84. Le Gall, F.; Reusch, U.; Little, M.; Kipriyanov, S. M., Effect of linker sequences between 
the antibody variable domains on the formation, stability and biological activity of a bispecific 
tandem diabody. Protein Engineering, Design and Selection 2004, 17 (4), 357-366. 
85. More, A. S.; Toprani, V. M.; Okbazghi, S. Z.; Kim, J. H.; Joshi, S. B.; Middaugh, C. R.; 
Tolbert, T. J.; Volkin, D. B., Correlating the impact of well-defined oligosaccharide structures on 
physical stability profiles of IgG1-Fc glycoforms. Journal of Pharmaceutical Sciences. 
86. Manning, M. C.; Chou, D. K.; Murphy, B. M.; Payne, R. W.; Katayama, D. S., Stability of 
Protein Pharmaceuticals: An Update. Pharm Res 2010, 27 (4), 544-575. 
87. Qi, P.; Volkin, D. B.; Zhao, H.; Nedved, M. L.; Hughes, R.; Bass, R.; Yi, S. C.; Panek, M. E.; 
Wang, D.; DalMonte, P.; Bond, M. D., Characterization of the photodegradation of a human 
IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form. Journal of 
Pharmaceutical Sciences 2009, 98 (9), 3117-3130. 
88. Wei, Z.; Feng, J.; Lin, H.-Y.; Mullapudi, S.; Bishop, E.; Tous, G. I.; Casas-Finet, J.; Hakki, F.; 
Strouse, R.; Schenerman, M. A., Identification of a Single Tryptophan Residue as Critical for 
53 
 
Binding Activity in a Humanized Monoclonal Antibody against Respiratory Syncytial Virus. 
Analytical Chemistry 2007, 79 (7), 2797-2805. 
89. Lorenz, C. M.; Wolk, B. M.; Quan, C. P.; Alcala, E. W.; Eng, M.; McDonald, D. J.; 
Matthews, T. C., The effect of low intensity ultraviolet-C light on monoclonal antibodies. 
Biotechnology Progress 2009, 25 (2), 476-482. 
90. Roy, S.; Mason, B. D.; Schöneich, C. S.; Carpenter, J. F.; Boone, T. C.; Kerwin, B. A., Light-
induced aggregation of type I soluble tumor necrosis factor receptor. Journal of Pharmaceutical 
Sciences 2009, 98 (9), 3182-3199. 
91. Vanhooren, A.; Devreese, B.; Vanhee, K.; Van Beeumen, J.; Hanssens, I., Photoexcitation 
of Tryptophan Groups Induces Reduction of Two Disulfide Bonds in Goat α-Lactalbumin. 
Biochemistry 2002, 41 (36), 11035-11043. 
92. Mozziconacci, O.; Sharov, V.; Williams, T. D.; Kerwin, B. A.; Schöneich, C., Peptide 
Cysteine Thiyl Radicals Abstract Hydrogen Atoms from Surrounding Amino Acids: The Photolysis 
of a Cystine Containing Model Peptide. The Journal of Physical Chemistry B 2008, 112 (30), 
9250-9257. 
93. Miller, B. L.; Hageman, M. J.; Thamann, T. J.; Barròn, L. B.; Schöneich, C., Solid-state 
photodegradation of bovine somatotropin (bovine growth hormone): Evidence for tryptophan-
54 
 
mediated photooxidation of disulfide bonds. Journal of Pharmaceutical Sciences 2003, 92 (8), 
1698-1709. 
94. Kroon, D. J.; Baldwin-Ferro, A.; Lalan, P., Identification of Sites of Degradation in a 
Therapeutic Monoclonal Antibody by Peptide Mapping. Pharm Res 1992, 9 (11), 1386-1393. 
95. Kerwin, B. A.; Remmele, R. L., Protect from light: Photodegradation and protein 
biologics. Journal of Pharmaceutical Sciences 2007, 96 (6), 1468-1479. 
96. Chumsae, C.; Gaza-Bulseco, G.; Sun, J.; Liu, H., Comparison of methionine oxidation in 
thermal stability and chemically stressed samples of a fully human monoclonal antibody. 
Journal of Chromatography B 2007, 850 (1–2), 285-294. 
97. Bertolotti-Ciarlet, A.; Wang, W.; Lownes, R.; Pristatsky, P.; Fang, Y.; McKelvey, T.; Li, Y.; 
Li, Y.; Drummond, J.; Prueksaritanont, T.; Vlasak, J., Impact of methionine oxidation on the 
binding of human IgG1 to FcRn and Fcγ receptors. Molecular Immunology 2009, 46 (8–9), 1878-
1882. 
98. Pan, H.; Chen, K.; Chu, L.; Kinderman, F.; Apostol, I.; Huang, G., Methionine oxidation in 




99. Liu, D.; Ren, D.; Huang, H.; Dankberg, J.; Rosenfeld, R.; Cocco, M. J.; Li, L.; Brems, D. N.; 
Remmele, R. L., Structure and Stability Changes of Human IgG1 Fc as a Consequence of 
Methionine Oxidation. Biochemistry 2008, 47 (18), 5088-5100. 
100. Nguyen, T. H., Oxidation Degradation of Protein Pharmaceuticals. In Formulation and 
Delivery of Proteins and Peptides, American Chemical Society: 1994; Vol. 567, pp 59-71. 
101. Yokota, H.; Saito, H.; Masuoka, K.; Kaniwa, H.; Shibanuma, T., Reversed phase HPLC of 
Met58 oxidized rhIL-11: oxidation enhanced by plastic tubes. Journal of Pharmaceutical and 
Biomedical Analysis 2000, 24 (2), 317-324. 
102. ER, S., Oxidation of Free Amino Acids and Amino Acid Residues in Proteins by Radiolysis 
and by Metal-Catalyzed Reactions. Annual Review of Biochemistry 1993, 62 (1), 797-821. 
103. Hovorka, S. W.; Schöneich, C., Oxidative degradation of pharmaceuticals: Theory, 
mechanisms and inhibition. Journal of Pharmaceutical Sciences 2001, 90 (3), 253-269. 
104. Hawkins, C. L.; Davies, M. J., Generation and propagation of radical reactions on 
proteins. Biochimica et Biophysica Acta (BBA) - Bioenergetics 2001, 1504 (2–3), 196-219. 
105. Davies, M. J., The oxidative environment and protein damage. Biochimica et Biophysica 
Acta (BBA) - Proteins and Proteomics 2005, 1703 (2), 93-109. 
56 
 
106. Griffiths, S. W.; Cooney, C. L., Relationship between Protein Structure and Methionine 
Oxidation in Recombinant Human α1-Antitrypsin. Biochemistry 2002, 41 (20), 6245-6252. 
107. Lu, H. S.; Fausset, P. R.; Narhi, L. O.; Horan, T.; Shinagawa, K.; Shimamoto, G.; Boone, T. 
C., Chemical Modification and Site-Directed Mutagenesis of Methionine Residues in 
Recombinant Human Granulocyte Colony-Stimulating Factor: Effect on Stability and Biological 
Activity. Archives of Biochemistry and Biophysics 1999, 362 (1), 1-11. 
108. Hovorka, S. W.; Hong, J.; Cleland, J. L.; Schöneich, C., Metal‐catalyzed oxidation of 
human growth hormone: Modulation by solvent‐induced changes of protein conformation. 
Journal of Pharmaceutical Sciences 2001, 90 (1), 58-69. 
109. Chelius, D.; Rehder, D. S.; Bondarenko, P. V., Identification and Characterization of 
Deamidation Sites in the Conserved Regions of Human Immunoglobulin Gamma Antibodies. 
Analytical Chemistry 2005, 77 (18), 6004-6011. 
110. Kossiakoff, A., Tertiary structure is a principal determinant to protein deamidation. 
Science 1988, 240 (4849), 191-194. 
111. Xie, M.; Shahrokh, Z.; Kadkhodayan, M.; Henzel, W. J.; Powell, M. F.; Borchardt, R. T.; 
Schowen, R. L., Asparagine deamidation in recombinant human lymphotoxin: Hindrance by 
three-dimensional structures. Journal of Pharmaceutical Sciences 2003, 92 (4), 869-880. 
57 
 
112. DeLuna, A.; Quezada, H.; Gómez-Puyou, A.; González, A., Asparaginyl deamidation in 
two glutamate dehydrogenase isoenzymes from Saccharomyces cerevisiae. Biochemical and 
Biophysical Research Communications 2005, 328 (4), 1083-1090. 
113. Liu, H.; Gaza-Bulseco, G.; Sun, J., Characterization of the stability of a fully human 
monoclonal IgG after prolonged incubation at elevated temperature. Journal of 
Chromatography B 2006, 837 (1–2), 35-43. 
114. Yan, B.; Valliere-Douglass, J.; Brady, L.; Steen, S.; Han, M.; Pace, D.; Elliott, S.; Yates, Z.; 
Han, Y.; Balland, A.; Wang, W.; Pettit, D., Analysis of post-translational modifications in 
recombinant monoclonal antibody IgG1 by reversed-phase liquid chromatography/mass 
spectrometry. Journal of Chromatography A 2007, 1164 (1–2), 153-161. 
115. Mozziconacci, O.; Okbazghi, S.; More, A. S.; Volkin, D. B.; Tolbert, T.; Schöneich, C., 
Comparative evaluation of the chemical stability of four well-defined IgG1 Fc glycoforms. 
Journal of Pharmaceutical Sciences. 
116. Kennedy, D. M.; Skillen, A. W.; Self, C. H., Glycation of monoclonal antibodies impairs 
their ability to bind antigen. Clinical and Experimental Immunology 1994, 98 (2), 245-251. 
117. Quan, C.; Alcala, E.; Petkovska, I.; Matthews, D.; Canova-Davis, E.; Taticek, R.; Ma, S., A 
study in glycation of a therapeutic recombinant humanized monoclonal antibody: Where it is, 
58 
 
how it got there, and how it affects charge-based behavior. Analytical Biochemistry 2008, 373 
(2), 179-191. 
118. Zhang, B.; Yang, Y.; Yuk, I.; Pai, R.; McKay, P.; Eigenbrot, C.; Dennis, M.; Katta, V.; 
Francissen, K. C., Unveiling a Glycation Hot Spot in a Recombinant Humanized Monoclonal 
Antibody. Analytical Chemistry 2008, 80 (7), 2379-2390. 
119. Morales, A. A. M.; Núñez-Gandolff, G.; Pérez, N. P.; Véliz, B. C.; Caballero-Torres, I.; 
Ducongé, J.; Fernández, E.; Crespo, F. Z.; Veloso, A.; Iznaga-Escobar, N., Freeze-dried 
formulation for direct 99mTc-labeling ior-egf/r3 MAb: additives, biodistribution, and stability. 
Nuclear Medicine and Biology 1999, 26 (6), 717-723. 
120. Kamat MS, T. G., Brown JM, Formulation development of an antifibrin monoclonal 
antibody radiopharmaceutical. Pharm Biotechnol Pharm Biotechnol. 1996;9:343-64, 9, 343-64. 
121. W. Jiskoot, E. C. B., A.A. de Koning, J.N. Herron, D.J., Analytical approaches to the study 
of monoclonal antibody stability. Pharm Res 1990, 7 (12). 
122. Usami, A.; Ohtsu, A.; Takahama, S.; Fujii, T., The effect of pH, hydrogen peroxide and 
temperature on the stability of human monoclonal antibody. Journal of Pharmaceutical and 
Biomedical Analysis 1996, 14 (8–10), 1133-1140. 
59 
 
123. Cleland, J. L.; Lam, X.; Kendrick, B.; Yang, J.; Yang, T. h.; Overcashier, D.; Brooks, D.; Hsu, 
C.; Carpenter, J. F., A specific molar ratio of stabilizer to protein is required for storage stability 
of a lyophilized monoclonal antibody. Journal of Pharmaceutical Sciences 2001, 90 (3), 310-321. 
124. Harris, R. J.; Kabakoff, B.; Macchi, F. D.; Shen, F. J.; Kwong, M.; Andya, J. D.; Shire, S. J.; 
Bjork, N.; Totpal, K.; Chen, A. B., Identification of multiple sources of charge heterogeneity in a 
recombinant antibody. Journal of Chromatography B: Biomedical Sciences and Applications 
2001, 752 (2), 233-245. 
125. Cacia, J.; Keck, R.; Presta, L. G.; Frenz, J., Isomerization of an Aspartic Acid Residue in the 
Complementarity-Determining Regions of a Recombinant Antibody to Human IgE:  
Identification and Effect on Binding Affinity. Biochemistry 1996, 35 (6), 1897-1903. 
126. Lam, X. M.; Oeswein, J. Q.; Ongpipattanakul, B.; Shahrokh, Z.; Wang, S. X.; Weissburg, R. 
P.; Wong, R. L., Stabilized antibody formulation. Google Patents: 2008. 
127. Johnson, R. E.; Qi, H.; Borgmeyer, J. R.; Kessler, R. K.; Zeng, D. L., Stable ph optimized 
formulation of a modified antibody. Google Patents: 2004. 
128. Amphlett G, C. J., Callahan W, Cannova-Davis E, Chang B, Cleland JL, Darrington T, 
DeYoung L, Dhingra B, Everett R, Foster L, Frenz J, Garcia A, Giltinan D, Gitlin G, Gombotz W, 
Hageman M, Harris R, Heller D, Herman A, Hershenson S, Hora M, Ingram R, Janes S, Watanabe 
C, A compendium and hydropathy/flexibility analysis of common reactive sites in proteins: 
60 
 
reactivity at Asn, Asp, Gln, and Met motifs in neutral pH solution. Pharm Biotechnol 1996, 9, 1-
140. 
129. Waterman, K. C.; Adami, R. C., Accelerated aging: Prediction of chemical stability of 
pharmaceuticals. International Journal of Pharmaceutics 2005, 293 (1–2), 101-125. 
130. Roberts, C. J., Kinetics of Irreversible Protein Aggregation:  Analysis of Extended 
Lumry−Eyring Models and Implications for Predicting Protein Shelf Life. The Journal of Physical 
Chemistry B 2003, 107 (5), 1194-1207. 
131. Stamper, G. F.; Lambert, W. J., Accelerated Stability Testing of Proteins and Peptides: 
pH-Stability Profile of Insulinotropin Using Traditional Arrhenius and Non-Linear Fitting Analysis. 
Drug Development and Industrial Pharmacy 1995, 21 (13), 1503-1511. 
132. Goldberg, D. S.; Bishop, S. M.; Shah, A. U.; Sathish, H. A., Formulation Development of 
Therapeutic Monoclonal Antibodies Using High-Throughput Fluorescence and Static Light 
Scattering Techniques: Role of Conformational and Colloidal Stability. Journal of Pharmaceutical 
Sciences 2011, 100 (4), 1306-1315. 
133. Sahin, E.; Jordan, J. L.; Spatara, M. L.; Naranjo, A.; Costanzo, J. A.; Weiss, W. F.; 
Robinson, A. S.; Fernandez, E. J.; Roberts, C. J., Computational Design and Biophysical 
Characterization of Aggregation-Resistant Point Mutations for γD Crystallin Illustrate a Balance 
61 
 
of Conformational Stability and Intrinsic Aggregation Propensity. Biochemistry 2011, 50 (5), 
628-639. 
134. Krapp, S.; Mimura, Y.; Jefferis, R.; Huber, R.; Sondermann, P., Structural Analysis of 
Human IgG-Fc Glycoforms Reveals a Correlation Between Glycosylation and Structural Integrity. 




Chapter 2  
Production, Characterization, and Biological Evaluation of Well-Defined IgG1 





Protein therapeutics are inherently structurally complex biological drugs whose active 
components are not a single, well-defined molecule, but a mixture of similar molecules which 
can differ by type and extent of post-translational modification,1-5 chemical modifications,6-11 and 
three-dimensional conformations.12-13 In addition, batch to batch variation of active components 
and production impurities can further complicate defining of the analytical characteristics of a 
protein drug.14 Because of this, the assessment of protein therapeutics in comparability studies 
or in the regulatory approval of biosimilars is not just a simple exercise in confirming the chemical 
structure of a single active chemical entity in the presence of excipients. Instead, the primary and 
higher order structures, physicochemical properties, and biological activities of the protein 
therapeutics must be analyzed. Often, even after extensive study, the relationship between 
safety and efficacy of a protein therapeutic and these analytical tests is not entirely clear because 
of the complexity of the mixtures in protein therapeutics and biological systems involved. In an 
effort to better understand how in-vitro analytical tests can be utilized to determine similarity in 
biosimilar studies and analysis assessments, we have developed a series of well-defined IgG1 Fc 
glycoforms as a model system. The use of a series of well-defined glycoproteins in these studies 
should enable identification of important structural and biological features for comparability and 
biosimilarity exercise.  
 A series of IgG1 Fc glycoforms were chosen as the protein model system for biosimilarity 
analysis because as a fragment of full-length IgG1 it is a simpler system to study but contains the 
CH2 and CH3 constant domains which are present in all human IgG1 based mAb therapeutics. The 
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Fc region is critical to antibody function in that it mediates effector functions such as antibody-
dependent cellular cytotoxicity (ADCC)15-24 and complement dependent cytotoxicity (CDC)25-27. 
The Fc region of an IgG1 is also important in antibody clearance because binding of the Fc region 
to the neonatal Fc receptor (FcRn) increases in-vivo half-life28-31. Also, N-linked glycosylation at 
asparagine 297 (N297) in the Fc region is known to modulate the biological activity19, 32-39 and 
physical properties of IgG1 Fc,1, 32, 40-48 and this can be used to establish similarities and 
differences between the members of this model system. A series of sequentially truncated 
glycoforms of IgG1 Fc (Figure 1), which differ only in the size of the N-linked glycan at N297 or a 
single conservative amino acid mutation (N297Q), were chosen as a model system. Previous 
studies have indicated that these glycoforms would display a range of biological activities and 
physical properties1, 32, 45 that would be advantageous for our biosimilarity studies.  
It was first necessary to develop laboratory production methods to produce sufficient 
quantities (≈100 mg each) of the well-defined IgG1 Fc glycoforms to conduct the wide range of 
analytical tests necessary for biosimilarity analysis. Presented here are the methods established 
to produce the glycoforms shown in Figure 1 through yeast expression, purification, and in-vitro 
enzymatic synthesis. Also presented in this work is the initial biochemical characterization of 
these glycoforms, the development of binding assays for IgG1 Fc binding to an Fc receptor using 
biolayer interferometry (BLI), and determination of the affinity of the different IgG1 Fc 






2.2 Materials and Methods 
2.2.1 Materials 
 Yeast nitrogen base (YNB) was obtained from Sunrise Biosciences, and BactoTM Tryptone 
and Yeast Extract was purchased from Becton Dickinson and Company (Franklin Lakes, NJ). 
Antifoam 204 was obtained from Sigma-Aldrich (St. Louis, MO). Certified ACS grade crystalline 
sucrose was purchased from Fisher Scientific (Pittsburg, PA). Boc-triglycine was supplied by 
Bachem Americas, Inc. (Torrance, CA). The enzymes PNGase F, Sortase, and B. thetaiotaomicron 
-1,2-mannosidase (BT3990, B.t. -1,2-mannosidase) were produced in-house.49-52 
Endoglycosidase H and restriction enzymes were obtained from New England Biolabs (Ipswich, 
MA). Protein G resin was produced by coupling protein G (recombinantly expressed in E. coli)53 
with Sepharose® CL-4B (Sigma-Aldrich, St Louis, MO) using divinyl sulfone as a coupling reagent.54 
General chemicals were purchased from Sigma-Aldrich and Fisher Scientific unless otherwise 
noted. 
2.2.2 Production and Initial Characterization of IgG1 Fc Glycoforms 
2.2.2.1 Expression of High-mannose IgG1 Fc (HM-Fc) 
 HM-Fc was expressed in a glycosylation-deficient strain of P. pastoris (an OCH1 and PNO1 
deleted, IgG1 Fc expressing, SMD1168 strain of P. pastoris produced by Xiao et.al.55 was utilized) 
using glycerol (growth phase) and methanol (induction phase) as carbon sources in a NBS BioFlo 
415 fermenter (Eppendorf). The starter culture (2 mL) was allowed to grow at 25°C for about 72 
hrs in YPD media (1% yeast extract, 2% peptone, 5% glucose and zeocin 100 µg/mL). This starter 
culture was then inoculated into 250 mL of YPD media in a baffled shake flask and incubated for 
about 72 hrs. Before inoculation with the starter culture, the fermenter was filled with 7 liters of 
fermentation basal salts medium (BSM).56 The components of BSM per liter are 26.7 mL 85% 
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phosphoric acid, 18.2 g potassium sulfate, 0.93 g calcium sulfate, 14.9 g magnesium sulphate 
heptahydrate, 4.13 g potassium hydroxide, and 40.0 g glycerol. Finally, water was added to the 
appropriate volume and the fermentation media was sterilized. After sterilization and cooling, 
the temperature was adjusted to 30°C and the pH of the BSM medium was adjusted to 6 with 
28% Ammonium hydroxide. Next, PTM156 trace salts solution was prepared by mixing the 
following components (per L):  6.0 g copper sulfate pentahydrate, 0.08 g sodium Iodide, 3.0 g 
manganese sulfate monohydrate, 0.2 g  Sodium Molybdate dihydrate, 0.02 g boric acid, 0.5 g 
cobalt(II) chloride, 20.0 g zinc chloride, 65.0 g Iron(II) sulfate heptahydrate, 0.2 g biotin and 5.0 
mL sulfuric acid. This step was followed by adding 4.31 mL of filter-sterilized PTM1 trace salts/liter 
of BSM. Next, the dense 250 mL starter culture media was added into the fermentor. The culture 
media was allowed to grow until the batch glycerol was consumed, and an additional 300 mL of 
glycerol were then added to increase the total cell biomass. Dissolved oxygen was kept ≥ 30% 
throughout the fermentation processes. Once the added glycerol was consumed and the desired 
cell biomass was attained, a 100% methanol feeding was initiated to induce the AOX1 promoter 
for IgG1 Fc expression. The temperature was reduced to 25°C for optimal IgG1 Fc expression prior 
to induction. Methanol induction was continued for approximately 72 hours. The resulting yeast 
suspension was pelleted by centrifugation at 12,390 x g for 20 min, and the supernatant was 
collected. Using this procedure, the amount of HM-Fc obtained after protein G affinity 
purification was approximately 50 mg/L. Four 7 liter fermentations were conducted to produce 
sufficient HM-Fc to develop the in-vitro enzymatic synthesis used to make the Man5-Fc and 
GlcNAc-Fc glycoforms, and to generate material for the subsequent experiments described in this 
and the accompanying papers. 
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2.2.2.2 Expression of Non-Glycosylated Mutant N297Q-IgG1 Fc (N297Q-Fc) 
 Spinner flask expression was utilized for the production of N297Q-Fc in a glycosylation-
deficient strain of SMD1168 P. pastoris (Clone produced in previous study1) as follows. A starter 
culture of 2 mL was inoculated in YPD that contained 100 µg/mL Zeocin. This culture media was 
incubated at 25 °C for 72 hrs. The 2 mL culture was then used to inoculate a 50 mL of YPD/Zeocin 
culture, which was incubated with shaking at 25°C for 72 hrs.  The 50 mL culture was then used 
to inoculate 1 L of Buffered Glycerol-complex Media (BMGY)57 containing 0.00004% biotin and 
0.004% histidine. After 48 hours, when the initial glycerol carbon source was metabolized, 
N297Q-Fc expression was induced by methanol feeding to a final concentration of 1% (by 
addition of 50 mL of 20% methanol every 24 hrs.) for about 72 hrs. The same protocol used for 
harvesting HM-Fc was applied for harvesting of the N297Q-Fc supernatant. Using this procedure, 
the amount of N297Q-Fc obtained after protein G affinity purification was about 20 mg/L. A total 
of seven 1 L spinner flasks were grown to produce the 130 mg of N297Q-Fc used in the research 
described in this and the accompanying papers. 
2.2.2.3 Purification of IgG1 Fc 
 Both HM- and N297Q-IgG1 Fc were purified using the same general procedure given 
below. The supernatant collected from yeast expression was filtered with 0.5 µm filter pads 
(Buon Vino Manufacturing) to remove particulates prior to protein G affinity chromatography. 
The protein G column (20 mL bed volume) was equilibrated with 20 mM potassium phosphate 
pH 6.0 in 10 column bed volumes (CV) and loaded with the filtered supernatant at pH 6.0. The 
column was subsequently washed with 20 mM potassium phosphate buffer, pH 6.0, containing 
0.5 M NaCl (5 CV) and then 20 mM potassium phosphate buffer, pH 6.0, (5 CV). IgG1 Fc was eluted 
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using 100 mM glycine at pH 2.7. Eluted protein was collected in 20 mL fractions into tubes 
containing 4 mL of 1 M Tris pH 9.0  (200 µL of 1 M Tris pH 9.0 per mL of elution volume) to 
neutralize the acidic elution buffer. Fractions of eluted protein detected by UV absorbance at 280 
nm were immediately dialyzed in 20 mM sodium phosphate buffer pH 7.0. HIC purification using 
phenyl sepharose™ high-performance resin (GE Healthcare) with a 125 mL column bed volume 
(packed in-house) and an ÄKTAmicro chromatographic system (GE Healthcare) were utilized to 
further purify the IgG1 Fc forms. The phenyl sepharose column was pre-equilibrated with Buffer 
A (20 mM sodium phosphate, pH 7.0, containing 1M ammonium sulfate) for 5 CV. The protein G 
purified IgG1 Fc was dialyzed in buffer A and then loaded onto the phenyl sepharose column with 
a loading volume of 50 mL (concentration, 1 mg/mL). The chromatographic separation was then 
conducted with three gradient segments from 0 to 50% buffer B (20 mM sodium phosphate, pH 
7.0): gradient segment 1 (0-25% B, 3.5 CV), gradient segment 2 (25-30% B, 2.6 CV), and gradient 
segment 3 (30-50% B, 6.7 CV). Collected fractions (10 mL) were analyzed by SDS-PAGE and mass 
spectrometry to check for purity and identity. Pure fractions were finally pooled and dialyzed in 
storage buffer (10% sucrose, 20 mM histidine pH 6.0) and frozen at -80˚C in aliquots. The final 
collected sample pool was analyzed by SEC, SDS-PAGE, mass spectrometry, and cIEF 
characterization to confirm overall purity and quality. Samples containing pure fractions were 
concentrated to 0.2 mg/mL using Vivaflow 50, (10,000 MWCO, Sartorius Stedim Biotech). Using 
this procedure, approximately 445 mg of the HM-Fc glycoform and 118 mg of the N297Q-Fc non-
glycosylated mutant were produced for use in synthesis of other glycoforms and biosimilar 




2.2.2.4 In-Vitro Enzymatic Synthesis of the Man5-IgG1 Fc Glycoform (Man5-Fc) 
 HM-IgG1 Fc was converted to Man5-IgG1 Fc in an in-vitro enzymatic reaction using B.t. 
-1,2-mannosidase (BT3990).51-52 It was found that the B.t. -1,2-mannosidase used in this study 
had very low activity in the IgG1 Fc sample storage buffer which contained 10% (w/v) sucrose 
and 20 mM histidine buffer at pH 6.0. Because of this, prior to the reaction HM-Fc (125 mg) was 
dialyzed extensively in 10 mM MES buffer pH 6.6 to remove the sucrose and histidine. Next, HM-
Fc was dialyzed in a reaction buffer containing 5 mM CaCl2, 150 mM NaCl, and 10 mM MES buffer 
pH 6.6 for 12 hrs. After dialysis the enzymatic reaction was started by adding 6.7 mg of the 
bacterial -1,2-Mannosidase (BT3990). The reaction was incubated at room temperature for 48 
hrs. The progress of the reaction was monitored by mass spectrometry, and the percentage of 
conversion to the Man5-Fc glycoform was estimated from the peak intensity (Table 2).  Finally, 
the reaction mixture was purified using protein G affinity chromatography to remove unwanted 
impurities and excess enzyme using the same protocol as described in the purification of IgG1 Fc 
section above.  The amount of Man5-Fc produced was 75 mg (60% yield), and the percentage of 
Man5-Fc in the final product was estimated to be 78% by mass spectrometry. 
2.2.2.5 In-Vitro Enzymatic Synthesis of the GlcNAc-IgG1 Fc Glycoform (GlcNAc-Fc) 
 HM-IgG1 Fc was converted to the GlcNAc-IgG1 Fc glycoform using endoglycosidase H 
(Endo H). Endo H displayed full activity in the IgG1 Fc storage buffer (10 % (w/v) sucrose, 20 mM 
histidine pH 6.0). Therefore, it was possible to digest HM-IgG1 Fc directly without a dialysis step. 
HM-IgG1 Fc (100 mg) at a concentration of 0.2 mg/mL was incubated with Endo H (for every 1 
mg of HM-IgG1 Fc, 1000 U of Endo H enzyme were added, which corresponds to approximately 
0.1 mg of Endo H per 100 mg HM-Fc) at room temperature for 24 hrs. The progress of the reaction 
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was monitored by SDS-PAGE and mass spectrometry. The sample was analyzed by mass-
spectrometry which showed a nearly quantitative reaction with the percentage of GlcNAc-Fc in 
the final product ≥99%.  
2.2.2.6 LC-MS analysis IgG1 Fc glycoforms 
 Samples of IgG1 Fc glycoforms at a concentration of 0.2 mg/mL were first reduced with 
10 mM dithiothreitol (DTT, Invitrogen) and then 30 µL were injected into the mobile phase of the 
LC. ESI spectra of the reduced samples were acquired on a Agilent 6520 Quadrupole Time-of-
Flight (Q-TOF) system. The instrument was operated in positive ion mode, and a spectrum was 
acquired covering the mass range from 300-3000 m/z with an acquisition rate of 1 
spectra/second. The samples were desalted on a reverse phase C4 column, 50 mm, 4.6 mm I.D. 
(Vydac 214 MS, 300 A pore size, 5 µm particle size) using a Agilent 1200 series Liquid 
Chromatography system. The solvents used were A (99.9% H2O, 0.08% formic acid, 0.02% 
trifluoroacetic acid (TFA) and B (99.9% acetonitrile, 0.08% formic acid, 0.02% TFA). A gradient 
was developed from 5% B to 90% B in 7 min with a flow rate of 0.5 mL/min. Data was collected 
using Agilent MassHunter Acquisition software (Version B.02.00). Protein MW was calculated 
using the Maximum Entropy Deconvolution function and associated peak intensities of the IgG1 
Fc glycoforms were obtained using Agilent MassHunter Qualitative Analysis software (Version 
B.03.01). 
2.2.2.7 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 For the reduced samples, each of the IgG1 Fc glycoforms (20 µg) were mixed with 2X 
TrisHCl SDS loading dye containing 100 mM DTT and incubated at 80 °C for 2 min.  The reduced 
IgG1 Fc samples were then separated by sodium dodecyl sulfate-polyacrylamide gel 
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electrophoresis using NuPAGE 4-12% Bis-Tris gradient gel (Life Technologies, Grand Island, NY) 
gels and a MES running buffer (Life Technologies). A similar method was followed for non-
reduced samples of IgG1 Fc proteins except DTT was omitted during the incubation step. The 
running time for all the gels was 60 min at 150 V. Protein bands were visualized by staining with 
Coomassie blue R250 (Teknova, Hollister, CA) and destained with a mixture of 30% methanol, 
10% acetic acid, and 60% ultrapure water. Gel images were recorded using an Alphaimager 
(Protein Simple, Santa Clara, CA) gel imaging system.   
2.2.2.8 Size Exclusion High-Performance Liquid Chromatography (SEC) 
 Experiments were performed using a Shimadzu high-performance liquid 
chromatography system equipped with a temperature controlled auto sampler and a photodiode 
array detector capable of recording UV absorbance spectra from 200−400 nm. A Tosoh TSK-Gel 
Bioassist G3SWXL column (7.8 mm ID x 30.0 cm L) and a corresponding guard column (TOSOH 
Biosciences, King of Prussia, Pennsylvania) were used for IgG1 Fc glycoform characterization. 
First, the SEC column was equilibrated for at least 10 CV with a mobile phase containing 200 mM 
sodium phosphate, pH 6.8 and a flow rate of 0.7 mL/min at 30 °C column temperature. Next, the 
column was calibrated using gel filtration molecular weight standards (Bio-Rad, Hercules, CA) 
before and after the runs of IgG1 Fc glycoform to ensure column and HPLC system integrity. All 
Fc samples were centrifuged at 14,000 g for 5 min before injection to remove insoluble protein 
aggregates. Protein samples at a concentration of 1 mg/mL were injected in a volume of 25 µL, 
and a 30 min. run time was used for elution. Peaks quantification was carried out using LC 
solutions software (Shimadzu, Kyoto, Japan). The error bars for monomer content for all the four 
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IgG1 Fc samples and soluble dimer aggregates (observed in N297Q IgG1 Fc) represent standard 
deviation (SD) of triplicate measurements.58,59 
2.2.2.9 Capillary Isoelectric Focusing (cIEF) 
The determination of isoelectric points (pIs) of all the IgG1 Fc glycoforms using capillary 
isoelectric focusing (cIEF) were performed with an iCE280 analyzer from Convergent Biosciences 
(now Protein Simple, Toronto, Canada) equipped with a microinjector. A FC Cartridge (Protein 
Simple, Toronto, Canada) with 50 mm, 100 µm I.D. fluorocarbon-coated capillary and built-in 
electrolyte tanks was used for focusing. The cartridge was calibrated by a hemoglobin standard 
(Protein Simple, Toronto, Canada) before and after focusing of IgG1 Fc samples to ensure its 
integrity. For focusing, a sample mixture was prepared where each of the IgG1 Fc glycoforms 
were mixed with urea (Fischer Scientific), methyl cellulose (Protein Simple, Toronto, Canada), 
sucrose (Pfanstiehl Inc., Waukegan, IL), N,N,N',N'-Tetramethylethane-1,2-diamine (Sigma-
Aldrich, St Louis, MO) and Pharmalyte 3–10 (GE Healthcare Biosciences, Pittsburgh, PA). The final 
protein concentration in the sample mixture was 0.2 mg/mL. All the IgG1 Fc glycoforms were 
resolved using a pre-focusing time of 1 minute at 1500 V and a focusing time of 12,12,7.5 and 7 
min. was used for HM-Fc, N297Q-Fc, GlcNAc-IgG1Fc, and Man5-Fc, respectively at 3000 V. 
Observed peaks were calibrated using two pI markers with values of 5.84 and 8.18. The 
separation was monitored at 280 nm by a CCD detector. Quantitation of the peaks was done 
using Chromperfect® software. The error bars for pI values of all the four IgG1 Fc samples 






2.2.2.10 Experimental Procedures for Synthesis of GGG-linker-Biotin (3) 
Synthesis of tert-butyl (22-amino-2,5,8-trioxo-13,16,19-trioxa-3,6,9-triazadocosyl) 
carbamate (1). Boc-triglycine (0.145 g, 0.50 mmol) and N-hydroxy-succinimide (0.079 g, 0.50 
mmol) were dissolved in 5 mL DMF followed by the addition of solution of DCC (0.134 g, 0.65 
mmol). After being stirred on room temperature with N2 protection overnight, the mixture was 
filtered and the filtrate was slowly added to the solution of 4,7,10-Trioxa-1,13-tridecanediamine 
(0.55 mL, 2.5 mmol). The reaction proceeded at room temperature for 5h. Removal of the solvent 
under reduced pressure followed by purification of the resulting residue through a silica flash 
column using EtOAc: MeOH 3:1 and then MeOH as the eluting solvents led to the desired 
compound (1) in a yield of 90 % (0.221 g). 1H-NMR (MeOD, 400 MHz): δ = 3.91 (s, 2H), 3.85 (s, 
2H), 3.76 (s, 2H), 3.66-3.64 (m, 5H), 3.61-3.58 (m, 7H), 3.31 (t, J = 7.1 Hz, 2H), 2.81 (t, J = 6.5 Hz, 
2H), 1.81-1.77 (m, 4H), 1.47 (s, 9H); 13C-NMR (MeOD, 100 MHz): δ =24.6, 27.3(x3), 28.9, 36.5, 
38.7, 42.1, 68.3, 68.4, 69.0, 69.7, 69.8,69.9, 70.0, 170.0, 170.1, 170.9, 172.3; HRMS (ESI) Calcd for 
C21H41N5O8Na (M + Na)+ : 514.2853; Found: 514.2849. 
Synthesis of tert-butyl(2,5,8,24-tetraoxo-28-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)-13,16,19-trioxa3,6,9,23-tetraazaoctacosyl) carbamate (2). Biotin (0.122 g, 0.50 
mmol) and N-hydroxy-succinimide (0.079 g, 0.50 mmol) were dissolved in 5 mL DMF followed by 
the addition of solution of DCC (0.134 g, 0.65 mmol). After being stirred at room temperature 
with N2 protection overnight, the mixture was filtered and the filtrate was slowly added to the 
solution of compound 1 (0.221 g, 0.45 mmol). The reaction proceeded at room temperature for 
2hrs. Removal of the solvent under reduced pressure followed by purification of the resulting 
residue through a silica flash column using EtOAc: MeOH 4:1 as the eluting solvent led to the 
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desired compound (2) in a yield of 80 % (0.258 g). 1H-NMR (MeOD, 400 MHz): δ = 4.50 (dd, J = 
7.8, 4.7 Hz, 1H), 4.50 (dd, J = 7.8, 4.4 Hz, 1H), 3.91 (s, 2H), 3.85 (s, 2H), 3.77 (s, 2H), 3.67-3.65 (m, 
4H), 3.62-3.60 (m, 4H), 3.54 (t, J = 5.7 Hz, 4H), 3.33 (t, J = 7.4 Hz, 2H), 3.23-3.23 (m, 1H), 2.94 (dd, 
J = 12.8, 5.0 Hz, 1H ), 2.72 (d, J = 12.7 Hz, 1H), 2.30 (t, J = 7.4 Hz, 2H), 2.03-1.61 (m, 8H), 1.52-1.47 
(overlap, 11H); 13C-NMR (MeOD, 100 MHz): δ =24.3, 24.5, 24.7, 24.9(x3), 25.3, 26.8, 27.3, 27.9, 
28.0, 28.3, 28.6, 30.6, 33.2, 33.4, 39.6, 47.0, 48.3, 50.6, 50.9, 55.5, 55.6, 164.7, 170.0, 173.5 
(overlap), 174.5; HRMS (ESI) Calcd for C31H55N7O10SNa (M + Na)+ : 740.3629; Found: 740.3627. 
Synthesis of N-(1-amino-2,5,8-trioxo-13,16,19-trioxa-3,6,9-triazadocosan-22-yl)-5-(2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (3). Compound 2 (0.255 g, 0.355 
mmol) was dissolved in 1 mL 95% TFA. After 30 min., 2 mL toluene was added to the solution. 
Removal of the solvent under reduced pressure led to the desired compound 3, also referred to 
as GGG-linker-Biotin, in a yield of around 100 % (0.220 g). 1H-NMR (MeOD, 500 MHz): δ = 4.52 
(dd, J = 7.8, 4.7 Hz, 1H), 4.33 (dd, J = 7.8, 4.4 Hz, 1H), 3.99 (s, 2H), 3.87 (s, 2H), 3.79 (s, 2H), 3.67-
3.65 (m, 4H), 3.62-3.60 (m, 4H), 3.54 (t, J = 5.7 Hz, 4H), 3.26 (t, J = 7.4 Hz, 2H), 3.23-3.20 (m, 1H), 
2.95 (dd, J = 12.8, 5.0 Hz, 1H ), 2.72 (d, J = 12.7 Hz, 1H), 2.27 (t, J = 7.4 Hz, 2H), 2.03-1.61 (m, 8H), 
1.52-1.46 (overlap, 11H); 13C-NMR (MeOD, 125 MHz): δ =25.5, 26.8, 28.4, 29.0, 35.2, 36.4, 43.5, 













2.2.2.11 FcRIIIa Binding Assays 
Production of a P. pastoris strain for Expression of Fc  receptor IIIa with a C-terminal 
sortase/histidine tag (FcRIIIa-ST-H6). The soluble region of the V158 polymorph of human 
FcRIIIa was PCR-amplified from pPICzA-FcRIIIa55 using primers (forward 5’-
ggcgccgaattcaaaagaatgcggactgaagatctc and reverse 
5'gccgcgcgcgcggccgcttaatgatgatggtggtggtgtccacctccagtttctggcaatccaccaccttgagtgatggtgatgttcac) 
that added a sortase recognition site (ST) and hexahistidine tag (H6) to the 3’ end of the amplified 
FcRIIIa DNA. The FcRIIIa-ST-H6 PCR product was inserted into the methanol-inducible Pichia 
expression vector pPICzA (Invitrogen, Carlsbad, CA) using the restriction sites EcoR I and Not I. 
The pPICzA-FcRIIIa-ST-H6 construct was confirmed by DNA sequencing, linearized using Sac I, 
and transformed into P. pastoris OCH1 deleted cells.55 Ten colonies were screened for levels of 
secreted FcRIIIa-ST-H6 expression by growing the colonies in 2 mL culture tubes containing 
BMGY57 media +100 µg/mL Zeocin 100 U at 25°C and 250 rpm. Once they reached density, 0.5% 
(v/v) methanol was added once per day for three days. Relative levels of FcRIIIa-ST-H6 in the 
media was determined by a dot blot using a mouse Anti-H6 primary antibody (Thermo Scientific, 
Rockford, IL) followed by a goat Anti-mouse IgG secondary antibody conjugated with alkaline 
phosphatase (Thermo Scientific, Rockford, IL). The colony that expressed the highest level of 
FcRIIIa-ST-H6 was selected for 1 L spinner flask expression.  
2.2.2.12 Expression and Purification of FcRIIIa-H6  and FcRIIIa-ST-H6 
 FcRIIIa-H6 and FcRIIIa-ST-H6  were expressed in glycosylation-deficient P. pastoris, and 
Ni+2-NTA was used as described previously by Xiao et al.55 After Ni+2-NTA purification, 
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approximately 30 mg/L of each receptor was obtained. The receptors were then further purified 
using hydrophobic interaction chromatography. A Hiprep™ Phenyl FF (high sub) 16/10 column 
with a 20 mL bed volume was utilized with an ÄKTAmicro (GE Healthcare) to accomplish this. The 
column was pre-equilibrated with buffer A (1.5 M Ammonium sulfate,100 mM sodium phosphate 
for 10 CV) prior to loading. The Ni+2-NTA purified receptors were first dialyzed in 100 mM sodium 
phosphate pH 7.0 buffer for 12 hrs and then adjusted with ammonium sulfate to a final 
concentration of 1.5 M. The receptors, in 10 mg portions, were loaded onto the column with a 
loading volume of 5 mL. Due to the capacity of the column, 3 columns were necessary to purify 
all 30 mg of receptor obtained from Ni+2-NTA chromatography. The chromatographic separation 
involves three segments from 0 to 100% B (100 mM sodium phosphate pH 7.0): gradient segment 
1 (0-25% B, 15 CV), gradient segment 2 (25-33% B, 15 CV), and gradient segment 3 (33-100% B, 
12 CV). Collected fractions (5 mL) were characterized using SDS-PAGE to check for purity. Samples 
containing pure receptor were concentrated to 1 mg/mL using Vivaflow 50, (10,000 MWCO, 
Sartorius Stedim Biotech) and the amount obtained after purification for each receptor was 
approximately 18 mg/L. 
2.2.2.13 Biotinylation of FcRIIIa-ST-H6 
Purified FcRIIIa-ST-H6 was extensively dialyzed in 50 mM Tris-hydrochloride pH 7.5. Next, 
this receptor was dialyzed in a reaction buffer containing 50 mM Tris-hydrochloride pH 7.5, 150 
mM sodium chloride. The sortase-mediated ligation reaction was carried out using a mixture 
containing 10 µM FcRIIIa-ST-H6, 6 mM CaCl2, 1 mM GGG-linker-Biotin (compound 3, Fig. 6) and 
5 µM sortase at room temperature. The reaction was terminated after 24 hours by adding excess 
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EDTA to capture the Ca+2 required for activity of the sortase.  Finally, the receptor was extensively 
dialyzed in PBS buffer to remove the unreacted GGG-linker-Biotin (3). 
2.2.2.14 Analysis of the Interaction of Immobilized IgG1 Fc Glycoforms with 
FcRIIIa using Biolayer Interferometry (BLI) 
 The interactions of the different IgG1 Fc glycoforms with the FcRIIIa-H6 were studied 
with biolayer interferometry using a BLITZ instrument (Fortebio, Menlo Park, CA) with protein G 
biosensor tips. Binding studies using this receptor were conducted as follows. The protein G 
biosensor tip was hydrated for 10 min with PBS buffer (150 mM NaCl, 50 mM sodium phosphate 
pH 7.4) and then incubated for 30 min with PBS kinetic buffer (PBS buffer containing 1 mg/mL 
casein as a blocking agent).  Next, an initial baseline (30 sec) was established with PBS kinetics 
buffer and then the protein G biosensor tips were loaded with the IgG1 Fc glycoforms at a 
concentration of 0.88 µM (120 sec) to a response level of 2 nm. A new baseline (30 sec) was then 
established and then the association (180 sec) and dissociation (360 sec) of FcRIIIa-H6 was 
measured by dipping the biosensor into solutions of FcRIIIa-H6 and PBS, respectively. To 
determine the dissociation constant (KD) for the IgG1 Fc glycoforms, a range of FcRIIIa-H6 
concentrations from 50 nM-800 nM were tested for HM-Fc and Man5-Fc. For GlcNAc-Fc, the 
concentration range of FcRIIIa-H6 tested was 200 nM to 1600 nM in two-fold serial dilutions. For 
N297Q-Fc, no binding was observed at 20 µM FcRIIIa-H6, the highest concentration of receptor 
tested. After each assay cycle, the biosensor tip was regenerated using two cycles of 10 mM HCl60 
for 30 sec and each time equilibrated using PBS kinetics buffer for 60 sec Data generated from 
the binding of the receptor to IgG1 Fc glycoforms were collected six times and globally fitted to 





2.2.2.15 Analysis of the Interaction of IgG1 Fc Glycoforms with Immobilized 
FcRIIIa using Biolayer Interferometry (BLI) 
 The interactions of the different IgG1 Fc glycoforms with the FcRIIIa were studied with 
biolayer interferometry using a BLITZ instrument (Fortebio, Menlo Park, CA) with streptavidin 
(SA) biosensor tips. Prior to the binding experiment, IgG1 Fc samples were dialyzed in PBS buffer 
to remove the storage buffer (10% sucrose, 20 mM histidine, pH 6.0) and to adjust the pH to 7.4. 
The concentration of the samples after dialysis was 2.3 µM. Next, a stock solution of each 
glycoform in PBS kinetic buffer (PBS buffer containing 1 mg/mL casein) were prepared by adding 
casein (the stock solution of casein used was 10 mg/mL in PBS buffer), and PBS buffer. For HM-
Fc and Man5-Fc, stock samples with a concentration of 1.6 µM were prepared and then serially 
diluted to prepare samples of 800 nM, 400 nM, 200 nM, 100 nM, and 50 nM concentrations by 
adding PBS kinetics buffer. For subsequent serial dilutions, PBS kinetic buffer containing 1 mg/mL 
of casein was used. Similarly, for GlcNAc-Fc a stock sample with a concentration of 2.0 µM was 
prepared and then used to prepare samples of 1600 nM, 800 nM, 400 nM, and 200 nM, by adding 
PBS kinetic buffer. For N297Q-Fc, after dialysis in PBS buffer, samples were first concentrated to 
25 µM using an Amicon® Ultra-15 Centrifugal Filter Device with a molecular weight cutoff of 10 
kDa (EMD Millipore, Billerica, MA). Next, a solution containing 20 µM of N297Q-Fc in PBS kinetic 
buffer was prepared by dilution with PBS buffer and casein (added from a stock solution of 10 
mg/mL casein in PBS buffer). This final sample concentration of 20 µM N297Q-Fc was then used 
for binding experiments without further dilution. 
After sample preparation, binding studies were conducted as follows. First, the 
streptavidin biosensor tip was hydrated for 10 min with PBS buffer and incubated with PBS kinetic 
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buffer for 30 min. Next, the biotinylated FcRIIIa-ST-H6 (0.1 µM) was immobilized onto the 
streptavidin biosensors to a response level of 0.4 nm and this step was followed by establishing 
an initial baseline (30 sec) with PBS kinetic buffer. Then the association (180 sec) and dissociation( 
360 sec) of the IgG1 Fc glycoforms were measured by dipping the biosensor into solutions of IgG1 
Fc glycoforms and PBS, respectively. After each assay cycle, the biosensor tip was regenerated 
using two cycles of 1 mM NaOH61 for 30 sec and each time equilibrated with  PBS kinetic buffer 
for 60 sec To determine the dissociation constant (KD), the concentration range tested for HM-Fc 
and Man5-Fc in solution were 50 nM to 800 nM in two-fold serial dilutions. The concentrations 
of GlcNAc-Fc tested in solution ranged from 200 nM to 1600 nM in two-fold serial dilutions. For 
N297Q-Fc, no binding was observed with 20 µM N297Q-Fc in solution. Data generated from the 
binding of the receptor to IgG1 Fc glycoforms were collected six times and globally fitted to a 1:1 
binding model and analyzed using BLItz Pro software.  
2.3 Results 
2.3.1 Production and Initial Characterization of the Four Well-Defined IgG1 Fc 
Glycoforms 
2.3.1.1 Expression and Purification of High-Mannose IgG1 Fc (HM-Fc) and Non-
Glycosylated Mutant N297Q-IgG1 Fc (N297Q-Fc) 
 Both HM-Fc and N297Q-Fc were recombinantly expressed in glycosylation-deficient 
strains derived from SMD1168 P. pastoris (Invitrogen, Carlsbad, CA). The expression strains were 
produced as described previously and have the genes OCH1 and PNO1 deleted to reduce the 
formation of higher order mannan structures and the addition of mannose-phosphorylation.55,1 
The resulting yeast strains produce glycoproteins containing human-like high-mannose N-linked 
glycans with some additional heterogeneous -1,2-linked mannose residues added onto an initial 
80 
 
Man8GlcNAc2 structure. Due to the large amount of HM-Fc required for production of the three 
glycosylated forms, HM-Fc, Man5-Fc, and GlcNAc-Fc, the HM-Fc was produced in a 10 liter 
fermentor using basal salts media supplemented with PTM1 trace salts solution. Protein 
expression was induced by methanol addition and yeast were harvested after approximately 3 
days of induction. Compared to HM-Fc, relatively smaller amounts of N297Q-Fc were required 
(since it is not used to produce the other Fc glycoforms). Accordingly, N297Q-Fc was expressed 
in spinner flasks using BMGY media to generate cell mass, and 3 days of methanol induction to 
produce protein prior to harvest similar to the HM-Fc form. Typical yields from this expression 
system for the two IgG Fc proteins are summarized in the next section. 
The same general purification procedure was utilized for both HM-Fc and N297Q-Fc. Yeast 
cells were removed by centrifugation, and the resulting supernatant was filtered through 0.5 µm 
filters to remove remaining particulates prior to chromatography. Secreted IgG1 Fc was then 
isolated by protein G affinity chromatography. The average yield of HM-Fc from fermenter 
growth after protein G affinity chromatography was approximately 50 mg/L. The average yield of 
N297Q-Fc after spinner flask expression was approximately 20 mg/L. After protein G affinity 
chromatography, there are still some residual yeast proteins remaining in both HM-Fc and 
N297Q-Fc. In the case of HM-Fc, incomplete glycosylation of the N297 site in yeast also results in 
microheterogeneity of the glycosylation site.1-2, 55, 62 Because of this, the disulfide bonded HM-Fc 
dimer consists of three forms, a completely non-glycosylated form, a form that has glycosylation 
on only one chain of the dimer (mono-glycosylated), and a form that is glycosylated on both 
chains of the dimer (di-glycosylated). Hydrophobic interaction chromatography (HIC) using 
phenyl sepharose resin was utilized to remove residual yeast impurities for both proteins and to 
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separate the di-glycosylated form of HM-Fc from its mono-glycosylated and non-glycosylated 
forms. Because protein G purified HM-Fc is distributed between three different forms, the yield 
of di-glycosylated HM-Fc from HIC purification is lower than that of N297Q-Fc. Nonetheless, after 
HIC purification 445 mg of HM-Fc and 118 mg of N297Q-Fc were produced for further synthesis 
and studies. Hereafter HM-Fc will refer to the di-glycosylated form of HM-IgG1 Fc obtained from 
yeast. Purified protein samples were pooled, dialyzed in storage buffer (10% sucrose, 20 mM 
histidine pH 6.0), concentrated or diluted to a final concentration of 0.2 mg/mL, and frozen at -
80°C in aliquots for future use.  
2.3.1.2 In-Vitro Enzymatic Synthesis of Man5-IgG1 Fc (Man5-Fc) and GlcNAc-IgG1 
Fc (GlcNAc-Fc) 
 HM-Fc was converted into the Man5-Fc glycoform using B.t. -1,2-mannosidase 
(BT3990).51-52 The outer mannose residues of high-mannose N-linked glycans produced in 
glycosylation-deficient yeast are -1,2-linked to a core of five mannose residues that are -1,3- 
and -1,6-linked to one another and -1,4-linked to the two N-acetylglucosamines attached to 
asparagine. Because of this, digestion the HM-Fc glycoform with a selective -1,2-mannosidase 
will result in the formation of the Man5-Fc glycoform. Unfortunately, initial trial mannosidase 
reactions revealed that the B.t. -1,2-mannosidase had very little activity in the sucrose 
containing storage buffer. Hence, before the reaction the starting material (HM-Fc) was 
extensively dialyzed to remove the storage buffer and exchange it into a buffer the -1,2-
mannosidase had higher activity. Addition of mannosidase (6.7 mg) and incubation at room 
temperature for 2 days resulted in conversion of the HM-Fc into the Man5-Fc glycoform. Protein 
G affinity chromatography was utilized to remove the mannosidase enzyme from Man5-Fc, and 
the protein was dialyzed into storage buffer and adjusted to 0.2 mg/mL concentration. At total 
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of 75 mg of Man5-Fc was produced from 125 mg of HM-Fc starting material. The low yield of 
Man5-Fc is likely due to the many extra dialysis steps and the protein G purification in this 
procedure. 
The enzyme endoglycosidase H (Endo H) was utilized to generate further truncation of 
the high-mannose glycan on HM-Fc. Endo H cleaves at the β-1,4 linkage between the two GlcNAc 
residues attached to asparagine in high-mannose N-linked glycans. This leaves a single GlcNAc 
monosaccharide attached at the glycosylation site (Figure 1). Endo H has high activity in the 
sample storage buffer used to store HM-Fc, and this greatly simplified the production of the 
GlcNAc-Fc glycoform. A small amount ( ≈ 0.1 mg) of Endo H added to 100 mg HM-Fc in storage 
buffer resulted in a quantitative conversion into the GlcNAc-Fc glycoform after incubation at 
room temperature for 24 hours. Since Endo H was active in storage buffer and only a minute 
amount was added, GlcNAc-Fc was utilized without any further purification. Approximately 100 
mg of GlcNAc-Fc was produced from 100 mg of HM-Fc starting material. 
2.3.2 Analytical Characterization of IgG1 Fc Glycoforms 
 Figure 2 shows intact mass spectrometry data of the four glycoforms, HM-Fc, Man5-Fc, 
GlcNAc-Fc, and N297Q-Fc, with their respective expected and observed masses. Since the amino 
acid sequence of HM-Fc, Man5-Fc, and GlcNAc-Fc are identical, the differences in observed 
masses are mainly due to differences in the attached N-linked glycans. For the HM-Fc glycoform, 
glycosylation is heterogeneous with high-mannose forms containing between 8 to 12 mannose 
residues with the major glycoform being the Man8GlcNAc2 form. The predominant forms of the 
truncated Man5-Fc and GlcNAc-Fc glycoforms on the other hand are largely one glycosylation 
state, with estimated abundance of 78% and 99% for the Man5-Fc and GlcNAc-Fc forms 
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respectively based on peak heights (Table 2). The N297Q-Fc form displays a single major peak 
corresponding to the non-glycosylated glutamine mutant as would be expected. 
The four glycoforms were analyzed by SDS-PAGE under reducing and non-reducing 
conditions and the results are shown in Figure 3. Purity was estimated to be ~99% for each 
glycoform and no proteolysis or significant impurities were detected.63 The shift in migration 
between the reduced and non-reduced gels indicate intermolecular disulfide bonds are present 
forming dimers as would be expected in the hinge region. Also, no monomeric IgG1 Fc was 
detected in the non-reduced gel for any glycoform indicating that all of the IgG1 Fc is present in 
the dimerized state. Migration of the different glycoforms in both the reduced and non-reduced 
gels correlates with the size of the N-linked glycans attached, with slower migration occurring for 
forms with larger N-linked glycans.  
Size exclusion chromatography (SEC) was utilized to characterize the size and distribution 
of high-molecular weight species (HMWS) and low molecular weight species (LMWS) which 
potentially could be generated during production and purification of IgG1 Fc glycoforms.  High 
molecular weight species could potentially be covalent aggregates, and low molecular weight 
species are related to fragments from the heavy chains.64-65 Representative SEC chromatograms 
of the IgG1 Fc glycoforms are shown in Figure 4 (also see Table 3). All of the IgG1 Fc proteins 
eluted at ~15 min, which corresponded to a monomer based on the elution pattern of molecular 
weight standards. As illustrated in Figure 4, the results indicate all the IgG1 Fc glycoforms are 
monomeric (96-99%) with low levels of aggregates present across the IgG1 Fc samples (1-3 %). 
No higher molecular weight species (HMWS) were visible in the chromatograms of all the four 
glycoforms except for the N297Q-Fc, which showed some soluble dimers (~3%). Additionally, the 
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data indicate no low molecular weight species (LMWS) which is in agreement with SDS-PAGE 
characterization. All glycoforms were ≥98% monomeric except for the non-glycosylated form, 
which was greater than 96.4% monomeric. This difference is presumably due to the absence of 
glycosylation in N297Q-Fc. It has been reported that removal of glycosylation increases the 
aggregation propensity of IgGs.47  
The charge distribution profiles of the four IgG1 Fc glycoforms were analyzed using cIEF. 
Representative electropherograms of HM-Fc, Man5-Fc, GlcNAc-Fc, and N297Q-Fc are shown in 
Figure 5 (Table 4). All the electropherograms show one major peak, which after resolution gave 
pI values of 7.0, 6.9, 7.1 and 7.4 for HM-Fc, Man5-Fc, GlcNAc-Fc, and N297Q-Fc, respectively. The 
theoretical isoelectric points (pI) of  IgG1 Fc from the amino acid sequence is 6.9 which is in close 
agreement with the experimental pI values obtained given assay variability. Nonetheless, the 
slightly basic shift of the aglycosyated form, compared to other three glycoforms, could be due 
to the lack of oligosaccharides at the N297 site. Although there are no visible basic variants 
observed, there are minor acidic peaks/shoulders near the main peaks with the pI values ranging 
from 5.6-6.8. The observed heterogeneity could potentially be from chemical modifications in 
IgG1 Fc proteins (e.g., deamidation) during production and/or purification. In summary, these 
results demonstrate that each of the IgG1 Fc glycoforms is an overall well-defined glycoform 







2.3.3 Evaluation of Affinity for IgG1 Fc Glycoforms with FcRIIIa Using Biolayer 
Interferometry (BLI) 
2.3.3.1 Expression and Purification of two Forms of FcRIIIa for use in Binding 
Assays 
 We have previously produced an expression strain for the production of the soluble 
domain of FcRIIIa in yeast with a C-terminal histidine tag for affinity purification, reported in 
Xiao et al.55, and this strain was utilized to produce FcRIIIa-H6 used in the binding assays with 
IgG1 Fc-immobilized on protein G biosensors. To reverse the immobilization format and have the 
receptor-immobilized, a new expression strain was also constructed that produces the soluble 
domain of FcRIIIa in yeast with a combined C-terminal histidine and sortase tag. This new 
receptor form, FcRIIIa-ST-H6, allows for affinity purification and the attachment of synthetic 
molecules, such as the synthetic biotin derivative used in this study, selectively to the C-terminus 
using sortase-mediated ligation.50, 66-68 Both receptors were expressed in a glycosylation-deficient 
strain of P. pastoris with glycerol and methanol as carbon sources. After centrifugation and 
filtration to remove yeast, Ni+2-NTA affinity chromatography was utilized to isolate the FcRIIIa 
forms. The receptors were further purified by phenyl sepharose chromatography, and after 
isolation and concentration approximately 18 mg/L of purified protein were obtained for both 
forms of FcRIIIa. 
2.3.3.2 Selective C-terminal Biotinylation of FcRIIIa-ST-H6 Using Sortase-Mediated 
Ligation 
Sortase mediated ligation50, 66-68 was utilized to attach biotin to the C-terminus of FcRIIIa. 
Bacterial sortases, such as the SrtA of S. aureus, are enzymes that catalyze transpeptidase 
reactions to attach proteins containing sortase recognition sites to the peptidoglycan of bacterial 
cell walls. Sortases have been adapted for biotechnology applications using the sortase reaction 
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for immobilization and to attach synthetic molecules and labels selectively to the N- or C-termini 
of recombinant proteins. The requirements for sortase ligations are N-terminal poly-glycine 
containing peptides, such as those found in peptidoglycan, and C-terminal recognition peptide 
motifs such as LPETG, as in the SrtA mediated ligation used in this study.50, 66-68 The C-terminal 
peptide is cleaved between threonine and glycine and a new peptide bond is formed between 
the N-terminal poly-glycine containing molecule and the C-terminal threonine. Accordingly, in 
order to selectively biotinylate FcRIIIa-ST-H6 it was necessary to synthesize a form of biotin 
containing an N-terminal poly-glycine. In addition, to ensure strong binding to streptavidin and 
prevent steric hindrance with streptavidin interfering with the interaction of FcRIIIa with IgG1 
Fc, a long hydrophilic diamine linker was used to separate biotin from the C-terminus of FcRIIIa. 
The synthesis of GGG-linker-Biotin (compound 3) is described in the Supporting information for 
this paper (Figure 10), and the ligation of GGG-linker-Biotin to FcRIIIa-ST-H6 is shown in Figure 
6. The sortase reaction proceeded efficiently to attach biotin to the C-terminus of FcRIIIa-ST-H6, 
and the resulting biotinylated FcRIIIa was immobilized in binding assays with streptavidin 
biosensors. 
2.3.4 Analysis of Binding of Immobilized IgG1 Fc Glycoforms to FcRIIIa Using Biolayer 
Interferometry (BLI)  
The affinity of FcRIIIa in solution for immobilized IgG1 Fc glycoforms was studied using 
BLI with protein G biosensors. The format for this binding study is shown in Figure 7A. Protein G 
biosensors were first loaded with IgG1 Fc glycoforms to a response level of 2 nm using 0.8 µM 
solutions of the various IgG1 Fc glycoforms. Then a baseline was established and the association 
of FcRIIIa was observed by dipping the biosensor into solutions of different concentrations of 
FcRIIIa. After the Fc-FcRIIIa complex had formed on the biosensor, dissociation of FcRIIIa was 
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observed by placing the biosensor in a solution of PBS kinetic buffer. The kinetic rate constants 
for association, ka, and dissociation, kd, were then obtained by fitting the resulting curves to a 1:1 
binding model which is consistent with previous biochemical and structural studies of this 
interaction.69 The equilibrium dissociation constant was determined by dividing kd by ka for each 
glycoform. Representative sensorgrams for each glycoform (HM-Fc, Man5-Fc, GlcNAc-Fc, and 
N297Q-Fc) are displayed in Figure 8, and the results for these binding experiments are given in 
Table 1 (Figure 13 also displays representative sensograms with curve fits added). HM-Fc and 
Man5-Fc have similar high affinity for FcRIIIa as would be expected for high-mannose IgG1 Fc 
glycoforms, with KD's of 27.7 nM and 31.8 nM, respectively.1-2, 70 In contrast, the GlcNAc-Fc 
glycoform has significantly weaker binding to FcRIIIa with a KD of 1115 nM, and this agrees with 
recent studies of this glycoform.71 Interestingly, the association rate constants (ka) are very 
similar for HM-Fc, Man5-Fc, and GlcNAc-Fc, such that the driving factor behind the GlcNAc-Fc's 
weaker affinity for FcRIIIa is its significantly faster dissociation rate (kd). This similarity in ka 
values and significant differences in kd and KD values is illustrated in Figure 12. No interaction was 
observed between FcRIIIa and the non-glycosylated N297Q-Fc form at the highest concentration 
of receptor tested (20 µM).  
2.3.5 Analysis of Binding of IgG1 Fc Glycoforms to Immobilized FcRIIIa Using Biolayer 
Interferometry (BLI) 
The affinity of the IgG1 Fc glycoforms in solution for immobilized FcRIIIa was studied 
using BLI with streptavidin biosensors. The format for this binding study is shown in Figure 7B. 
Streptavidin biosensors were first loaded with C-terminally biotinylated FcRIIIa to a response 
level of 0.4 nm using 0.1 µM biotinylated FcRIIIa. Next a baseline was established and the 
association of IgG1 Fc glycoforms was observed by dipping the biosensors into solutions of 
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different concentrations of IgG1 Fc glycoforms. After the complex had formed on the biosensor, 
dissociation of the IgG1 Fc glycoforms was observed by dipping the biosensor into of PBS kinetic 
buffer. Kinetic rate constants and equilibrium dissociation constants were determined as 
described for the protein G method above. Representative sensorgrams for each glycoform (HM-
Fc, Man5-Fc, GlcNAc-Fc, and N297Q-Fc) are displayed in Figure 9, and the results for these binding 
experiments are given in Table 1 (Figure 14 also displays representative sensograms with curve 
fits added). Perhaps not surprisingly, the affinities determined for this receptor-immobilized 
binding format were very similar to the results observed for the IgG1 Fc-immobilized binding 
format. HM-Fc and Man5-Fc showed similar high affinity for FcRIIIa with KD's of 26.4 nM and 
32.8 nM, respectively.1-2, 70 Also, the GlcNAc-Fc glycoform displayed much weaker binding with a 
KD of 995 nM, and this weak affinity was again due to a larger dissociation rate constant (kd) for 
GlcNAc-Fc relative to the other glycoforms. Finally, the N297Q-Fc form displayed no affinity for 
immobilized FcRIIIa even at 20 µM N297Q-Fc. 
2.4 Discussion 
2.4.1 Production and Initial Characterization of Well-Defined IgG1 Fc Glycoforms 
As a first step to develop a model system for biosimilar analysis studies, it was desirable 
to not only have a group of related well-defined proteins that differ from one another in specific 
attributes, but also to be able to produce relatively large amounts of those proteins, on an 
academic laboratory scale, to provide sufficient material to conduct biosimilarity assessments 
through a combination of biochemical, physicochemical and biological tests. To achieve this, 
glycosylation-deficient yeast (OCH1/PNO1 deleted P. pastoris derived from strain SMD1168) that 
express human-like, high-mannose type N-linked glycosylation were utilized to produce the IgG1 
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Fc glycoproteins and the non-glycosylated mutant used in this study. IgG1 Fc was secreted into 
culture media, and after centrifugation and filtration the IgG1 Fc was captured and purified using 
protein G affinity chromatography. Residual yeast impurities and, in the case of HM-Fc, removal 
of mono- and non-glycosylated IgG1 Fc forms was accomplished using HIC chromatography. The 
non-glycosylated N297Q-Fc mutant (Figure 1) was utilized directly as a negative control for the 
effects of glycosylation in these studies. The glycosylated HM-Fc glycoform (Figure 1) is a member 
of this model system and also serves as the starting material for the production of the remaining 
two glycoforms of the model system. The HM-Fc glycoform was treated with B.t. -1,2-
mannosidase and Endo H to produce the Man5-Fc and GlcNAc-Fc glycoforms respectively (Figure 
1). The HM-Fc, Man5-Fc, and GlcNAc-Fc glycoforms form a well-defined series where HM-Fc 
contains the largest N-linked glycan and the remaining glycoforms are sequentially truncated to 
give the intermediate glycosylation state of Man5-Fc, and the minimally glycosylated state of 
GlcNAc-Fc. This series of glycoproteins with decreasing N-linked glycan size all derived from the 
same precursor should be useful in elucidating effects of glycosylation on the biological and 
physicochemical properties of IgG1 Fc.  
In terms of ease of production, the HM-Fc and N297Q-Fc are both derived directly from 
fermentation, and therefore more easily accessed than the other two glycoforms. Because 
N297Q-Fc has no glycosylation site occupancy heterogeneity, its HIC purification is simplified 
compared to the HM-Fc form which requires separation of di-, mono-, and non-glycosylated 
forms. After HIC purification of both forms, 445 mg of HM-Fc and 118 mg of N297Q-Fc were 
produced for this study from approximately 28 and 7 liters of growth media, respectively. 
Conversion of 100 mg of HM-Fc into GlcNAc-Fc using Endo H (approximately 0.1 mg) was 
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straightforward and nearly quantitative, allowing relatively easy access to 100 mg of the GlcNAc-
Fc glycoform. Production of the Man5-Fc glycoform was more problematic since it was 
discovered that the B.t. -1,2-mannosidase had little activity in sucrose containing storage buffer 
after the HM-Fc had been transferred into the storage buffer. This required additional dialysis 
steps to transfer the HM-Fc into a different buffer to conduct the B.t. -1,2-mannosidase 
reaction. In addition, a larger amount of B.t. -1,2-mannosidase (6.7 mg) relative to Endo H (0.1 
mg) was required for the reaction to produce Man5-Fc, and this made it necessary to purify the 
Man5-Fc glycoform by an additional protein G affinity chromatography step after the 
mannosidase reaction. All of these factors combined to result in a 60% yield for conversion of 
HM-Fc into Man5-Fc and only 75 mg of the Man5-Fc glycoform being produced. The amount of 
Man5-Fc produced was sufficient to conduct this and the accompanying studies, but the 
procedure to produce this glycoform could be optimized in the future to produce more of this 
glycoform in a higher yield. Taken together, these methods allow easy access to the four well-
defined glycoforms from Figure 1 in quantities sufficient to enable a wide range of biosimilar 
analysis and stability studies. 
Initial characterization of the glycosylation state of the model glycoforms was conducted 
using intact protein mass spectrometry. Mass spectrometry was used to confirm the type of 
glycosylation on each glycoform and determine if there were any significant proteolytic products 
present (Figure 2). None of the IgG1 Fc glycoforms showed any evidence of internal proteolysis, 
and all were found to be in forms containing their complete amino acid sequences including C-
terminal lysine residues. The intact protein mass spectra also allowed evaluation of the 
glycosylation state of the IgG1 Fc glycoforms. The N297Q-Fc and GlcNAc-Fc glycoforms were 
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highly homogeneous with single peaks corresponding to no glycosylation with a glutamine 
mutation and a single GlcNAc attached to asparagine, respectively. The HM-Fc glycoform 
obtained directly from yeast was heterogeneously glycosylated with high-mannose type glycans 
ranging in size from Man8GlcNAc2 to Man12GlcNAc2, with the form containing Man8GlcNAc2 being 
the major form at approximately 49% of its glycosylation sites based on peak intensities (Table 
2). The mannosidase treated Man5-Fc glycoform is much more homogeneous and estimated to 
contain Man5GlcNAc2 on 78% of its glycosylation sites based on peak intensities (Table 2). The 
remainder of the glycoform peaks observed in the Man5-Fc mass spectra correspond to small 
amounts of incompletely cleaved high-mannose glycosylated forms, indicating the mannosidase 
reaction could be further optimized in the future. The mass spectrometry results demonstrate 
well-defined differences between the model IgG1 Fc glycoforms based on the size or absence of 
N-linked glycosylation. 
Additional biochemical characterization was conducted using SDS-PAGE, size exclusion 
chromatography (SEC), and capillary isoelectric focusing (cIEF). This was done to further define 
the chemical state and purity of the IgG1 Fc glycoforms and to establish a baseline prior to the 
chemical and physical stability studies described in  other works.72-73 Reducing and non-reducing 
SDS-PAGE (Figure 3) display an absence of proteolytic fragments and show high purity for each 
glycoform. In addition, the non-reduced SDS-PAGE indicated complete intermolecular disulfide 
bond formation corresponding to 100% dimerized form for all glycoforms. Analysis of the 
glycoforms by SEC (Figure 4) revealed that all members of the model system were largely in the 
monomeric state with the amount of monomer ranging from 96-99%. The non-glycosylated 
N297Q-Fc form displayed the most amount of soluble dimers present in SEC at 3%, which may 
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be a consequence of the absence of glycosylation to stabilize protein folding and prevent 
aggregation. Analysis of the isoelectric points for the four glycoforms also identified a difference 
between the N297Q-Fc form and the other forms, with the N297Q-Fc form having a pI of 7.4 
compared to 7.0, 6.9, and 7.1 for HM-Fc, Man5-Fc, and GlcNAc-Fc, respectively (Figure 5). The 
significance and cause of this difference in the pIs between the non-glycosylated form and the 
others is not clear at this time since none of the N-linked glycans present on the glycoforms are 
charged and neither is glutamine or asparagine. Interestingly, it has been noted by our laboratory 
and others that cation exchange chromatography can be used to separate glycosylated and non-
glycosylated proteins from one another even when only neutral oligosaccharides are present on 
the glycosylation sites. The elution order observed from cation exchange chromatography in the 
cases of separation of glycosylated and non-glycosylated IL-1ra and di-glycosylated IgG from 
mono- and non-glycosylated IgG are consistent with the non-glycosylated forms having higher 
isoelectric points.2-3, 74 
2.4.2 Biological Evaluation of Well-Defined IgG1 Fc Glycoforms 
Potential biological activities of the IgG1 Fc glycoforms in our model system were assessed 
using binding to an activating Fc receptor, FcRIIIa, as a measure of the potential to activate 
antibody dependent effector functions. In full-length antibodies, simultaneous binding of the 
antigen binding regions of an antibody to a polyvalent antigen and the antibody Fc region to 
FcRIIIa can activate antibody dependent cell-mediated cytotoxicity (ADCC).75 FcRIIIa is also 
important in the function of natural killer cells, since it is the only Fc receptor expressed on 
natural killer cells (NK cells).76 ADCC and NK cells are both believed to be important in the function 
of many therapeutic mAbs.76-77 Additionally, FcRIIIa is sensitive to the type of glycosylation 
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present on the Fc region of antibodies, having high affinity to antibodies that do not contain core-
linked fucose, and like most Fc receptors, lower affinity for truncated N-linked glycans.77 This 
makes FcRIIIa useful in distinguishing the different IgG1 Fc glycoforms in our model system. 
The interactions of the IgG1 Fc glycoforms with FcRIIIa were assessed with kinetic binding 
studies using biolayer interferometry (BLI). Observation of binding using surface techniques such 
as BLI or surface plasmon resonance (SPR) generally do not require large amounts of material to 
conduct binding studies, and this is an advantage for biosimilarity analysis studies where many 
samples may be required to be analyzed. Kinetic binding studies using BLI or SPR allow 
determination of kinetic rate constants for association (ka) and dissociation (kd), and by taking 
the ratio of the kinetic rate constants, equilibrium dissociation constants (KD) can be determined. 
One drawback of surface binding techniques is that one binding partner, receptor or ligand, 
needs to be immobilized to conduct the experiment (Figure 7). Choice of which component, 
receptor or ligand, to immobilize and method of immobilization can both affect the outcome of 
the experiment. In addition, from the perspective of conducting experiments with samples of 
formulated drug products, the format of binding assays can have practical effects on how the 
assays are conducted and what kind of information is obtained. To gain a better understanding 
of how binding format affects the results of binding studies, we developed two formats for 
studying the interaction of IgG1 Fc glycoforms with FcRIIIa (Figure 7), one with the IgG1 Fc-
immobilized and one with the receptor-immobilized. 
For a BLI binding format where the IgG1 Fc glycoforms were immobilized (Figure 7A), we 
decided to use protein G biosensors for immobilization of IgG1 Fc glycoforms. Protein A and/or 
protein G have previously been used in SPR binding studies of IgG interactions with Fc receptors, 
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and immobilization using these proteins have many advantages.78-79 Since protein G binds tightly 
to IgGs over a wide pH range (≈ pH 5-8), protein G biosensor tips can be loaded under a variety 
of formulation conditions without having to adjust the buffer conditions of samples to promote 
immobilization. In addition, once IgG1 Fc (or full-length IgG) has been immobilized onto a protein 
G biosensor, binding experiments can be conducted in buffers optimized for receptor binding by 
simply dipping the IgG1 Fc loaded protein G biosensor into receptor solutions with optimized 
buffer conditions. Also, protein G biosensors can be regenerated by acidic treatment much the 
way protein A and protein G affinity resins are eluted during affinity chromatography, allowing 
for relatively easy reuse of protein G biosensors. A disadvantage of using protein G biosensors to 
immobilize IgG1 Fc in binding studies may arise during stability studies when there is the potential 
of the formation of damaged forms of IgG1 Fc which would no longer be capable of binding to 
protein G, but which could still retain the ability to bind to Fc receptors. Such proteins would not 
be measured in this assay format. Also, this assay format is relatively insensitive to the actual 
concentration of IgG1 Fc glycoforms in samples, since to obtain reproducible binding curves the 
biosensors are loaded to the same approximate level, and because of this changes in 
concentrations in the samples may be difficult to detect. Nevertheless, this assay format provides 
valuable information about the kinetics and thermodynamics of the interaction of IgG1 Fc 
glycoforms with FcRIIIa.  
Figure 8 shows representative binding curves and Table 1 summarizes the resulting rate 
constants and dissociation constants obtained for the interaction of immobilized IgG1 Fc 
glycoforms with FcRIIIa in solution using this binding format. As can be seen in Table 1, both 
HM-Fc and Man5-Fc have high affinity for FcRIIIa (KD's of 28 and 32 nM respectively), GlcNAc-Fc 
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showed a much lower affinity (KD of 1115 nM), and N297Q-Fc had no observable affinity for 
FcRIIIa (all measurements were conducted at 25˚C). Examination of the rate constants for the 
different interactions reveals that the main factor in the GlcNAc-Fc glycoform's lower affinity is 
due to significantly faster dissociation of the complex once it forms relative to HM-Fc and Man5-
Fc, and this can be seen in the magnitudes of the dissociation rate constants, kd (Table 1), and 
the ratios of kinetic and thermodynamic values when compared to HM-Fc values (Figure 12).  
For a BLI binding format where FcRIIIa is immobilized and IgG1 Fc glycoforms were in 
solution (Figure 7B), we utilized selectively biotinylated FcRIIIa and streptavidin biosensors. 
Streptavidin biosensors were chosen for immobilization of FcRIIIa because the high affinity of 
non-fucosylated IgG1 Fcs, such as HM-Fc and Man5-Fc (KD ≈ 30 nM), required either covalent or 
significantly higher affinity immobilization to prevent artifacts related to dissociation of receptors 
during binding measurements. The high affinity of streptavidin for biotin (KD ≈ 10-14 M)80 was 
appropriate for this application, therefore we developed a novel method to selectively 
biotinylate the C-terminus of FcRIIIa using sortase-mediated ligation. This required constructing 
an expression strain of FcRIIIa which contained a C-terminal sortase tag, expression and 
purification of the sortase tagged FcRIIIa, synthesis of a triglycine containing biotin derivative 
(compound 3, Figure 10), and sortase-mediated ligation to produce the C-terminally biotinylated 
FcRIIIa, and these methods are described in the supporting information. An advantage of using 
an immobilized FcRIIIa binding format such as that shown in Figure 7B is that binding 
measurements can be made directly in solutions of IgG1 Fc glycoforms. This type of format is also 
potentially more sensitive to changes in IgG1 Fc concentration since measurements are done 
with the samples directly in solution rather than in an immobilized format.  
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A disadvantage of this binding format is that buffer conditions present in samples must 
be compatible with receptor binding measurements. The affinity of many receptors is pH 
dependent, so formulation pH could affect binding measurements. In addition, high 
concentrations of sugars, such as the 10% sucrose in our sample storage buffer, can have 
significant effects on the kinetics and thermodynamics of binding measurements. Because of 
these factors, in our experiments it was necessary to transfer the IgG1 Fc glycoforms from storage 
buffer (10% sucrose, 20 mM histidine pH 6.0) to kinetics buffer (PBS buffer containing 1 mg/mL 
casein as a blocking agent) by dialysis, prior to binding measurements. This added a step to the 
binding measurements and has the potential to skew results if there is loss of sample or changes 
in concentration during the transfer of samples to the new buffer. The results of the receptor-
immobilized binding format are shown in Figure 9 and Table 1. The binding results for the 
receptor-immobilized format (Figure 7B) are highly similar to the IgG1 Fc-immobilized format 
(Figure 7A), suggesting the extra dialysis step in the receptor-immobilized format did not affect 
the binding measurement significantly. Both HM-Fc and Man5-Fc displayed high affinity for 
FcRIIIa with KD's of 26 and 33 nM respectively, while the GlcNAc-Fc had lower affinity at 995 nM, 
and the N297Q-Fc form had no observable affinity (all measurements were conducted at 25˚C). 
The driving factor in the difference between the high affinity HM-Fc and Man5-Fc and the lower 
affinity GlcNAc-Fc was again faster dissociation of the complex (Table 1 and Figure 12). These 
results suggest that these two different binding formats are complementary in these experiments 
using well-defined IgG1 Fc glycoforms. These model IgG1 Fc glycoforms are also utilized to assess 
how glycosylation alters the chemical stability  and physical stability.72-73 
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In summary, we have presented here the production and biological evaluation of four well-
defined IgG1 Fc glycoforms as the initial steps of developing a model system for biosimilarity 
analysis. The methods developed here allow relatively easy access to the four well-defined IgG1 
Fc glycoforms (HM-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc) on a laboratory scale in quantities 
sufficient to enable a wide variety of biosimilarity analyses. Initial characterization of the 
glycoforms demonstrate that they are well-defined glycoproteins which vary significantly only in 
their glycosylation state, or in the case of non-glycosylated N297Q-Fc, in the presence of a 
conservative N to Q amino acid mutation. The four IgG1 Fc glycoforms form a set of sequentially 
truncated glycoproteins which can be used to assess the effects of glycosylation on biological 
activity and protein physicochemical stability. Potential biological activity of the IgG1 Fc 
glycoforms was evaluated using BLI to study the interaction of the glycoforms with the activating 
Fc receptor FcRIIIa. Two BLI binding formats were developed, one utilizing protein G biosensors 
to immobilize IgG1 Fc, and one utilizing C-terminally biotinylated FcRIIIa produced by a novel 
method to immobilize FcRIIIa on streptavidin biosensors. The two assay formats resulted in 
complementary information about the affinity of the IgG1 Fc glycoforms for FcRIIIa (Table 1). 
From the perspective of developing a model system for biosimilarity analysis, the binding studies 
also identified members of the model system that exhibited highly similar biological activity and 
those with distinct differences. The HM-Fc and Man5-Fc glycoforms exhibited highly similar 
affinity for FcRIIIa (approximate KD's of 27 and 32 nM respectively), while GlcNAc-Fc had much 
weaker affinity (KD of around 1000 nM), and N297Q-Fc displayed no affinity at the highest 
concentrations (20 µM) tested. These similarities and distinct differences in biological activity 
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may be useful in identifying physical and chemical features that correlate with changes in 











2.5 Figures   
 
  
Figure 1. Production of homogenous IgG1 Fc glycoforms. HM-Fc was expressed in glycoengineered 
P. pastoris and utilized as a precursor for generation of GlcNAc-Fc and Man5-Fc. N297Q-Fc was 

















Figure 3. SDS-PAGE analysis of the four different IgG1 Fc glycoforms (1. HM; 2. Man5; 3. GlcNAc; 
4. N297Q) under reduced and non-reduced conditions. The purified IgG1 Fc glycoforms showed 
~99% purity under both conditions. The HM-Fc glycoform that has the highest molecular weight 





Figure 4. Representative size exclusion chromatograms of the IgG1 Fc glycoforms. Results 
showed the following total monomer content (n=3; SD ~1.0%): HM-Fc 98.0% for HM-Fc, 







Figure 5. Representative charge heterogeneity profiles of IgG1 Fc glycoforms as measured by 
capillary isoelectric focusing (cIEF).  The isoelectric point (pI) of the main peak (n=3; SD ~0.1 pI 






Figure 6. Production of biotinylated FcRIIIa using sortase-mediated ligation between 







Figure 7. Steps followed in kinetic binding experiments using biolayer interferometry. A) Top panel 
shows steps followed for measuring binding kinetics using protein G biosensors (Fc-immobilized 
format), where IgG1 Fc glycoforms were immobilized and FcRIIIa-H6 was present in solution. B) 
Bottom panel shown steps involved in binding kinetics using streptavidin biosensor (receptor-
immobilized format), where biotinylated FcRIIIa was immobilized and IgG1 Fc glycoforms were 






Figure 8. Representative BLI binding data for the interaction of FcRIIIa with IgG1 Fc glycoforms 
immobilized on protein G biosensors (Fc-immobilized format). The binding curves correspond to a 
range of receptor concentrations in solution. For HM-Fc and Man5-Fc data is shown for FcRIIIa at 
concentrations of 800 nM, 400 nM, 200 nM, and 100 nM, which corresponds with the curves from 
top to bottom. For GlcNAc-Fc data is shown for FcRIIIa at concentrations of 1600 nM, 800 nM, 400 
nM, and 200 nM, which corresponds with the binding curves from top to bottom.  For N297Q-Fc a 




    
Figure 9. Representative BLI binding data for the interaction of IgG1 Fc glycoforms with FcRIIIa 
immobilized on streptavidin biosensors (receptor-immobilized format). The binding curves 
correspond to a range of IgG1 Fc glycoform concentrations in solution. For HM-Fc and Man5-
Fc data is shown at concentrations of 800 nM, 400 nM, 200 nM, and 100 nM, which 
corresponds with the curves from top to bottom. For GlcNAc-Fc data is shown at 
concentrations of 1600 nM, 800 nM, 400 nM, and 200 nM, which corresponds with the binding 
curves from top to bottom.  For N297Q-Fc a single concentration of 20 µM was tested and no 


























Figure 11. ESI-MS analysis of IgG1 Fc glycoform after protein G affinity chromatography 
purification. The mass spectrometry data shows the molecular weight of the Fc monomer and 
its N-linked glycan at Asn297. The peaks represent Man8GlcNAc2, Man9GlcNAc2, Man10GlcNAc2, 
Man11GlcNAc2, and Man12GlcNAc2 with MWs of 26767.53, 26926.67, 27091.99, 270253.68, 
and 27416.33Da, respectively. The peak with MW 25063.7Da is a nonglycosylated Fc monomer 





Figure 12. Bar graphs show ratios of ka, kd, and KD for the IgG1 Fc glycoforms obtained by dividing 
with ka, kd, and KD  of HM-Fc for A, B, and C, respectively. The data indicates a slight difference in 
the ratio of ka values (A), but significant difference in the ratio of kd and KD as shown in panels B and 
C, respectively. Streptavadin immobilization represents the receptor-immobilized format, while the 




  Figure 13. Representative BLI binding curves (fitted) for the interaction of FcRIIIa with IgG1 Fc glycoforms 
immobilized on protein G biosensors (Fc-immobilized). The binding curves correspond to a range of 
receptor concentrations in solution. For HM-Fc and Man5-Fc data is shown for FcRIIIa at concentrations 
of 800 nM, 400 nM, 200 nM, and 100 nM, which corresponds with the curves from top to bottom. For 
GlcNAc-Fc data is shown for FcRIIIa at concentrations of 1600 nM, 800 nM, 400 nM, and 200 nM which 
corresponds with the binding curves from top to bottom.  For N297Q-Fc a single concentration of 20 µM 





Figure 14. Representative BLI binding curves (fitted) for the interaction of IgG1 Fc glycoforms with 
FcRIIIa immobilized on streptavidin biosensors (receptor-immobilized format). The binding curves 
correspond to a range of IgG1 Fc glycoform concentrations in solution. For HM-Fc and Man5-Fc data is 
shown for IgG1 Fc glycoforms at concentrations of 800 nM, 400 nM, 200 nM, and 100 nM, which 
corresponds with the curves from top to bottom. For GlcNAc-Fc data is shown at concentrations of 
1600 nM, 800 nM, 400 nM, and 200 nM, which corresponds with the binding curves from top to 
bottom.  For N297Q-Fc a single concentration of 20 µM was tested and no binding was observed. 
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Biosensor   Avg ka x 10-5 (1/Ms) Avg. kd x 103 (1/s) Avg.KD (nM) 
HM-Fc  
IgG1 Fc Protein G 1.94 ± 0.26 5.37 ± 1.02 27.71± 6.42 
FcRIIIa Streptavidin  3.00 ± 0.59 7.93 ± 1.38 26.41 ± 6.94 
Man5-Fc  
IgG1 Fc Protein G 1.61 ± 0.12 5.10 ± 0.86 31.75 ± 5.88 
FcRIIIa Streptavidin 2.23 ± 0.18 7.31 ± 0.32 32.82 ± 3.08 
GlcNAc-Fc 
IgG1 Fc Protein G  1.23 ± 0.18 139.53 ±9.15 1115 ± 136.82 
FcRIIIa Streptavidin  1.62 ± 0.28 161.27 ± 21.75 995 ± 219.32 
N297Q-Fc  
IgG1 Fc / 
FcRIIIa 
Protein G / 
Streptavidin  
* * * 
Table 1.  Kinetic parameters obtained for binding of FcRIIIa with IgG1 Fc glycoforms. Binding 
kinetics were measured at 25˚C. The data shows kinetic association rate ka, kinetic dissociation 
rate kd, and equilibrium dissociation constant KD. These data are averaged values of six 
independent experiments. *For N297Q, there was no detectable binding at the highest 












             Glycoform Expected mass Observed mass Δ Mass Peak intensity Est. Abund. (%)  
HM-IgG1 Fc Man8 26769.97 26767.87 2.10 370000 49 
Man9 26932.11 26930.01 2.1 250000 33 
Man10 27094.25 27091.93 2.32 50000 7 
Man11 27256.39 27253.94 2.45 40000 5 
Man12 27418.53 27416.00  2.53 40000 5 
Man5-IgG1 Fc Man5 26283.55 26282.16 1.39 92940 78 
Man6 26445.69 26444.17 1.52 5970 5 
Man8 26769.97 26767.92 2.05 3600 3 
Man9 26932.11 26929.92 2.19 4032 3 
Man10 27094.25 27092.64 1.61 7573 6 
Man11 27256.39 27254.67 1.72 4766 4 
GlcNAc-IgG1 Fc GlcNAc 25269.67 25267.84 1.83 136433 ≥ 99 
N297Q-IgG1 Fc  Non-glycosylated  25080.49 25078.01 2.48 25240 ≥ 99 
Table 2.  Expected mass, observed mass, and peak intensity for each glycoform as observed by MS.  
Peak intensity was obtained using Agilent Masshunter qualitative analysis software and estimated 









Number of runs 
                   Percentage of monomer 
HM-Fc Man5-Fc GlcNAc-Fc N297Q-Fc 
1 99.0 >99.0 >99.0 96.4 
2 99.0 >99.0 >99.0 97.3 
3 99.0 >99.0 >99.0 96.3 
4 97.0    
5 97.3    
6 96.9    
Average 98.0 >99.0 >99.0 96.7 



















                   
 
 





Number of runs 
                      PI of the main peak 
HM-Fc Man5-Fc GlcNAc-Fc N297Q-Fc 
1 7.1 6.9 7.1 7.4 
2 7.1 6.9 7.1 7.4 
3 7.1 6.9 7.1 7.4 
4 7.0    
5 6.9    
6 6.9    
Average 7.0 6.9 7.1 7.4 
Std Dev 0.1 0.0 0.0 0.0 
Table 4.  pI values of the main peak for IgG1 Fc glycoforms measured using cIEF. 













(1/s) KD (nM) 
HM-Fc 
3.42 8.93 26.1 
3.64 9.33 25.66 
3.54 9.24 26.09 
2.41 6.28 26.05 
2.57 6.97 27.17 
2.43 6.80 28.03 
Man5-Fc 
2.28 7.54 32.99 
2.28 7.04 30.88 
2.44 7.83 32.1 
2.18 7.03 32.25 
1.89 7.10 37.58 
2.29 7.31 31.91 
GlcNAc-Fc 
1.53 1.53 996 
1.36 1.51 1112 
1.45 1.33 9191 
1.48 1.64 1110 
2.11 1.97 935 
1.80 1.70 946 
N297Q-Fc * * * 
 
Table 5. Raw data for the protein G immobilization technique (Fc-immobilized format) for six 





  Glycoforms  ka x 10
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(1/s) KD (nM) 
HM-Fc  
3.42 8.93 26.1 
3.64 9.33 25.66 
3.54 9.24 26.09 
2.41 6.28 26.05 
2.57 6.97 27.17 
2.43 6.80 28.03 
Man5-Fc  
2.28 7.54 32.99 
2.28 7.04 30.88 
2.44 7.83 32.1 
2.18 7.03 32.25 
1.89 7.10 37.58 
2.29 7.31 31.91 
GlcNAc-Fc 
1.53 1.53 996 
1.36 1.51 1112 
1.45 1.33 9191 
1.48 1.64 1110 
2.11 1.97 935 
1.80 1.70 946 
N297Q-Fc  * * * 
 
Table 6.  Raw data for the streptavidin immobilization technique (receptor-immobilized format) for six 












(Protein G purified) 
Amount after phenyl 
sepharose purification 
(HIC) 






HM-Fc  1000 mg  445 mg  --------- ------- -------- 
Man5-Fc  ----------- -------- 125 mg  75 mg 60 % 
GlcNAc-Fc ------- -------- 100 mg  100 mg  ≥ 99% 
N297Q-Fc  130 mg  118 mg  ----- ----- ------ 
 
Table 7.  The amount of IgG1 Fc glycoforms produced using a combination of expression, enzymatic 
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The patents of several best-selling biologic therapeutic products are expiring soon; 
consequently, the interest in developing biosimilar products is growing. The exact chemical 
structure of small-molecule drugs and their purities can be well-established. This gives an 
opportunity for generic manufacturers to produce a generic product without clinical trials by 
demonstrating bioequivalence in pharmacokinetics studies. Unlike small-molecule drugs, protein 
molecules are structurally complex, often containing a mixture of different species produced 
after posttranslational modification. In fact, most of the heterogeneity of protein molecules is 
attributed to variably complete N-linked glycosylation.1  
For a protein-based product, it is nearly impossible to produce identical products from 
two different manufacturing plants.2 Moreover, it is even difficult to produce an identical product 
by the innovator from lot-to-lot as there is always inherent variability. In general, protein 
therapeutics are mixtures because of posttranslational modifications, chemical modifications, 
and potentially multiple conformations or aggregated forms. In fact, as the definition of 
biosimilar indicates, it is unlikely that all the structure and function aspects of the biosimilar will 
be identical to the originator. However, the innovator should demonstrate consistency in 
manufacturing the therapeutic product within a set of defined and acceptable criteria for the 
critical quality attributes.2 The other challenge is that the manufacturing process and criteria are 
not disclosed, and the sponsor of a biosimilar is required to perform extensive characterization 
to show that the originator and biosimilar candidate are highly similar.2 In addition, a biosimilar 
sponsor can never exactly replicate the complex bioprocess of the originator, and it is well known 
that “the process defines the product” with regard to the structural and functional aspects of a 
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biologic product.3 Therefore, protein therapeutics contain a mixture of structurally similar 
molecules, which differ by the type and extent of posttranslational modifications. These 
modifications include glycosylation, deamidation, oxidation, phosphorylation, and C-terminal 
lysine variability. Because of this structural complexity, even after extensive characterization, the 
safety and efficacy of protein therapeutics cannot be guaranteed. Hence, the need to have 
sensitive and robust analytical methods to demonstrate the similarity and differences between 
a biosimilar candidate with the originator is urgently needed.2, 4  
Monoclonal antibodies are the most prevalent type of biologic therapeutic products used 
today.5 Among the four IgG subclasses (IgG1, IgG2, IgG3, and IgG4), IgG1 is the most widely used 
antibody in the treatment of various diseases, such as cancer, inflammation, and rheumatoid 
arthritis.6-9 IgG1 has a conserved N-linked glycosylation site at Asn297,10-11 and the glycosylation 
can vary with production condition, media composition, cell-line used, and duration of 
expression.12-16 It is well studied that the type of glycosylation at Asn297 can have a significant 
impact on the effector function, stability, solubility, pharmacokinetics, and immunogenicity.4, 12-
13, 17-24 Therefore, monitoring glycosylation during production is critical for safety and efficacy of 
therapeutic proteins. This is particularly important during comparability and biosimilarity 
exercises since a shift in glycosylation caused by a change in the manufacturing process and/or 
cell line can have a detrimental effect on the biological activity and physical stability of mAb 
therapeutics.2, 25-26 Monoclonal antibodies are inherently heterogeneous with respect to their N-
linked glycosylation on the Fc region.27 Therefore, glycosylation is a critical quality attribute that 
requires close monitoring during biosimilarity exercises.28 
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Glycosylation of mAbs modulates interaction to the Fc-receptors and plays a key role in 
complement dependent-cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity 
(ADCC).12, 29-30 Thus, comparability assessments of the Fc-mediated effector functions (CDC and  
ADCC) is an integral component of the data package during a biosimilar exercise.31  Fc-mediated 
effector functions include binding with Fc gamma RIIIa (FcRIIIa), which can be measured 
accurately using biolayer interferometry (BLItz), surface plasmon resonance (SPR), and flow 
cytometry techniques.31 Although there is an inherent variability in bioassays, there is a 
continuous effort to develop robust analytical methods.26, 31 Most mAb therapeutics rely on 
specific binding interaction of the Fc region to target receptors to achieve desired clinical 
outcomes.32-33 Hence, comparing the binding activities of a biosimilar to an innovator product 
using a reliable binding assay can yield valuable information about similarity and potential 
biological activity.31, 34 
A functional activity assay provides valuable information about the characteristics related 
to a product’s functional activity and conformational stability, and it is critical in demonstrating 
similarity. These assays complement the physicochemical analysis by demonstrating potential 
effects of observed structural difference between the originator and the biosimilar candidate.26, 
31 In addition to their use in demonstrating biosimilarity, functional assays are utilized for 
candidate selection, product release, and stability assessment.25-26, 31 A functional assay can 
potentially predicts how a biosimilar may behave in-vivo, and such assays may provide, together 
with other analytical data, evidence about clinical outcomes.26, 31 Biosimilar sponsors conduct 
biological activity tests to examine the impact of process changes on the potency of the product 
in development. In addition, functional tests are used as a surrogate to confirm a protein’s higher-
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order structure in parallel to the physical techniques. However, if the physicochemical and 
functional tests are inconclusive or not enough to confirm the higher-order structure of the 
originator and biosimilar, then further clinical and nonclinical studies may be necessary for 
regulatory approval.2, 26 
Biosimilarity exercises are performed in a step-wise fashion where the level of similarity 
demonstrated by multifaceted analytical techniques guides the pre-clinical and clinical evaluation 
required to demonstrate biosimilarity.31, 35 If higher similarity is demonstrated by the analytical 
techniques, then a reduced clinical test may be required for regulatory approval. In other words, 
demonstrating a high level of similarity using a battery of analytical techniques is critical for 
achieving a biosimilar development process with a reduced clinical package.29, 31, 36-37 Hence, the 
first goal is to achieve analytical similarity between the originator and the biosimilar; then the 
biosimilar sponsor can partially rely on the previous findings of safety, purity, and potency of the 
originator.31 This is because biosimilars are developed to be used at the same dose and dosing 
regime as the originator product. Consequently, a phase II finding study may not be a 
requirement.2, 37-38 Therefore, a biosimilar can be approved with a reduced clinical data package, 
compared with the one required for the originator product.37  
During biosimilar development, a biosimilar candidate is expected to have similar 
glycosylation pattern and the same sequence as the originator.27 Therefore, it is important to 
understand how a change in glycosylation of a therapeutic mAb impacts its functional, physical, 
and chemical quality attributes in the development processes.25 The role of analytical techniques 
in comparing a biosimilar with the originator is getting significant interest in biosimilar 
assessments. The three most important characteristics of a protein molecule for establishing 
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similarity are: post-translational modifications, three-dimensional structure, and protein 
aggregation. However, no single analytical method can fully demonstrate the similarity between 
a biosimilar and the originator.25 Thus, a battery of analytical techniques is employed to 
demonstrate molecular equivalence.31 Moreover, it is time- and cost-demanding to demonstrate 
all aspects of the biosimilar that are necessary for evaluating the critical quality attributes.31 In 
general, the type of comparison between the originator and biosimilars should include primary 
and higher order structures. In addition, post-translational modifications, such as glycosylation, 
oxidation, and deamidation, should be examined. For instance, analytical techniques, such as 
mass spectrometry, play a vital role in the identification of post-translational modifications.35 
Other analytical techniques, such as circular dichroism, fourier transformation infrared 
spectroscopy, and differential scanning calorimetry, are used to demonstrate higher-order 
structure similarity between the originator and the biosimilar.26   
In this study, a combination of recombinant expression of the human IgG1 Fc in P. 
pastoris, coupled with in-vitro enzymatic reaction and site-directed mutagenesis, was used to 
produce well-defined homogeneous glycoforms: HM-Fc, Man5-Fc, GlcNAc-Fc, and N297Q-Fc.4, 21  
Our previous studies have shown that the HM-Fc and Man5-Fc glycoforms both exhibited similar 
high receptor binding affinities (FcRIIIa) and physical stabilities, whereas the GlcNAc-Fc showed 
minimal functional activity and physical stability. The non-glycosylated IgG1 Fc (N297Q-Fc) 
showed the least physical stability as well as no detectable binding affinity to FcRIIIa and was 
used as a negative control for the effects of glycosylation in these functional and physical stability 
characterizations.4, 24 These four control glycoforms with decreasing N-linked glycan size and the 
same amino acid sequence were found to be useful in examining the effect of glycosylation on 
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the functional activity and physicochemical characteristics of IgG1 Fc.4, 21, 24, 39 Therefore, these 
glycoforms were selected to make well-defined mixtures as a model for biosimilar comparability 
analysis. For example, these mixtures can model the impact of change in glycosylation during a 
biosimilar product development. In this work, the functional and physical assay methods were 
tested for their ability to differentiate between mixtures of IgG1 Fc glycoforms. Moreover, the 
pre-defined mixtures of glycoforms were investigated to mimic more heterogeneous glycoforms 
typically present in monoclonal antibodies. The study of glycoform mixtures prepared in this work 
will help to understand the contribution of the individual glycoforms to the overall functional 
activity. 
3.2 Materials and Methods 
3.2.1 Material 
 Yeast nitrogen base (YNB) was supplied by Sunrise Biosciences. Bacto TM tryptone and 
yeast extract were obtained from Beckman, Dickinson and company (Franklin Lakes, NJ). Casein 
was purchased from Sigma-Aldrich (St. Louise, MO). The enzymes, B. Thetaiotaomicron α-1,2-
mannosidase (BT3990, B.t. α-1,2-mannosidase) was produced in-house.4, 40-42 Endoglycosidase 
HF (Endo HF) was purchased from New England Biolabs (Ipswich, MA). The components of all 
buffers including, sodium phosphate, sodium chloride, and PEG-10,000, were purchased from 
Sigma-Aldrich (St Louis, MO), while citric acid monohydrate and citric acid anhydrous were 
purchased from Fisher Scientific at the highest purity grade. All other general chemicals were 






3.2.2 Expression of High-Mannose IgG1 Fc (HM-Fc) 
 HM-Fc was expressed using a glycosylation-deficient strain of P. pastoris43 using the same 
protocol as previously described elsewhere.4 One minor change to the expression protocol was 
a mixture of methanol and sorbitol were utilized during the induction phase to increase the yield 
of HM-Fc.  
3.2.3 Expression of Non-Glycosylated Mutant N297Q-IgG1 Fc (N297Q-Fc) 
  Fermentor expression was utilized to produce N297Q-Fc in a glycosylation-deficient P. 
pastoris. The cDNA plasmid for N297Q produced from previous work was linearized with Sac I 
endonuclease and transformed into a strain of P. pastoris (an OCH1 and PNO1 deleted, N297Q-
IgG1 Fc expressing, SMD1168 strain containing sttd3) by electroporation. The yeast colonies were 
selected on YPD plates containing 100 µg/mL Zeocin. Following this step, colonies were tested 
for N297Q-IgG1 Fc expression using SDS-PAGE. Additionally, the molecular weight of the 
expressed protein was confirmed by mass spectrometry after expression trial from 1 L spinner 
flask. A single colony with higher N297Q-IgG1 Fc expression was selected for further protein 
production. A starter culture of 2 mL was inoculated in Yeast extract-Peptone-Dextrose (YPD) 
media that contained 100 µg/mL Zeocin. This culture media was incubated at 25°C for 72 hrs. The 
2 mL culture media was then inoculated into a 250 mL of YPD/Zeocin, which was incubated with 
shaking for 72 hrs.  The 250 mL culture was then used to inoculate 7 L of Buffered Glycerol-
complex Media (BMGY) containing 0.00004% biotin. N297Q-IgG1 Fc expression was induced by 
methanol feeding with the addition of sorbitol as a carbon source to maximize the yield for about 
72 hrs. The cell pellets were harvested, and the N297Q-IgG1 Fc  was purified from the 
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supernatant using protein G affinity chromatography in a similar protocol as described above for 
HM-IgG1 Fc.  
3.2.4 Purification of IgG1 Fc 
 Both HM- and N297Q-IgG1 Fc were purified using the same general procedure given 
below. The supernatant collected from yeast expression was filtered with 0.5 µm filter pads 
(Buon Vino Manufacturing) to remove particulates before protein A affinity chromatography. The 
protein A column (100 mL bed volume) was equilibrated with 20 mM potassium phosphate pH 
6.0 in 10 column bed volumes (CV) and loaded with the filtered supernatant culture medium at 
pH 6.0. The column was then washed with 20 mM potassium phosphate buffer, pH 6.0, 
containing 0.5 M NaCl (5 CV) and then 20 mM potassium phosphate buffer, pH 6.0, (5 CV). HM-
Fc or N297Q-Fc was eluted using 50 mM citrate buffer pH 3.0. Eluted protein was collected in 20 
mL fractions into tubes containing four mL of 1 M Tris pH 9.0  (200 µL of 1 M Tris pH 9.0 per mL 
of elution volume) to neutralize the acidic elution buffer. Fractions of eluted protein detected by 
UV absorbance at 280 nm were immediately dialyzed in 20 mM sodium phosphate buffer pH 7.0 
(4 L exchanged twice every eight hours). After protein A, the samples were purified using 
hydrophobic interaction chromatography (HIC) in a similar protocol as described previously.4 
After  HIC purification, approximately 940 mg of the HM-Fc glycoform and 400 mg of the N297Q-







3.2.5 Production of Man5-Fc 
 HM-Fc was converted to Man5-Fc in an in-vitro enzymatic reaction using B.t. α-1,2-
mannosidase (BT3990).4 Initially, the sample was at a concentration of 0.6 mg/mL in 20 mM 
histidine pH 6.0. Before the reaction, HM-Fc (175 mg) was dialyzed extensively in 10 mM MES 
buffer pH 6.6 to remove the traces of phosphate buffer, and adjust the pH for maximum enzyme 
activity. Next, HM-Fc was dialyzed in a reaction buffer containing 5 mM CaCl2, 150 mM NaCl, and 
10 mM MES buffer pH 6.6 for 12 hrs. After dialysis, the enzymatic reaction was started by adding 
10 mg of the bacterial α-1,2-Mannosidase (BT3990) in a 6000 MWCO dialysis bag. The reaction 
was kept at room temperature for about 48 hrs. Mass spectrometry was utilized to monitor the 
progress of the reaction, and the percentage of conversion to the Man5-Fc glycoform was 
estimated from the peak intensity.  Finally, the reaction mixture was purified using protein A 
affinity chromatography to remove unwanted impurities, salts, and excess enzyme using the 
same protocol as described previously in the purification of HM-Fc.4 The amount of Man5-Fc 
produced was 140 mg (85% yield) and the percentage of conversion to Man5-Fc in the final 
product was estimated to be 81%. The percentage of conversion to Man5-Fc was determined 
from the MS peak intensity.  
3.2.6 Production of GlcNAc-Fc 
 Treatment of HM-Fc with endoglycosidase HF (Endo HF) under mild conditions (20 mM 
histidine, pH 6.0) provides an efficient conversion to GlcNAc-Fc. Endo HF displayed full activity in 
the IgG1 Fc storage buffer (20 mM histidine pH 6.0); therefore, it was possible to digest HM-Fc 
directly without a dialysis step. Samples of HM-Fc were at 0.65 mg/mL and for every 1mg of 
protein, 800 U of Endo HF enzyme was added (which corresponds to approximately 0.08 mg of 
145 
 
Endo H per 100 mg HM-Fc). The mixture was incubated at room temperature for 24 hours, and 
the reaction progress was monitored by mass spectrometry and SDS-PAGE. Finally, the reaction 
mixture was purified using protein A (Using the same protocol mentioned in the purification of 
HM-Fc) to remove unwanted impurities and excess enzyme.  The sample was dialyzed in a 4L of 
20 mM Histidine buffer pH 6.0 (exchanged three times in 16 hrs). The percentage of conversion 
from HM-Fc to the GlcNAc-Fc glycoform was calculated from the peak intensity obtained from 
mass spectrometry, which showed a nearly quantitative reaction with the percentage of GlcNAc-
Fc in the final product ≥ 95%. The percentage of yield from the reaction was > 60%. 
3.2.7 Preparation of Control and Mixtures of Glycoforms for Functional Study 
 The four control glycoforms (HM, Man5, GlcNAc, and N297Q) were first extensively 
characterized using mass spectrometry and SDS-PAGE to test for purity. Enzymes used to 
digestion the glycoforms were removed using protein A affinity chromatography. Before 
preparing the mixture, control glycoforms were buffer exchanged into 20 mM citrate-phosphate 
pH 6.0 containing 150 mM NaCl. Each control glycoform concentration was adjusted to 0.5 
mg/mL.  
3.2.8 Preparation of IgG1 Fc glycoform Mixtures 
 The four control glycoforms (HM-Fc, Man5-Fc, GlcNAc-Fc, and N297Q-Fc) were first 
extensively characterized using mass spectrometry, and SDS-PAGE to test for purity. Enzymes 
used to digestion the glycoforms were removed using protein A affinity chromatography 
purification. Before preparing the mixture, control glycoforms were dialyzed at 4°C overnight in 
a 20 mM citrate phosphate buffer with ionic strength adjusted to 0.15 by NaCl at pH 6.0. Dialysis 
was performed at 4°C using Slide-A-Lyzer dialysis cassettes (Life Technologies, Grand Island, NY) 
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with a 10 kDa molecular weight cutoff with three buffer exchanges, two exchanges at 4h intervals 
and one overnight. After dialysis, the final concentrations of the control IgG1 Fc glycoforms 
were adjusted to 0.5 mg/mL and were mixed in different ratios as seen in Figure 1 to obtain 
seven different mixtures. The final concentration of protein in the mixtures was 0.5 mg/mL, 
and the seven mixtures and 4 controls were stored in aliquots of 5 mL at -80°C for further 
analysis.  
3.2.9 Intact protein MS 
 Samples of control and mixture IgG1 Fc glycoforms at a concentration of 0.5 mg/mL were first 
incubated with 10 mM dithiothreitol (DTT, Invitrogen) and then 60 µL was injected into the 
mobile phase of the LC. ESI spectra of the reduced samples was acquired on an Agilent 6520 
Quadrupole Time-of-Flight (Q-TOF) system. The same protocol was followed for running the 
experiment and data collection as described previously.4 Data was collected in triplicates and, 
based on the peak intensities, the percentages of the compositions of the mixtures and control 
glycoforms were analyzed.  
3.2.10  Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 The experiment was performed under reducing and non-reducing conditions using the 
Bio-Rad MiniPROTEAN® electrophoresis. Samples containing 10 μg proteins were mixed with an 
equal volume of loading buffer (62.5 mM Tris-HCl, 2% w/v SDS, 0.01% Bromophenol blue, 25% 
glycerol) with and without DTT for reducing and non-reducing conditions, respectively. The Fc 
glycoforms were kept in a boiling-water bath for 2 min before loading. Samples and molecular 
weight markers were loaded into pre-cast 4-20% gradient gels with a running buffer containing 
25 mM Tris, 192 mM glycine, and 0.1% SDS at constant 200V for about 45 min. Gels were then 
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stained with a staining solution containing 0.05% Coomassie brilliant blue, 10% acetic acid, 40% 
water, and 50% methanol for one hour. Next, the gels were destained with 30% methanol, 10% 
acetic acid, 60% methanol. Band densitometry measurement was performed using the Image J 
program (NIH) as described in detail elsewhere.21, 44 The percentage of the total area in a band 
was determined and used to calculate the percentage of the composition of the mixtures. 
3.2.11 Production of FcReceptors 
 FcRIIIa was expressed and purified in the same manner as described in detailed elsewhere.4 The 
cDNA of pGAP-FcRIIb was linearized using Bgl II and transformed into P pastoris OCH1 deleted 
cells. Expression and purification of FcRIIb were conducted similarly to the expression of FcRIIIa 
as described in detail elsewhere.4 The histidine-tagged protein was first affinity isolated from 
yeast media by Ni+2-NTA and then extensively buffer exchanged in 20 mM sodium phosphate, pH 
7.0, for a further HIC purification outlined below.  A hydrophobic interaction chromatography 
(HIC) method using phenyl sepharose™ high-performance resin (GE Healthcare) with a 75 mL CV 
(packed in-house) and an AKTAmicro chromatographic systems (GE Healthcare) were used to 
purify FcRIIB.  First, the HIC column was equilibrated with Buffer A (20 mM sodium phosphate, 
1.5 M ammonium sulfate pH 7.0) for 10 CV. Next, Ni+2-NTA purified FcRIIB (dialyzed in buffer A) 
was loaded onto the pre-equilibrated column. The chromatographic purification was then 
performed with a linear gradient from 1.5 to 0 M ammonium sulfate (15 CV) using Buffer B (20 
mM sodium phosphate, pH 7.0). Fractions (5 mL) containing pure FcRIIB was collected and 
concentrated to 1 mg/mL using Vivaflow 50 (10,000 MWCO; Sartorius Stedim Biotech). The total 
amount of protein produced using this technique was 20 mg. After that, the sample was dialyzed 




3.2.12  Interaction of Immobilized Fc Glycoforms with FcRIIIa Using Biolayer 
Interferometry  
 
 The interactions of the different controls and mixtures of IgG1 Fc glycoforms with the FcRIIIa 
was studied with biolayer interferometry using a BLItz instrument (Fortebio, Menlo Park, CA) with 
protein G biosensor tips. Samples for the binding study were prepared in different compositions 
(Figure 1) as follows: The first set of samples includes control glycoforms (HM-Fc, Man5-Fc, 
GlcNAc-Fc, and N297Q-Fc). The second set contains a mixture of HM-Fc with a small percentage 
of the other glycoforms, which includes 90%HM:10%Man5, 90%HM:10GlcNAc, and 
90%HM:10%N297Q. The third set of samples are 50% composition as follows: 50%HM:50%Man5, 
50%HM:50GlcNAc, and 50%HM:50%N297Q. The fourth set is a mixture of the four glycoforms 
25%HM-Fc:25%Man5:25%GlcNAc:25%N297Q. The binding of controls and mixtures of the IgG1 
Fc glycoforms with FcRIIIa were performed as described previously.4 The concentration range of 
the FcRIIIa in solution was 50 nM to 800 nM in a two-fold serial dilution. Briefly, the binding 
progress was monitored, which is proportional to the surface bound protein. At the end of the 
association phase, the unbound analyte in the cuvette was removed from the vicinity of the 
biosensor, and the dissociation of the complex formed was monitored by dipping in an analyte-
free PBS kinetic buffer. The formation of the complex during incubation followed a typical binding 
profile, with the exponential increase in signal. After dipping the biosensor into Fc-free PBS 
buffer, the dissociation was monitored with a signal eventually returning close to the baseline. 
Data generated from the binding of the receptor to IgG1 Fc glycoforms were collected in 
triplicates and globally fitted to a 1:1 using the first-order rate equation binding model in 
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BLItz® Pro software. The same binding method as described for FcRIIIa above was used for 
studying the interaction of FcRIIb with mixtures of IgG1 Fc glycoforms, except the concentration 
range of the receptor in solution was 200 nM to 10,000 nM in a two-fold serial dilution. Similarly, 
data were collected in triplicates and globally fitted to a 1:1 binding model using BLItz® Pro 
software. 
3.2.13  Interaction of Immobilized FcRIIIa with Fc Glycoforms Using Biolayer 
Interferometry 
The interactions of the different pure and mixtures of  IgG1 Fc glycoforms with biotinylated 
FcRIIIa was studied with biolayer interferometry using a BLItz instrument (Fortebio, Menlo Park, 
CA) with streptavidin (SA) biosensor tips. The concentration range of the Fc in solution was 50 
nM to 800 nM in a two-fold serial dilution. 
 Before the binding experiment, the mixture of glycoforms were dialyzed in PBS buffer to remove 
the storage buffer (20 mM Histidine, pH 6.0) and to adjust the pH to 7.4. The same protocol was 
followed as described in detail elsewhere.4 
3.2.14 Binding Response Measurements 
The responses of the controls and mixtures of IgG1 Fc glycoforms with the FcRIIIa were 
studied with biolayer interferometry using a Blitz instrument (Fortebio, Menlo Park, CA) using 
protein G biosensor tips.  One protein G biosensor was used for each of the mixtures including 
its reference for generating the sensorgrams. The biosensor was regenerated after each cycle of 
runs. Response measurements using FcRIIIa were conducted as follows. The protein G biosensor 
tip was hydrated for 10 min with PBS buffer (150 mM NaCl, 50 mM sodium phosphate pH 7.4) 
and incubated for 30 min with PBS kinetic buffer (PBS buffer containing 1 mg/mL casein as a 
blocking agent).  Next, an initial baseline (30 sec) was established with PBS kinetic buffer and the 
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protein G biosensor tips were loaded with the IgG1 Fc glycoforms (control and mixtures) at a 
concentration of 0.8 µM (120 sec). The Fc concentration was based on the total of all glycoform 
component's concentration in the mixture. The Fc concentration was based on the total of all 
glycoform component's concentration. Next, a new baseline (30 sec) was established, and the 
association (180 sec) and dissociation (360 sec) of FcRIIIa were measured by dipping the 
biosensor into solutions of FcRIIIa (0.8 µM) and PBS, respectively. The response curves were 
then reference subtracted and exported into Microsoft excel. The last five points at the end of 
the association phases were averaged to measure the response for each curve. These responses 
obtained from the three curves were averaged to measure the response for each sample. The 
same protocol was followed for all the controls and the mixtures of glycoforms to determine their 
responses. The same protocol was also followed for measuring the binding responses for all of 
the interactions between the glycoforms and FcRIIb. The concentration of the FcRIIb used was 
3.2 µM. 
3.3 Results 
3.3.1 Characterization of Control and Mixture of IgG1-Fc Glycoforms 
A large amount of HM-Fc was required as a starting material to produce GlcNAc Fc, and 
Man5-Fc using in-vitro enzymatic digestion. Additionally, HM-Fc is a common component of the 
mixture of IgG1 Fc glycoforms. Hence, to make a large quantity, HM-Fc was expressed in a 10 L 
fermenter using a glycosylation-deficient strain of P. pastoris. Using fermenter expression, 940 
mg of the HM-Fc and 400 mg of the N297Q-Fc glycoforms were produced for this study. Several 
attempts to produce N297Q-Fc in expression media containing BSM and PTM1 salts resulted in 
low yields. Thus, BMGY media was used to generate higher yields. Man5-Fc was produced using 
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an in-vitro enzymatic reaction by treating HM-Fc with B.t. α-1, 2-mannosidase (BT3990),4 and the 
percentage of conversion was 81% calculated from the mass spectrometry peak intensity. The 
amount of Man5-Fc produced was 140 mg with 86% yield. 
Characterization was performed to establish baseline characteristics of the controls and 
mixtures of glycoforms. Thus, rigorous analytical characterizations were conducted on the 
controls and mixtures of glycoforms to identify aggregation level, glycosylation state, chemical 
modification, and intact protein mass. In biosimilarity and comparability studies, extensive 
characterization is performed on the structure and function of the originator and biosimilar to 
identify the critical quality attributes.2, 25 Thus, SEC, cIEF, mass spectrometry, SDS-PAGE, and 
densitometry were used to characterize the controls and mixtures of glycoforms. These 
characterizations include the following: glycosylation profile, the percentage of composition, 
purity, aggregation, and charge heterogeneity. The size exclusion high-performance liquid 
chromatography (SEC) was used (under nondenaturing condition) to determine if aggregates 
were present in the controls and mixtures of glycoforms. Table 6 showed average monomer 
percent results indicated that the controls and mixtures glycoforms were present as monomers 
with small levels of aggregates across the samples (1-3%). Next, characterization of the isoelectric 
pH (pI) range by capillary isoelectric focusing was done to monitor charge heterogeneity, and the 
(Table 6) showed similar pI values of the major species for all the samples tested. This initial 
characterization demonstrated the homogeneity and purity of the samples prepared. Thus, any 
difference observed in their functional and physical characteristics was mainly attributed to 
differences in their glycosylation profile. 
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Next, mass spectrometry was used to characterize the controls and mixtures of IgG1 Fc 
glycoforms. Mass spectrometry is used to characterize post-translational modifications, such as 
oxidation, phosphorylation, truncation, proteolysis, glycosylation state. Mass spectrometry is 
increasingly becoming an important tool in biosimilarity and comparability studies to establish 
structural similarities for the proteins under test.2 In this work, the control and mixture of 
glycoforms were well-characterized using mass spectrometry with regard to their glycosylation 
profiles and purities. Figure 3 shows intact mass spectrometry data for HM-Fc, Man5-Fc, N297Q-
Fc, and GlcNAc-Fc, under reducing conditions. These four glycoforms were used as controls in 
this study. As shown from the mass spectrometry data, the differences observed in mass were 
mainly due to the differences in their glycosylation profile because the same precursor (HM-Fc) 
was used to produce GlcNAc-Fc and Man5-Fc glycoforms, except N297Q-Fc in which there was a 
single amino acid mutation (i.e., N297Q).  
On mass spectrometry, a shift to a lower molecular weight was observed in the order of 
HM-Fc>Man5-Fc>GlcNAc-Fc>N297Q-Fc. Moreover, the mass spectrometry data showed the 
purity and relative homogeneity of the IgG1 Fc glycoforms produced after protein A and HIC 
purifications. The peak intensities of the intact mass spectra of the control glycoforms under 
reducing conditions were shown in Table 2.  The estimated abundances of the control glycoforms 
were >81% for Man5, ≥ 96% for GlcNAc-Fc and ≥ 97% for N297Q-Fc, which were consistent with 
our previously reported data.4 The predominant forms of the truncated Man5-Fc and GlcNAc-Fc 
contained a single major peak as would be expected. For N297Q-Fc, a single major peak was 
observed, which corresponded to the non-glycosylated Fc monomer containing glutamine at the 
297 position. HM-Fc contained high-mannose glycans ranging from Man8GlcNAc2 to 
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Man12GlcNAc2 with their corresponding percentages ranging from 45% to 5% as shown in Figure 
3. All these glycosylation profiles agreed with our previously reported work.4 Next, the 
glycosylation profiles and compositions of the mixtures were examined using mass spectrometry. 
For instance, the mass spectrometry data for the first set of the mixtures of HM-Fc and N297Q-
Fc, Mix6 was shown in Figure 3; the N297Q-Fc (25078 Da) showed a smaller peak intensity, which 
corresponded to its proportion present in the sample. The sum of the intensities of Man8GlcNAc2, 
Man9GlcNAc2, Man10GlcNAc2, and Man11GlcNAc2 was considered when comparing the intensities 
of HM-Fc with N297Q-Fc. To determine the percentage of composition of these mixtures, each 
intensity of the glycoforms (N297Q-Fc and HM-Fc) was divided by the total intensities of both 
components. The mass spectrometry characterizations were run in triplicates, and the estimated 
percentage of compositions were the average of these triplicate runs (Table 2). The estimated 
compositions from the peak intensities were 89.6±0.1% and 10.4±0.1% for HM-Fc and N297Q-Fc, 
respectively. The calculated values agreed with the percentage of components present in the 
mixture. Moreover, the data suggested that the mass spectrometry data can be utilized for 
estimation of the percentage compositions consistently.  
The second mixture of HM-Fc and N297Q-Fc contained an equal amount of each 
glycoform (i.e., 50% of each glycoform). The peak intensity of N297Q-Fc significantly increased, 
which was proportional to its amount present in this particular mix (Figure 3). The percentage of 
compositions of HM-Fc and N297Q-Fc in the mixture were 48.2±0.6% and 51.8±0.6%, 
respectively, as shown in Table 2. Again, these values indicated that the mass spectrometry data 
could be utilized to differentiate or identify both the subtle as well as obvious differences in 
glycosylation profiles and compositions of the mixtures. The second set of the mixtures contained 
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HM-Fc and GlcNAc-Fc with proportions of the Mix2 and Mix5. A smaller peak of GlcNAc-Fc at 
25265 Da compared to HM-Fc was observed, which corresponded to its proportion present in 
the sample. The estimated percentage of compositions from the peak intensities were 89.6±0.4% 
and 10.4±0.4% for HM-Fc and GlcNAc-Fc, respectively. Similarly, with Mix2 mixture, the 
percentage of compositions calculated from the peak intensities were 54.7±2.9% for HM-Fc and 
45.3±2.9% for GlcNAc-Fc, which agreed with the composition of the samples prepared.  
The third mixture contained HM-Fc and Man5-Fc mixed in a similar proportion to the 
previous two mixtures described above. The mass spectrometry data for Mix4 showed a lower 
peak intensity at 26280 Da for Man5-Fc, as expected from the percentages of the composition. 
The estimated percentages of composition were 90.5±0.3% and 10±0.3% for HM-Fc and Man5-
Fc, respectively. Similarly, the percentages of composition for Mix1 mixture were 55.5±0.4% and 
44.4±0.4% for HM-Fc and Man5-Fc, respectively. These values corresponded to the percentages 
of the composition of the glycoforms in the mixture. The fourth set of the mixtures contained a 
combination of HM-Fc, Man5-Fc, GlcNAc-Fc, and N297Q-Fc. This mixture contained an equal 
proportion (i.e., 25% each glycoform) of the four glycoforms as indicated from their peak 
intensities (Figure 3 and Table 2). The calculated percentages of the composition from the peak 
intensities were 32.0±2.1%, 21.3±0.8%, 25.8±0.6%, and 20.8±2.0% for HM-Fc, Man5-Fc, GlcNAc-
Fc, and N297Q-Fc, respectively. These percentages of the glycoforms were close to their 
compositions in the mixture. Overall,  the mass spectrometry tool demonstrated the ability to 




Next, SDS-PAGE was used to examine the purity, presence of covalent aggregation, and 
fragments of the control and mixture of glycoforms. In addition, the SDS-PAGE was conducted to 
examine if the mixtures with an evident and subtle difference in molecular weight could be 
differentiated. The SDS-PAGE (Figure 2) shows reducing and non-reducing conditions for the 
control and mixture of glycoforms. The control glycoforms (Lanes 8, 9, 10, and 11) each showed 
a single band, suggesting purity of the glycoforms prepared. Also, no fragment of the glycoforms 
tested was observed when tested under reducing and non-reducing conditions. Furthermore, the 
SDS-PAGE under non-reducing condition showed no heavy chain monomer, which again, 
indicated that the samples prepared were homogenous, containing no trace of monomers or 
fragments. For instance, a mixture of HM-Fc and N297Q-Fc (i.e., Mix6) under non-reducing 
conditions (Lane 4) showed a major and a minor band. The intensities of the bands were 
proportional to the amount of HM-Fc and N297Q-Fc present in the mixture. Likewise, the non-
reducing condition showed a major band for HM-Fc and minor band for the N297Q-Fc.  
The second mixture of HM-Fc and N297Q-Fc (50% of each glycoform) was also examined 
by SDS-PAGE, and as shown in lane 5 (reducing and non-reducing), the band intensities were 
nearly equivalent, reflecting the composition of the sample. A similar pattern was observed for 
the mixture of HM-Fc and GlcNAc-Fc, in which the band intensities indicated the nature of the 
composition. Equal band intensities were observed in the 50% composition, whereas for the 
Mix6, a faint band for the 10% GlcNAc-Fc and a major band for the 90%HM-Fc were observed 
(Lane  6). The reducing and non-reducing SDS-PAGE for the control glycoforms showed migration 
according to their molecular weights (HM-Fc>Man5-Fc>GlcNAc-Fc>N297Q-Fc) as illustrated in 
Figure 2. The difference between GlcNAc-Fc and N297Q-Fc was only a single glycan. Hence, their 
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difference was not obvious from the band migrations, suggesting that the mass spectrometry 
characterization might be the best choice in such mixture of glycoforms. 
The SDS-PAGE bands of the mixture of HM-Fc and Man5-Fc were shown in Figure 2. The 
molecular weight difference between these two glycoforms was small, and thus, no resolution 
was achieved as expected. Therefore, there was less information that can be obtained from the 
SDS-PAGE that indicated a difference in their glycosylation state. The last set of the mixtures was 
25% composition of the four control IgG1-Fc glycoforms. Two bands were observed; the upper 
band was a combination of Man5-Fc and HM-Fc, and the lower band corresponds to GlcNAc-Fc 
and N297Q-Fc (Figures 2, Lane 3).  This data suggested that, even for a complex mixture, SDS-
PAGE can be helpful in identifying differences in glycosylation profile and estimating the 
percentages of the composition as shown below.  
The mixture of glycoforms were further characterized using densitometry as shown in 
Table 3. The densitometry analysis includes a combination of HM-Fc with GlcNAc-Fc and N297Q-
Fc glycoforms at different proportions that showed band resolution. In the Mix6 mixture, the 
percentages of compositions determined by densitometry were 89.5% HM-Fc and 10.5%  N297Q-
Fc, respectively. These percentages of composition were in close agreement with the estimated 
percentages calculated from the mass spectrometry intensities. Likewise, with the Mix3 mixture, 
the percentages of composition from the densitometry analysis were 48.0% HM-Fc and 51. 6% 
N297Q-Fc. Again, these percentages of the composition were in close agreement with 
percentages calculated from the mass spectrometry peak intensities. In the Mix5 mixture, the 
percentages of the composition were 89.3% and 10.7%, for HM-Fc and GlcNAc-Fc, respectively. 
A similar characterization with the Mix2 mixture indicated the following percentages of 
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composition: 54.7% HM-Fc and 45.3% GlcNAc-Fc. All these percentages were in close agreement 
with the percentages calculated from the mass spectrometry peak intensities. However, less 
information can be obtained from the mixture of HM-Fc and Man5-Fc regarding their 
composition because they have similar molecular weight. Therefore, the bands were not resolved 
on the gel. A more sensitive method, such as mass spectrometry, could be used as the method 
of choice to characterize the percentage of these particular glycoforms. 
3.3.2 Binding of Control IgG1 Fc Glycoforms with FcRIIIa 
The binding interactions of immobilized controls and mixtures of glycoforms to FcRIIIa 
were performed using biolayer interferometry with protein G biosensors. First, the biosensors 
were loaded with Fc glycoforms to a response level of 2 nm. The association (kon) and dissociation 
(koff) phases were measured, which corresponded to the formation and dissociation of the 
complex formed between the immobilized Fc glycoforms and FcRIIIa. The kon and koff  were 
utilized to calculate the equilibrium dissociation constant (KD). The kon, koff,  and KD values for the 
Fc-immobilized format were given in Table 1. The KD values were 26.6±2.1 nM, 30.7±5.6 nM, 
1073.6±240.2 nM for HM-Fc, Man5-Fc, and GlcNAc-Fc, respectively. These KD values were 
consistent with previously reported data.4 In addition, no binding was observed for N297Q-Fc at 
the highest concentration tested (10 µM). The comparison in KD values between the four control 
glycoforms was demonstrated in Figure 4F. Similarly, representative binding curves were given 
in Figure 9A. As shown from the bar graphs, HM-Fc and Man5-Fc bound to FcRIIIa similarly, 
whereas GlcNAc-Fc bound weakly. Furthermore, no detectable binding was observed for N297Q-
Fc. In these studies, significant differences in the koff values of these glycoforms were found as 
shown in Table 1 and illustrated in Figure 4B. These large differences in binding affinities make 
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the glycoforms prepared in this work an excellent model to study the behavior of mixtures during 
binding to Fc-receptors.   
3.3.3 Binding of Control IgG1 Fc Glycoforms with Immobilized FcRIIIa 
This technique was the reverse of the above method in which FcRIIIa was selectively 
immobilized to streptavidin biosensors.4  A linker between streptavidin and FcRIIIa was expected 
to avoid steric hindrance. In addition, the level of immobilization was kept < 0.4 nm to prevent 
any crowding effect since streptavidin is a tetrameric protein.   
The interactions of control IgG1 Fc glycoforms were measured with streptavidin 
biosensors. In this format, the FcRIIIa was selectively immobilized onto the biosensor, whereas 
the Fc glycoforms were kept in solution. A range of concentrations of the controls and mixtures 
of glycoforms were used to determine the KD values of the interactions. FcRIIIa was loaded onto 
the streptavidin biosensors to a response level of 0.4 nm and then incubated with the Fc 
glycoforms in solution. For dissociation, the biosensor was incubated with analyte-free PBS buffer 
and monitored for the rate of dissociation of the complex formed. From the binding curves 
generated, the association (kon)  and dissociation (koff) rate constants were obtained and utilized 
to calculate the equilibrium dissociation constant (KD) values. As shown in Table 1, the KD values 
were 27.7±2.7 nM, 31.5±4.7 nM, and 1079.5±109.9 nM for HM-Fc, Man5-Fc, and GlcNAc-Fc, 
respectively. These results demonstrated a range of binding affinities and were in agreement 
with our previous work.4 The Fc-immobilized (FRIIIa in solution) and receptor-immobilized (Fc 
glycoform in solution) formats provided nearly the same KD values for the control IgG1 Fc 
glycoforms as shown in Table 1. These data suggested that both methods were equally sensitive 
and behaved similarly at detecting changes in glycosylation state, which consequently, changes 
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the binding affinities to FcRIIIa. Figure 4 shows a comparison of the KD values of control Fc-
glycoforms generated using the immobilized Fc and receptor (Table 1). Overall, the data indicated 
that the same KD values were obtained from both formats for HM-Fc, Man5-Fc, and GlcNAc-Fc 
control glycoforms. Representative binding curves generated for the association and dissociation 
of the control glycoforms were given in Figure 9. Fast kinetic dissociation rate constants (koff) was 
observed for GlcNAc-Fc and, consequently, weaker binding affinity. Comparatively, slow kinetic 
dissociation rate constants (koff ) were observed for HM-Fc and Man5-Fc. No signal was observed 
for N297Q-Fc, which underlined the significance of the N-linked glycan (N297) for maintaining 
the functional activity. The control glycoforms were used to optimize both methods and 
demonstrated that the two formats were complementary. Thus, any difference between the 
mixtures could be identified based on the individual glycoforms they were made of (components 
of the mix) and attributed to the characteristics of the mixture. 
3.3.4 Interaction of Mixture Fc Glycoforms with FcRIIIa 
3.3.4.1 Mixtures of HM-Fc and N297Q-Fc 
 HM-Fc and N297Q-Fc were combined to make two mixtures with the compositions as 
follows: Mix3 and Mix6. These two mixtures were prepared to observe the behavior of the 
mixtures during association and dissociation phases using both the Fc-immobilized and receptor-
immobilized formats. Furthermore, the Mix6 mixture was designed to observe any subtle change 
that can be detected using the binding assays. The Mix3 mixture was designed to represent a 
major shift in the composition, and understand how this mixture with equal proportion behaves 
using the two binding assay formats. In other words, the main goal was to test whether the 
methods can identify both subtle and major changes in binding affinities in a given sample with 
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either a subtle or a major change in composition. Thus, in this work, the interactions were 
measured using the two immobilization techniques as described below. 
3.3.4.2 Binding of Immobilized Mixtures of N297Q-Fc and HM-Fc to FcRIIIa 
 Mixtures of N297Q-Fc and HM-Fc were prepared and loaded onto the biosensor; both 
mixtures (i.e., Mix3 and Mix6) were tested and analyzed. The formation and dissociation of the 
complex formed were measured in the same protocol used for the control glycoforms. 
Interestingly, N297Q-Fc in these mixtures was functionally inactive and does not bind with the 
FcRIIIa. Thus, it is relevant to monitor how the effect of this inactive protein affects the overall 
apparent equilibrium dissociation constant. The KD values for Mix6 and Mix3 were 24.9±1.3 nM 
and 24.9±1.1 nM, respectively, as shown in Table 1. 
The results indicated that regardless of the amount of N297Q-Fc present in the mixture, 
no differences in apparent KD were detected using the Fc-immobilized format. Moreover, the 
data demonstrated the presence of inactive protein (N297Q-Fc) has no effect on the apparent 
equilibrium dissociation constant measured. This phenomenon was observed because the level 
of immobilization (active or inactive) did not influence the kinetic parameters ( kon and koff) used 
for determination of the KD values. In other words, the KD  determined by kinetic parameters was 
dependent on the kon and koff values and independent of the amount of immobilized Fc proteins. 
The other factor that contributed to the KD values was the concentration of protein in solution: 
in this case, the Fc receptor. The concentration of the Fc receptor used for both sets of mixtures 
was the same. As a result, this technique was not able to detect the presence of the inactive 
protein (N297Q-Fc) present in the mixture. This result highlights the need to carefully analyze 
binding experiments performed with the Fc-immobilized format since the technique is blind to 
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inactive proteins. A typical example of inactive protein could be a denatured protein (physical 
and chemical) or non-native aggregates caused by various stress factors. 
3.3.4.3 Binding of N297Q-Fc and HM-Fc Mixtures with Immobilized FcRIIIa 
The receptor-immobilized format was used to test the two mixtures of  N297Q-Fc and 
HM-Fc. Mixture with different concentrations of HM-Fc and N297Q-Fc was prepared and kept in 
solution, whereas FcRIIIa was immobilized selectively onto the streptavidin biosensors. The KD 
value obtained for Mix6 was 31.5±2.9 nM, showing subtle change compared to the control HM-
Fc KD value measured, which was 27.7 ±2.7 nM. Next, the second mixture of HM-Fc and N297Q-
Fc (50% each) was examined, and the KD value increased by two-fold. Unlike the Fc-immobilized 
format, the inactive protein (N297Q-Fc) was included in the total concentration of Fc used for 
determination of the KD value. In other words, in the 50% mixture of HM-Fc and N297Q-Fc, the 
KD value increased by two-fold, which was due to the presence of 50% inactive protein (N297Q-
Fc) in the solution. This inactive protein accounted for 50% of the concentration of Fc used for 
determination of the KD value. Thus, when 50% N297Q-Fc (inactive protein) was present, the KD 
value increased by two-fold. From the kinetic parameters, the association rate constant was 
concentration dependent and showed a significant reduction when the proportion of N297Q-Fc 
increased. However, the dissociation constant (koff) was independent of concentration, so the 
differences observed were attributed to the kon values. In other words, the dissociation rate 
constant value was independent of the concentration, and no change was observed as shown in 
Table 1. Representative binding curves for this mixture were shown in Figure 9B. The kon, koff ,and 
KD values were illustrated in Figure 4. 
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Unlike the the dissociation rate constant, the association rate constant (kon) and the 
equilibrium dissociation constant (KD) were dependent upon the concentration. To prove our 
concept that the change in KD value was only due to the presence of N297Q-Fc (functionally 
inactive), the data was re-processed by adjusting the actual concentration of the HM-Fc present 
in the mixture without accounting for the N297Q-Fc concentration. As shown in Table 1, the kon 
values showed a significant increase from (1.7± 0.1)x105 M-1s-1to (3.1±0.4)x105 M-1s-1, and the KD 
value decreased from 52.7±3.7 nM to 29.0±4.2 nM as expected for pure HM-Fc control glycoform 
measured (Table 1). The re-processed KD values were similar to the pure HM-Fc values, indicating 
that the changes were mainly due to the apparent concentration. Overall significant differences 
in KD values were observed between the two immobilization formats, highlighting the impact of 
the sample composition and immobilization technique on the binding outcome. 
The KD values from the 50% mixture of HM-Fc and N297Q-Fc measured using the Fc-
immobilized and receptor-immobilized formats were 24.9±1.1 nM and 52.7±3.7 nM, respectively. 
As shown above, the difference in KD values between the two formats was nearly two-fold. The 
result demonstrated that care must be exercised when designing an experiment and analyzing 
the data since the selected immobilization technique could have a significant impact on the 
equilibrium dissociation constant. Overall, the receptor-immobilized method successfully 
determined the presence of inactive protein in the samples and must be the method of choice 
when the sample is expected to have impurities or inactive protein. 
3.3.4.4 Mixtures of Man5-Fc and HM-Fc Glycoforms 
HM-Fc and Man5-Fc controls showed a similar high affinity to FcRIIIa, as would be 
expected for high-mannose IgG glycoforms. Two sets of mixtures of HM-Fc and Man5-Fc were 
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prepared with subtle and major differences in composition, Mix1 and Mix4, respectively. These 
two Fcs model mixture of non-fucosylated glycoforms with differences in the α-1,2-linked high 
mannose-terminal glycans. The HM-Fc glycoforms contained high-mannose glycans consisting 
primarily of 8 mannoses (Man8GlcNAc2), whereas the Man5-Fc contained high-mannose glycans 
consisting primarily five mannoses (Man5GlcNAc2). The binding studies for both immobilizations 
were conducted with the same protocol as described above. In the Fc-immobilized, the KD values 
were 25.9±1.2 nM and 26.9±1.4 nM for Mix4 and Mix1, respectively. No change in KD values 
between the mixtures was observed. For the immobilized FcRIIIa binding with the mixture, the 
KD values for Mix4 and Mix1 were 27.03±1.1 nM and 25.74±2.9 nM, respectively. Similar to the 
Fc-immobilized, no change in KD values was observed regardless of composition of the mixture 
or immobilization technique used. Likewise, no change in KD values was found between the two 
immobilization technique.  
The similarity in KD values was presumably due to both HM-Fc, and Man5-Fc binding 
similarly to FcRIIIa. Mixing the glycoform did not seem to change the apparent binding affinity. 
Additionally, both glycoforms behaved similarly with regard to their interaction with the FcRIIIa 
in both formats, suggesting the α-1,2 glycans have minimum effect on the binding affinities. This 
result indicates that when the components of the mixture have the same binding affinity, then 
neither the percentage of composition nor the immobilization technique influences the apparent 
binding affinities. See Table 1 for kinetic data and Figures 9A and 9B for representative binding 





3.3.4.5 Mixtures of HM-Fc and GlcNAc-Fc Glycoforms 
HM-Fc and GlcNAc-Fc have a slight difference in their kinetic association rate constants 
(kon) but a significant difference in their kinetic dissociation rate constants (koff). The differences 
in koff values ultimately give differences in equilibrium dissociation constants (KD). Two mixtures, 
namely: Mix2 and Mix5, were prepared and determined using both immobilization format. The 
KD values generated from the Fc-immobilized technique for HM-Fc and GlcNAc-Fc control 
glycoforms were 26.6±2.1 nM and 1073.6±240 nM, respectively. Similarly, using the receptor-
immobilized technique, the KD values were 27.7±2.7 nM for HM-Fc and 1079.5±109.9 nM for 
GlcNAc-Fc. There was a 40-fold difference between the two KD values, mainly attributed to their 
differences in kinetic dissociation rate constant (koff) values as shown in Table 1. The KD values 
obtained using the Fc-immobilized technique were 44.4±2.8 nM and 76.7±5.6 nM for Mix5 and 
Mix2, respectively. This decrease in binding affinity was due to the presence of a weak binding 
component (GlcNAc-Fc) in the mixtures. The result demonstrated that the Fc-immobilized 
technique was able to detect the contribution of the weak binding components (i.e., GlcNAc-Fc) 
in the mixture.  
For Mix2, in which there was a higher proportion of GlcNAc-Fc, the kinetic dissociation 
constant (koff) values increased as shown in Table 1. Hence, there was a significant increase in koff 
compared to the second set of the mixture (Mix5). This result indicated that when there was a 
weak binding component in the mixture that can still bind to FcRIIIa, the Fc-immobilized 
technique could pick up the contribution, and thus the KD values reflect the nature of the mixture 
composition. This was important, specifically when compared to the previous sets of mixtures 
(N297Q-Fc and HM-Fc) on which the Fc-immobilized method was blind to the inactive protein 
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(N297Q-Fc) but sensitive to partially active protein (GlcNAc-Fc) present in the mixture. Again, this 
highlights the complexity of directly interpreting the KD value without looking at the composition 
of the sample. It is well known that mAbs contain heterogeneous glycoforms that can bind 
differently to FcRIIIa.45 Thus the selected binding assay method has a significant impact on the 
measured binding affinities. Next, to see how this partially active component might affect the 
kinetic values and apparent dissociation constant, the FcRIIIa immobilization technique was 
tested. The KD values obtained for this reverse immobilization technique (immobilized FcRIIIa) 
were 31.7±1.0 nM and 43.3±4.1 nM for Mix5, and Mix2, respectively. The kinetic values from this 
immobilization were significantly different from the Fc-immobilized format as shown in Table 1.  
The difference in KD values in this mixture was presumably due to the difference in the 
mechanism of complex formation between Fc glycoforms and FcRIIIa, which was dependent on 
the immobilization platform used. When the two mixtures (GlcNAc-Fc and HM-Fc) were 
immobilized, there was a single component in the solution (FcRIIIa), which interacted with both 
components independently (heterogeneous ligand binding model) as illustrated in Figures 5 and 
6. When the receptor was immobilized, the two Fcs in the solution were competing for a single 
binding site (FcRIIIa). Thus, there was a competition for a single binding site during the 
association phase leading to the enrichment of the high binding component (i.e., HM-Fc) 
compared to GlcNAc-Fc at the end of the association phase as demonstrated in Figures 5 and 6. 
The competition continued during the association phase leading to the displacement of the weak 
binding component, and consequently, resulted in the enrichment of HM-Fc at the end of the 
association phase. This made the dissociation phase to behave more like HM-Fc than reflecting 
the percentages of the components present in the sample. As a result of this phenomenon, the 
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dominant component of the dissociation phase was HM-Fc, which was evident from the koff 
values obtained. As shown in Table 1, the koff values for HM-Fc control was (7.1±0.5)x10-3 M-1s-1  
and for Mix2 the koff value was (8.5±0.6)X10-3 M-1s-1. Given the standard deviation, there was no 
significant difference between these two koff values, indicating that the major component of the 
dissociation phase was enriched HM-Fc glycoform.  
Furthermore, for the Fc-immobilized format, the koff values of Mix2 was (14.1±1.0)x10-3 
M-1s-1  and  HM-Fc control was (5.5±0.0)x10-3 M-1s-1. This koff value showed a nearly three-fold 
difference, suggesting there was a significant contribution of GlcNAc-Fc on the dissociation 
phase. Once the Fc was immobilized, there was no competitive displacement since the two sites 
were independent, and a single component (FcRIIIa) was in the solution. The result 
demonstrated that when there was a weak binding component, the immobilized Fc was the 
method of choice and reflected the composition of the mixture. Additionally, this result 
demonstrated that the binding kinetic results should be carefully interpreted since the binding 
results depend on the immobilization selected. Moreover, knowing the sample composition 
before the experiment gives important clues about the expected binding result. Therefore, care 
must be exercised not to make a conclusion based on the KD values without looking into the 
sample composition. This is because the result may not represent the actual KD value or could be 
skewed due to the presence of a high binding affinity component present in the sample. The 
binding results of both immobilization formats were illustrated in Figure 4.  
3.3.4.6 Time Course Binding Assessment  
 To prove our concept of the complex binding as well as displacement of GlcNAc-Fc by 
HM-Fc observed in the receptor immobilized format, a time course binding experiment was 
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performed. The dissociation curves were measured at different incubation times for the mixtures 
of GlcNAc-Fc and HM-Fc control glycoforms (Figure 6A). The control HM-Fc showed the slowest 
dissociation phase, whereas GlcNAc-Fc showed the fastest dissociation phase at 180 sec 
association time. Next, we monitored the dissociation phase at different incubation times ranging 
from 30 sec to 180 sec As shown from the dissociation phases, it was evident that the incubation 
time influences the shape of the dissociation curve. This was because of the competitive 
displacement of GlcNAc-Fc by HM-Fc as the incubation time increased. In addition, as the 
incubation time increases, the koff values decreased, which was also evident from the % 
dissociation curves (Figure 6B). Even at the lowest incubation time of 30 sec, the dissociation 
curve behaved more like HM-Fc dissociation than GlcNAc-Fc. This event demonstrated the impact 
of the difference in their binding interaction, which ultimately leads to the fast displacement of 
GlcNAc-Fc by HM-Fc on the surface of the biosensor. For ease of comparison, a similar % 
dissociation was examined for the Mix2, using both immobilization formats as shown in Figure 
6C, and the shape of the dissociation curve behaved more like HM-Fc when the Fc-immobilized 
technique was used. In the Fc-immobilized, however, the dissociation curve reflected both HM-
Fc and GlcNAc-Fc, indicating the contribution of both components. This was because the two 
binding events were independent, and no competitive displacement existed. Again, these events 
prove the differences observed between the two formats. 
3.3.4.7 A mixture of HM-Fc, Man5-Fc, GlcNAc-Fc, and N297Q-Fc glycoforms 
A four component mixture containing an equal proportion of four glycoforms (Mix7) was 
prepared to represent a more complex system. The KD value obtained from the Fc-immobilized 
technique was 52.5±4.0 nM. Since both HM-Fc and Man5-Fc bind with high affinity similarly and 
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N297Q-Fc has no effect on the binding affinity, this change in KD value was presumably due to 
the contribution of the GlcNAc-Fc present in the sample. In the receptor-immobilized format, the 
KD value obtained was 35.6±1.3 nM, which was significantly lower than the KD value measured 
by the Fc-immobilized technique. This lower KD value was presumably due to competitive 
displacement described previously for HM-Fc and GlcNAc-Fc mixtures. Representative binding 
curves for both immobilization techniques are shown in  Figures 9A and 9B. 
3.3.5 Binding of Control IgG1 Fc Glycoforms with FcRIIb 
FcRIIb is the only inhibitory Fcreceptor produced in humans and specifically expressed 
in B-cells.46 Hence, it is relevant in many clinical effects of mAb therapeutics that exert their effect 
through the Fc region.47 The KD values obtained for HM-Fc and Man5-Fc were 3419.8±288.4 nM 
and 3274.5±957.4 nM, respectively. This result indicated that the HM-Fc and Man5-Fc have 
similar binding affinities to FcRIIb. For the N297Q-Fc and GlcNAc-Fc control glycoforms, no 
detectable binding affinities were observed at the highest concentration of FcRIIb tested (10 
µM). See Table 4 for kinetic data and Figure 9C for the binding curve of the control glycoforms. 
3.3.5.1 Mixtures of Glycoforms Binding with  FcRIIb 
 HM-Fc and Man5-Fc glycoforms have similar binding affinities to FcRIIb; no difference 
was observed between Mix4 and Mix1. This was in agreement with the previously observed 
phenomenon when a mixture of HM-Fc and Man5-Fc were examined using FcRIIIa (Figure 4 and 
Table 4). The N297Q-Fc and GlcNAc-Fc glycoforms have no contribution to the observed apparent 
equilibrium dissociation constant. As a result, all the mixtures showed no significant difference 
in apparent equilibrium dissociation constant (KD) values. The data indicated that the KD values 
provided less information about the nature of the sample composition, but since the GlcNAc-Fc 
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glycoform interacted differently to FcRIIb than FcRIIIa, this might be utilized to differentiate 
mixtures containing it. Representative binding curves for the mixture and control glycoforms are 
given in Figure 9C. 
3.3.6 Response Comparison for Controls and Mixtures of Glycoforms  
The kinetic (kon and koff) and the equilibrium dissociation constant were not related to the 
response of the complex formed. In this case, the response was monitored for the control and 
mixture of glycoforms using the Fc-immobilized method. Interestingly, the responses as shown 
from the bar graphs (Figure 8A and Table 5) were able to detect the presence of inactive or weak 
binding component (i.e., N297Q-Fc). For instance, the decrease in response was proportional to 
the presence of inactive protein (N297Q-Fc) or a low-affinity binding protein. This result indicated 
that although the KD values for a mixture of HM-Fc and N297Q-Fc does not show any difference 
regardless of their composition, the proportional decrease in response does indicate the 
presence of the inactive component. Hence, it is important to look not only at the KD values but 
also at the response as critical quality attributes of the sample under test. For instance, the 
response value for Mix6 was approximately 9% less than the HM-Fc control, which was in 
agreement with the amount of inactive protein (N297Q-Fc) present in the mixture. Similarly, the 
response value for Mix3 was approximately 52% of control HM-Fc glycoform, indicating that half 
of the mixture was an inactive component (i.e., N297Q-Fc). A similar pattern was observed for 
mixtures of GlcNAc-Fc and HM-Fc, in which a high proportion of GlcNAc (50%) gave a lower 
response. However, unlike the N297Q-Fc, the GlcNAc-Fc contributes to the observed response of 
the mixture, and the decrease in response was proportional to its contribution to the binding 
response. Mixtures of Man5-Fc and HM-Fc (Mix4 and Mix1) showed a comparable response in 
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agreement with their close  KD values.  Compared to all sample components that can potentially 
bind with FcRIIIa, GlcNAc-Fc showed the lowest response, which was in agreement with its weak 
binding affinity. No response of N297Q-Fc binding to FcRIIIa was observed as described 
previously.   
The binding response comparison was performed using the immobilized Fc technique as 
shown in Figures 7, 8A and Table 5. The data clearly demonstrated the difference in binding 
responses between the different sets of mixtures. Hence, the response measured can be used in 
evaluating critical quality attributes because it showed a trend with the percentage of the 
composition and the nature of the components in the mixtures. Furthermore, it was evident from 
the data that subtle as well as obvious differences were observed, suggesting response 
measurement could differentiate different mixtures. The same method was also used to 
determine the response using FcRIIb. The response showed that the glycoforms bind differently, 
and both N297Q-Fc and GlcNAc-Fc showed no binding response. Also, mixtures containing 
GlcNAc-Fc and N297Q-Fc showed the lowest responses. 
The surface capacity (loading) of a biosensor could significantly affect the binding 
response. Hence, these binding response measurements were performed by carefully monitoring 
the loading capacity and loading level of the Fc glycoforms. Any defective and low surface 
capacity biosensors were excluded from the experiment. Multiple regenerations can also 
decrease the loading capacity of a biosensor and, consequently, reduce the binding response. 
Therefore, the regeneration cycles were kept minimum (three cycles), and one biosensor was 
used for each sample. The response measurements were conducted in triplicates at a single 
concentration. To minimize day-to-day variability in response, the samples were run head-to-
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head. The above protocol ensures that the differences in binding responses observed among the 
glycoforms were mainly attributed to the differences in their receptor binding affinity.  
3.4 Discussion  
The structure of an IgG comprises the Fc and Fab portions, linked by the disulfide bond at 
the hinge region.11 Unlike the Fab region, which is variable in sequence among different IgGs, the 
Fc is homologous and constant in sequence across all IgGs in the same subclass.10 By studying the 
constant Fc portion of IgG1 Fc, rather than a single full-length mAb with variable regions, it should 
be possible to apply the assays developed in this study to differentiate the critical quality 
attributes of the mAbs. The Fc portion is a simpler system to study but contains the CH3 and 
glycosylated CH2 domains, which are present across all human IgG1 mAbs.4 Thus, in this study, 
the human IgG1 Fc was used as a model that can potentially represent all monoclonal antibodies. 
It is well known that the glycan profile in monoclonal antibodies varies with the type of cell line 
and expression conditions. Thus, it is important to study the effect of changes in the glycan profile 
on the biological activity using comparability studies.48-49  Such variations in glycosylation profile 
include the following: core fucosylation, terminal sialic acid, N-acetylglucosamine, and high 
mannose, which are known to affect binding affinity to Fc receptors.50 Therefore, the effect of 
glycosylation on the functional activity of the mAbs is often examined, even if the Fc functionality 
is not part of the mAbs mechanism of action.25 Due to these reasons the Fc region is critical for 
the safety and structural integrity of mAbs.51 In addition to their use in demonstrating 
biosimilarity, functional assays are utilized for candidate selection, product release, and stability 
assessment.26, 31 The biological assay examinations, which include potency form the backbone of 
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the quality control (QC) testing scheme. The biological test used for QC testing needs to be 
sensitive to relevant structural changes with a potential effect on product safety and efficacy.25  
These four glycoforms were selected in this study as controls because they exhibit a broad 
range of biological and physicochemical quality attributes. Hence, these control glycoforms are 
suitable to use as a model for typical changes in quality attributes encountered during biosimilar 
comparability assessments. The mixtures of IgG1 Fc glycoforms were prepared by combining the 
homogeneous glycoforms to make well-defined mixtures with differences in biological and 
physical quality attributes. An advantage of producing homogeneous glycoforms is that it allows 
for developing comparative assays with well-known differences in functional and 
physicochemical quality attributes. Then the assay can be optimized with well-defined mixtures 
that exhibit subtle differences.  
Previously, we developed two functional assay formats: an Fc-immobilized and a 
receptor-immobilized format. Moreover, we demonstrated that the two methods were 
complementary, providing the same KD values for the well-defined homogeneous glycoforms 
(utilized as controls in this study).4 In this study, our goal is to examine how the immobilization 
formats impact the binding outcome of the mixture of IgG1 Fc glycoforms. Also, we want to gain 
a better understanding of which format efficiently differentiates the mixtures with subtle and 
major differences in critical quality attributes. Functional activity assessments are needed 
because physicochemical tests alone cannot provide full information on the structure of the 
molecule necessary for potency. Hence, the functional activity can be used as a surrogate of the 
protein conformational integrity, which is required for activity.25 To achieve our goal, we first 
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tested the control glycoforms and then we used optimized assays to evaluate the mixture of 
glycoforms prepared with the different composition of these glycoforms. 
In biosimilarity studies, the assessment of similarity requires multiple orthogonal 
analytical approaches to adequately define the characteristics of the original biotherapeutics and 
their potential biosimilarity.2 Therefore, as an initial characterization, the purity profiles of the 
control and mixture of glycoforms were assessed using SDS-PAGE, mass spectrometry (MS), 
capillary isoelectric focusing (cIEF), and size exclusion chromatography (SEC). In addition, the 
overall glycosylation profiles of the glycoforms were examined using mass spectrometry to 
confirm their identity and homogeneity. Mass spectrometry plays a vital role in the identification 
of posttranslational modifications, such as oxidation, reduction, deamidation, fragmentation and 
N-linked glycosylation, which can be examined at the protein levels.29, 35 Thus, initial 
characterization of the glycosylation profiles of the control glycoforms was examined using intact 
protein mass spectrometry. In addition, mass spectrometry was utilized to identify the presence 
of proteolytic fragment, C-terminal lysine variability, and oxidation that could arise during 
expression and purification steps. These control glycoforms were found to be highly pure with 
no evidence of chemical modifications, and their glycosylation profiles were consistent with our 
previously reported work.4 Next, we used the intact mass of the control glycoforms and their 
glycosylation profiles as a base characterization to evaluate the composition of the mixture of 
glycoforms. Moreover, the percentage of composition of the mixture of glycoforms was 
examined using the mass spectrometry peak intensity, and the results demonstrated that the 
estimated percentages of the components were accurately determined as shown in Table 2. 
Therefore, the mass spectrometry can be used efficiently to not only identify the glycosylation 
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profiles but also in the estimation of the composition of the mixture of glycoforms. This approach 
could be applied when measuring glycoform composition in mAb therapeutics.  
In general, the mass spectrometry demonstrated distinct differences between the control 
glycoforms based on the size and absence of N-linked glycosylation. Furthermore, the mixtures 
were differentiated based on the size, type and percentages of the glycoform in the mixture used 
in preparing them. For instance, in the mixture containing the four control glycoforms (i.e., HM-
Fc, Man5-Fc, GlcNAc-Fc, and N297Q-Fc), the mass spectrometry demonstrated distinct 
differences as well as the percentage composition of each glycoform as shown in Table 2 and 
Figure 3. This data illustrates the importance of mass spectrometry in characterizing complex 
mixtures, a tool highly needed in biosimilarity assessments.  
We also performed further characterization using SDS-PAGE, size exclusion 
chromatography (SEC), and capillary isoelectric focusing (cIEF). These characterizations were 
carried out to evaluate the presence of dimers, fragments, and charge variants of the control and 
mixture of glycoforms of IgG1 Fc. The SDS-PAGE under reducing condition confirmed an absence 
of any proteolytic and fragment of the control and mixture of glycoforms, consistent with mass 
spectrometry data. In addition, the non-reducing SDS-PAGE confirmed intact Fc homodimer (i.e., 
an intramolecular disulfide bond) in all the samples tested. Furthermore, the percentages of 
mixture compositions were examined using densitometry, and the results agreed with the 
percentages estimated using mass spectrometry as shown in Table 3. The SEC data (Table 6) 
confirmed the absence of low molecular species and showed low levels of dimers across all the 
samples (1-3%). Further characterization with ciEF (Table 6) indicated no charge heterogeneity 
with the major peak being the same across all the control and mixtures of glycoforms.  In mAbs, 
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differences in the relative proportions of charge variants are usually observed during production 
or process changes and present a challenging task in demonstrating product comparability. 
Chemical modifications that result in charge variants include deamidation, isomerization, 
fragmentation, and oxidation. Thus, these charge variants ultimately lead to modification of their 
isoelectric pH (pI) values.52 
In the biosimilarity assessment, extensive characterizations are performed, which 
includes physical, chemical, and biological on the originator; then this characterization is used as 
a base characteristic to compare with their corresponding biosimilar molecule and thereby to 
establish molecular equivalence.31 In our work, all these initial characterizations were conducted 
to establish baseline characteristics of the control and mixture of glycoforms prior to their 
functional and physical stability studies. Therefore, any differences observed between these 
different mixtures during functional and physical characterizations were attributed to the 
differences in their glycosylation profiles as well as their percentages of composition in the 
mixture.  
In this study, binding measurements were first conducted on the control glycoforms (i.e., 
HM-Fc, Man5-Fc, GlcNAc-Fc, and N297Q-Fc) to characterize binding differences and to identify 
critical quality attributes that could help differentiate mixtures.  Furthermore, mixtures of IgG1 
Fc glycoforms were then analyzed for binding to two receptors: the activating receptor (FcRIIIa) 
and the inhibitory receptor (FcRIIb), using biolayer interferometry (BLI). We selected FcRIIIa 
because of its functional relevance, and it is known to bind to the Fc portion of mAbs. 
Furthermore, FcRIIIa is the only activating receptor expressed in natural killer cells and linked to 
antibody-dependent cellular cytotoxicity (ADCC).53-54 Previously, we demonstrated this receptor 
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could differentially bind to Man5-Fc, HM-Fc, and GlcNAc-Fc and showed no detectable binding 
affinity to N297Q-Fc.4 Also, we employed FcRIIb because of its functional relevance to the 
mechanism of action of mAbs therapeutics it being the only inhibitory receptor expressed in B-
cells.47 In addition to having opposite effects on antibody-dependent effector functions, FcRIIIa 
and FcRIIb have different binding specificity for IgG1 Fc glycoforms, allowing the receptors to be 
utilized to differentiate particular glycoforms. To further characterize the IgG1 Fc glycoform 
mixtures and to investigate the effect of binding assay format on biological characterization, the 
two BLI binding formats were utilized for FcRIIIa binding assays.  
The two binding assay formats produced remarkably different results for the mixtures of 
glycoforms. Our result demonstrated that the advantage of using the Fc-immobilized format is 
its ability to detect the presence of a low-affinity glycoform mixed with a high-affinity glycoform 
in binding to FcRIIIa (i.e., a mixture of HM-Fc and GlcNAc-Fc). In mAb therapeutics, a mix of high 
and low-affinity glycoforms could be the non-fucosylated and fucosylated glycoforms, 
respectively, which are known to bind differentially to FcRIIIa.55 Since protein G is not sensitive 
to changes in Fc glycosylation, both HM-Fc and GlcNAc-Fc can be immobilized equally, and their 
interaction with the FcRIIIa is evident in the biphasic nature of the dissociation phases. This type 
of dissociation phase is attributed to the fast dissociation of GlcNAc-Fc and slow dissociation of 
HM-Fc, ultimately resulting in a biphasic dissociation curve. In the Fc-immobilized method, the 
association phase is monophasic given the fact that both HM-Fc and GlcNAc-Fc have similar 
kinetics of association (kon). The dissociation phase shows a biphasic behavior, suggesting the 
two-components (HM-Fc and GlcNAc-Fc) have a different dissociation rate. Although 5% 
dissociation could be enough to describe the dissociation phase as explained elsewhere,56  it is 
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necessary to follow a longer dissociation phase to fully define the biphasic or monophasic 
behavior of the curve, specifically for samples containing mixtures of glycoforms with differential 
binding to FcRIIIa. 
In the mixtures of HM-Fc and GlcNAc-Fc glycoforms, competitive displacement was 
observed in the receptor immobilized format. This competitive displacement of GlcNAc-Fc by 
HM-Fc exists because the two binding events were dependent on each other. Also, GlcNAc-Fc 
has a low binding affinity to FcRIIIa compared to HM-Fc, and this leads to the enrichment of HM-
Fc during the association phase (incubation time). Thus, the dissociation phase behaves more like 
HM-Fc than the dissociation behavior of the mixture of components. Therefore, during 
competitive displacement, slow dissociating component (HM-Fc) displaced fast dissociating 
(GlcNAc-Fc). Hence, the dissociation phase was strongly influenced by the incubation time. Data 
collected over different incubation times can be utilized to understand the behavior of 
components present in the sample. In general, as the contact time increases, there is less and 
less information about the dissociation phases to describe the nature of the composition. 
The ratio of the koff values of GlcNAc-Fc to HM-Fc was estimated to be about 27.2.  This 
data indicated the differences in koff values were significant and controlled the binding interaction 
to the receptor. For instance, the half-life of GlcNAc-Fc complex with the receptor was 5 sec, 
which indicated the residence time on the biosensor surface was short. Similarly, the half-life of 
HM-Fc was 100 sec, which was significantly higher residence time than GlcNAc-Fc. These 
differences in half-life explained the displacement of GlcNAc-Fc by HM-Fc in the association 
phase, which was observed when the receptor-immobilized format was used. Consequently, this 
displacement resulted in the enrichment of HM-Fc at the end of the association phase in 
178 
 
agreement with their half-life. Therefore, the dissociation phase behaves more like HM-Fc.  The 
competitive binding model at equilibrium can explain the displacement of GlcNAc-Fc by HM-Fc 
observed in the receptor immobilized format. For instance, with the Mix2 the complex formed 
between HM-Fc and the immobilized receptor was 40-fold higher than the complex formed 
between the GlcNAc-Fc and the receptor. Since both HM-Fc and GlcNAc-Fc are at the same 
concentration, the ratio of the complex formed at equilibrium is simply the ratio of their 
equilibrium dissociation constant (KD). Although no displacement of GlcNAc-Fc by HM-Fc was 
anticipated in the Fc-immobilized format, the fast dissociation phase was attributed to the short 
half-life of GlcNAc-Fc whereas the slower dissociation phase was attributed to the longer half-life 
of HM-Fc.  
The association and dissociation phases of HM-Fc and Man5-Fc were very similar, and the 
ratio of koff  value of Man5-Fc to HM-Fc was estimated to be about 1.23. In addition, the half-life 
of HM-Fc and Man5-Fc were 100 sec and 87 sec, respectively. The similarity in kon, koff, and half-
life of HM-Fc and Man5-Fc indicated their binding to the immobilized receptor was competitive. 
Therefore, no displacement was anticipated in the mixture of HM-Fc and Man5-Fc, unlike the 
mixtures of GlcNAc and HM-Fc. Furthermore, the ratio of the KD values of HM-Fc and Man5-Fc is 
estimated to be about 1.13, which indicated their similar binding affinities to the immobilized 
receptor.  
The receptor-immobilized technique is a widely-used method to characterize protein 
interaction quantitatively. Our data indicates that this approach is less sensitive when mixtures 
of glycoforms with different affinities are present in the sample. This data suggests that different 
binding protocols can result in different KD values, which will eventually lead to a wide range of 
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reported values in the literature. Moreover, this variability in KD value can potentially create 
difficulty in correlating with in-vitro cell-based assays. This binding displacement was not 
observed in the Fc-immobilized format because the two immobilized mixture components bind 
independently to FcRIIIa and no competition was observed. As a result, the dissociation phase 
represents both elements of the mixtures. 
In the mixture of HM-Fc and N297Q-Fc, the Fc-immobilized method was not able to detect 
the presence of inactive protein (i.e., N297Q-Fc). Moreover, no change in KD value was obtained 
regardless of the percentage of composition of these two glycoforms (50%HM vs. 90%HM). This 
event is observed because in the Fc immobilized format the concentration of IgG1 Fc is not 
relevant for the determination of KD value. In other words, the concentration of the FcRIIIa in 
solution is used in determining the KD value, not the immobilized Fc (HM-Fc and N297Q-Fc). 
Additionally, N297Q-Fc was not contributing to the association and dissociation phases, and the 
binding interaction was purely controlled by the immobilized HM-Fc present in the mixture (Mix3 
or Mix6) and FcRIIIa. Thus, this binding interaction behaves similarly to the interaction of 
100%HM-Fc (control) and FcRIIIa, generating the same KD value, except the response was higher 
in the latter as discussed below.  In practice, the inactive protein could be non-native aggregates, 
fragmented, and chemically degraded protein, with the capacity to be immobilized into protein 
G. However, it would be unable to bind with FcRIIIa. Also, the inactive protein could be the 
presence of non-glycosylated IgG, typically observed in the yeast expression system.21, 57 One way 
to overcome this issue is to monitor the binding response by comparing it head-to-head with a 
well-characterized reference product, and a decrease in response will indicate a change in the 
quality of the sample under examination.  
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We performed the binding response measurement of the controls and mixtures of 
glycoforms.  Therefore, the binding response measurements in this experiment were able to 
differentiate the controls as well as the mixtures of glycoforms with subtle and major changes in 
composition (Figure 7). For instance, in the mixture containing 90%HM and 10%N297Q, the 
response measurement showed 10% decrease compared to 100% HM-Fc, indicating the amount 
of inactive protein present (i.e., N297Q-Fc) was a 10% in the mixture. Similarly, with the mixture 
containing a 50%N297Q, the response decreased nearly two-fold, which is proportional to the 
amount of inactive protein present in the mixture. These results demonstrated that in addition 
to measuring the KD value, monitoring the binding response as a measure of critical quality 
attributes of the sample under test is necessary.  
Unlike the Fc-immobilized, the receptor-immobilized format could detect and 
differentiate mixtures of N297Q-Fc and HM-Fc. This is because the concentrations of the mixtures 
in the solution containing both glycoforms were used in determining the KD values (i.e., receptor 
was immobilized). Furthermore, the change in the KD value was proportional to the amount of 
N297Q-Fc present in the mixture. For example, in the Mix6 mixture, a subtle decrease in binding 
affinity was observed. However, with the Mix3 mixture, a two-fold decrease in binding affinity 
was observed, which was proportional to the amount of N297Q-Fc present in the mixture.  
We noticed remarkable differences between the two immobilization formats in 
differentiating the mixtures. Using well-defined mixtures, we uncovered the importance of 
sample composition and selection of immobilization platforms in achieving accurate and reliable 
binding affinity results. Furthermore, understanding the binding event is important as mAbs 
therapeutics are heterogeneous with respect to their glycosylation on N297.25 It is also well 
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known that glycosylation could shift upon a change in a cell line, manufacturing sites, and scale 
up; hence, a sensitive method is required to monitor batch- to-batch variation. Thus, this study 
contributes to developing the analytical aspects of biosimilar comparability analysis.25 
Analysis of a complex mixture of glycoforms is not a trivial assessment, specifically if there 
is no prior knowledge of the composition of the sample to be examined. Knowledge of the 
glycoform composition of the sample using mass spectrometry can be helpful to achieve 
unambiguous data. Hence, a combination of in-depth glycan characterization, coupled with 
knowledge of the individual glycan contribution to binding, can be useful to analyze the data 
more accurately. In this work, we illustrated the complexity of the methods and analysis of the 
data for mixtures with different affinities. The data highlights the extra care required to get a 
reliable biological activity with samples containing mixtures of glycoforms. Additionally, this work 
demonstrates the need to monitor the response of a sample in comparison to a well-
characterized control when measuring the quality of the protein. In addition, our data highlights 
the importance of analytical techniques in biosimilar comparability analysis, and both functional 
assay formats could differentiate the mixture of glycoforms with different sensitivity depending 
on the immobilization format selected and type of mixture composition. The methods and 
concepts developed in this work can be applied during a biosimilar comparability assessment. 
Today similar challenges exist in comparing products after processes change or in the 
development of a biosimilar candidate.25 
In summary, the four control glycoforms and seven mixtures were evaluated with their 
functional activities using to the two assay platforms. To examine how a functional activity test 
can be used in assessing similarity in biosimilar comparability exercises, we compared the two 
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assay platforms. These assay platforms were tested with a series of homogeneous and well-
defined IgG1 Fc glycoforms (controls). Next, the two-assay platform was tested in a mixture of 
IgG1 Fc glycoforms with subtle and major differences in functional and physical properties. 
Future work should address to correlate in-vivo activity assay with the in-vitro binding assay.  
These functional characterization techniques generated large amount and different type of data. 
Thus, raw characterization data will be utilized to develop a mathematical model for determining 








Figure 1.  HM-Fc and N297Q-Fc were recombinantly expressed in glycoengineered 
P.pastoris. Man5-Fc and GlcNAc-Fc were produced using in-vitro enzymatic reaction. The 
four glycoforms HM-Fc, Man5-Fc, GlcNAc-Fc, and N297Q-Fc were used as a control and to 
prepare the mixtures. Fifty percent mixtures were prepared to monitor for obvious 
differences. Mixtures containing 90% HM with 10% of the other glycoforms were prepared 
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Figure 2. SDS-PAGE characterizations of control and mixture glycoforms under reduced (A) and 
non-reduced (B) conditions. The SDS-PAGE bands represent: (1) 90%HM:10%Man5; 2) 
50%HM:50%Man5; 3) 25%HM:25Man5:25GlcNAc:25%N297Q; 4) 90%HM:10%N297Q; 5) 
50%HM:50%N297Q; 6) 90%HM:10%GlcNAc; 7) 50%HM:50%GlcNAc. The bands 8, 9, 10, and 11 















Figure 3: Intact protein ESI-MS analysis of IgG1 Fc control and mixture of glycoforms under 
reducing conditions. About ten µg of each glycoform was loaded into the LC-MS, and the data 
was acquired on an Agilent 6250 quadrupole time-of-flight system. No fragment or degradation 


















Figure 4. Bar graphs show kon, koff, and KD for the control and mixture of IgG1 Fc glycoforms. The top 
panel is data for the receptor-immobilized format (FcRIIIa immobilized), and the middle panel is for 
the Fc-immobilized format (FcRIIIa in solution). The bottom panel represents data for binding of 
FcRIIb with IgG1 Fc glycoforms using protein G immobilization method. A significant difference in 
the equilibrium dissociation constants was observed between the mixtures, depending on their 
percentage of composition. Additionally, a substantial difference was found between the two 
immobilization techniques, indicating that the two binding formats differ in their capacity to 
distinguish the mixtures. For the interaction of the controls and mixtures of IgG1 Fc glycoforms with 
FcRIIb, no significant difference in biological activity was obtained. For N297Q-Fc and GlcNAc-Fc, no 


















Figure 5. The diagram shows the binding events on the surface of the streptavidin (top) and protein 
G (bottom) for 50%HM:50%GlcNAc binding with FcRIIIa. The receptor was immobilized onto 
streptavidin biosensors and 50%HM:50%GlcNAc mixture was in solution. During the early phase of 
the association phase, both GlcNAc-Fc and HM-Fc binds onto FcRIIIa. However, as incubation time 
increases, HM-Fc displaces GlcNAc-Fc. Therefore, slowly dissociating HM-Fc is shown in the 
dissociation phase. For the Fc-immobilized format, the two binding events are independent of each 
other, and no displacement is expected during the association phase. Therefore, the dissociation 












Figure 6. Dissociation curves (A) measured at different incubation times for 50%HM:50%GlcNAc. 
HM-Fc control (100%HM-Fc) showed the slowest dissociation phase, while GlcNAc-Fc control 
(100% GlcNAc-Fc) showed the fastest dissociation phases. As incubation time increases, the rate of 
dissociation gets slower. The koff for each curve is represented in the bar graph (B). Comparison 













Figure 7. Representative BLI binding curves for the interaction of FcRIIIa with control and mixture 
of IgG1 Fc glycoforms using the Fc immobilization technique. The binding curve shown is for FcRIIIa 















Figure 8.  Bar graphs showing a binding response to the interaction of FcRIIIa (A) and FcRIIb (B) 
with control and mixture of IgG1 Fc glycoforms measured using Fc immobilization technique.  A 
difference in response was observed, depending on the percentage of the composition and 






Figure 9. Representative BLI binding curves for the interaction of FcRIIIa with a mixture of IgG1 Fc 
glycoforms using the Fc immobilization technique (Figure 1A) and the receptor immobilization 
technique (Figure 1B). Data shown is for the protein in solution (FcRIIIa or Fc) at concentrations of 
800 nM, 400 nM, 200 nM, 100 nM, and 50 nM, which corresponds with the curves from top to bottom. 
For Figure 1C, the data shown is for the protein in solution (FcRIIb) at concentrations of 10000 nM, 
5000 nM, 2500 nM, 1250 nM, and 625 nM, which corresponds with the curves from top to bottom. 























3.6 Tables   
Glycoforms Method kon 
(1/Ms)x105 
koff (1/s)X10-3  KD (nM) 
100% HM-Fc PG 2.1±0.1 5.5±0.2 26.7±2.1 
100% HM-Fc   SA 2.6±0.2 7.2 ±0.5 27.7±2.7 
100% Man5-Fc  PG 2.1±0.3 6.3± 0.8 30.7±5.6 
100% Man5-Fc  SA 2.8±0.3 8.9 ± 0.9 31.7±4.7 
100% GlcNAc-Fc  PG 1.1±0.2 120.3±17.4 1073.6±240.2 
100% GlcNAc-Fc  SA 1.8±0.1 194.2±16.5 1079.5±109.9 
90%HM:10%Man5 (Mix4) PG 2.2±0.0 5.7±0.3 25.9± 1.2 
90%HM:10%Man5 (Mix4) SA 3.4±0.1 9.1 ±0.2 27.0 ±1.1 
50%HM:50%Man5 (Mix1) PG 2.2±0.1 6.0±0.2 26.9 ±1.4 
50%HM:50%Man5 (Mix1) SA 2.7±0.2 7.0 ±0.5 25.7±2.9 
90%HM:10%N297Q (Mix6) PG 2.3 ±0.1 5.7±0.2 24.9 ±1.2 
90%HM:10%N297Q (Mix6) SA 2.4±0.1 7.6±0.6 31.5±2.9 
50%HM:50%N297Q (Mix3) PG 2.7±0.1 6.9± 0.2 24.9± 1.1 
50%HM:50%N297Q (Mix3) SA 1.7±0.1 9.2±0.5 52.7±3.7 
90%HM:10%GlcNAc (Mix5) PG 1.5±0.4 5.7±0.3 44.4 ±2.8 
90%HM:10%GlcNAc (Mix5) SA 2.0±0.1 6.4±0.1 31.7±1.0 
50%HM:50%GlcNAc (Mix2) PG 1.6±0.1 14.2±1.0 76.7±5.6 
50%HM:50%GlcNAc (Mix2) SA 2.0±0.1 8.50±0.56 43.3 ±4.1 
25%HM:25%GlcNAc:25%Man5:25%N297Q (Mix7) PG 1.7±0.1 8.6±0.5 52.5 ± 4.00 
25%HM:25%GlcNAc:25%Man5:25%N297Q (Mix7) SA 2.0±0.1 7.3±0.1 35.6±1.3 
90%HM:10%N297Q* (Mix6) SA 2.9±0.3 7.6±0.6 28.3±2.4 
50%HM:50%N297Q* (Mix3) SA 3.1 ± 0.4 9.1± 0.5 29.0 ± 4.2 
Table 1.  Kinetic parameters obtained for binding of FcRIIIa with control and mixture of IgG1 Fc 
glycoforms using Fc and receptor immobilization techniques. Binding kinetics were performed 
at 25˚C. The data shows kinetic association rate (kon), kinetic dissociation rate (koff), and the 
equilibrium dissociation constant (KD). The entries are averaged values of three independent 
experiments.  For N297Q-Fc, there was no detectable binding at the highest concentration 
tested (10 µM) from both techniques. * Only active component concentration (HM-Fc) was used 





  Glycoforms composition Glycoform Percentage of composition 
90%HM:10%N29Q (Mix6) HM 89.6 ± 0.1 
N297Q 10.4 ± 0.1 
50%HM:50%N297Q (Mix3) HM 48.2 ± 0.6 
N297Q 51.8 ± 0.6 
90%HM:10%Man5 (Mix4) HM 90.5 ± 0.3 
Man5 9.5 ± 0.3 
50%HM:50%Man5 (Mix1) HM 55.6 ± 0.4 
Man5 44.5 ± 0.4 
90%HM:10%GlcNAc (Mix5) HM 89.6 ± 0.4 
GlcNAc 10.4 ± 0.4 
50%HM:50%GlcNAc (Mix2) HM 54.7 ± 2.9 
GlcNAc 45.3 ± 2.9 
25%HM:25%Man5:25%GlcNAc:25N297Q (Mix7) HM 32.0 ± 2.1 
Man5 21.4 ± 0.8 
GlcNAc 25.8 ± 0.6 
N297Q 20.8 ± 2.0 
Table 2. Estimated percentage of composition for each glycoform observed by intact protein 
mass spectrometry.  The percentage of composition in the mixtures was calculated using all 








Glycoforms composition Glycoform Band intensity Percentage of composition 
90%HM:10%N29Q (Mix6) HM 127009 89.5 
N297Q 14852.9 10.5 
50%HM:50%N297Q (Mix3) HM 80274.7 48.4 
N297Q 85447.5 51.6 
90%HM:10%GlcNAc (Mix3) HM 66603.0 89.3 
GlcNAc 8003.2 10.7 
50%HM:50%GlcNAc (Mix2) HM 77413.6 54.7 
GlcNAc 64146.9 45.3 
Table 3. Estimated percentage of composition of the mixtures determined from SDS-PAGE 









Glycoforms Method kon 
(1/Ms)x105 
koff (1/s)x10-3   KD (nM) 
100% HM-Fc PG 0.8±0.1 279.2±9.0 3419.8±288.4 
100% Man5-Fc PG 0.4 ±0.1 119.0 ±25.1 3274.5±957.4 
90%HM-Fc:10%Man5 (Mix4) PG 0.9±0.1 321.0±19.0 3368.6±469.3 
50%HM-Fc:50%Man5 (Mix1) PG 0.4±0.0 127.0±8.9 3187.1±361.2 
90%HM-Fc:10%N297Q (Mix6) PG 0.4 ±0.0 142.9 ±2.0 3190.4±124.0 
50%HM-Fc:50%N297Q (Mix3) PG 0.2±0.0 83.3±4.9 3500.3±272.8 
90%HM-Fc:10%GlcNAc (Mix5) PG 0.4±0.0 132.6±17.1 3496.9±598.6 
50%HM-Fc:50%GlcNAc (Mix2) PG 0.3 ±0.0 110.6 ±23.9 3471.7 ±993.6 
25%HM:25%GlcNAc:25%Man5:25%N297Q(Mix7) PG 0.2±0.0 60.5±7.7 3307.5±624.1 
N297Q-Fc and GlcNAc-Fc* PG    
Table 4.  Kinetic parameters obtained for binding of FcRIIb with control and mixture of IgG1 Fc 
glycoforms using Fc immobilization method. Binding kinetics were performed at 25˚C. The data 
shows kinetic association rate (kon), kinetic dissociation rate (koff), and the equilibrium 
dissociation constant (KD). These data entries are the average of three independent 
experiments. * For N297Q-Fc and GlcNAc-Fc, there was no detectable binding at the highest 






Glycoforms Response for FcRIIIa Response for FcRIIb 
100%HM 0.799 ± 0.005 0.465± 0.001 
90%HM:10%N297Q 0.684 ± 0.003 0.346 ± 0.000 
50%HM:50%N297Q 0.422 ± 0.005 0.245 ± 0.007 
100%N297Q 0.005 ± 0.001 0.001 ± 0.001 
90%HM:10%Man5 0.786 ± 0.005 0.431 ± 0.005 
50%HM:50%Man5 0.758 ± 0.005 0.379 ± 0.020 
100%Man5  0.618 ± 0.018 0.369 ± 0.018 
90%HM:10%GlcNAc 0.734 ± 0.010 0.366 ± 0.000 
50%HM:50%GlcNAc 0.527 ± 0.005 0.2615 ± 0.009 
100%GlcNAc 0.248 ±0.006 0.001 ± 0.001 
25%(HM:Man5:GlcNAc:N297Q) 0.472 ±0.003 0.246 ± 0.001 
Table 5. Raw data for the response to FcRIIIa and FcRIIb interaction with control and mixture 
Fc glycoforms using Fc-immobilized format. The concentration of FRIIIa and FRIIb in solution 
was 800 nM and 10,000 nM, respectively. The data was the averaged values of triplicates 











HM‐Fc control 99.7±0.0 7.2±0.0 
Man5‐Fc Control 99.7±0.1 7.2±0.0 
GlcNAcFc‐Control 99.8±0.1 7.2±0.0 
N297Q-Fc Control 97.8±0.0 7.2±0.0 
Mix 1 99.7±0.0 7.2±0.0 
Mix 2 99.6±0.1 7.2±0.0 
Mix 3 98.9±0.1 7.2±0.0 
Mix 4 99.6±0.1 7.2±0.0 
Mix 5 99.6±0.0 7.2±0.0 
Mix 6 99.4±0.1 7.2±0.0 
Mix 7 99.3±0.0 7.2±0.0 
Table 6. Average monomer percent and pI values measured using size exclusion 
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Chapter 4  
  Characterization of IgG1 Fc Glycoforms After Prolonged Storage at Low and  







The stability of monoclonal antibodies is a critical component of a product development 
to ensure safety and efficacy. The most reliable information regarding the stability of the 
monoclonal antibody can be achieved by monitoring the normal storage conditions throughout 
its shelf-life. However, to obtain the most susceptible degradation pathway, the stability of the 
glycoforms can be tested at an elevated temperature. Valuable information about the functional 
difference between samples stored at high and low temperatures can be obtained. In addition, 
stress conditions can be used for formulation screening, accumulation of degraded products, and 
evaluation of molecular entity. In one study, a mouse IgG1 and a IgG2a monoclonal antibodies 
were examined at different pHs and temperatures, and the results indicated that these 
antibodies were more prone to degradation at 37˚C than at 4˚C. Moreover, peptide bond 
cleavage was found to be the primary degradation pathway at 37˚C, while irreversible 
aggregation was the dominant degradation pathway at 4˚C.1  Furthermore, an acidic shift at a 
higher pH was also observed, which could be due to deamidation. Similarly, it has been reported 
that the stability of mouse monoclonal IgG2a antibody acidic shift was observed by cation-
exchange and cIEF after incubation at 37˚C for six weeks.2-3   
In another study, deamidation of an asparagine residue in the constant region was found 
to be the primary degradation pathway when stored at 37˚C, while aggregation was the major 
degradation pathway when it was at 2-8˚C after long-term storage (>14 months). In addition, 
oxidation of methionine, tryptophan, and non-disulfide linked cysteine (Cys) residue was also 
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observed in different sites of the antibody.4 Similar studies indicated that with a chimeric mouse-
human monoclonal antibody incubated at 60˚C at a higher pH, fragmentation was the major 
degradation pathway, while at the lower pH range, aggregation was the primary degradation 
pathway. Furthermore, deamidation and disulfide bond cleavage were observed at a high pH 
range.4 In other similar reports, significant chemical degradation of antibody was found among 
the stability samples, including peptide bond cleavage, Asn deamidation, Gln deamidation, and 
pyroglutamate formation (i.e., N-terminal Glu cyclization).4 In general, deamidation is a major 
degradation pathway in proteins, and it has been reported for several monoclonal antibodies.3,5-
10  Furthermore, deamidation is a commonly observed chemical modification during storage, and 
it is well known that the three-dimensional structure of the protein affects the deamidation rate 
of Asn residue.5-10 Formation of pyroglutamic acid has been reported for several antibodies, 
which was formed from N-terminal Gln. Moreover, formation of pyroglutamine from Glu is less 
common than from Gln.11-13 Other reports indicate +16 Da in the protein mass during storage, 
presumably due to the oxidation of methionine and other residues.1-2, 14  
Stability testing is required to establish shelf life of therapeutic products. It is well known 
that environmental factors, such as pH, temperature, ionic strength, and the presence of 
stabilizers, can impact the conformational stability of the product. Therefore, the stability of the 
biosimilar in the formulation should be studied.15 Accelerated stability studies are based on the 
underlying assumption that the degradation profile follows Arrhenius behavior. This is true in 
small molecules where studies performed at a higher temperature can predict stability during 
longer and lower temperature storage.16 However, in proteins, the degradation profile at high 
and low temperature may be different and uncorrelated. Thus, to address such issues, a non-
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Arrhenius behavior was introduced to account for protein aggregation where the rate depends 
on equilibrium  (for the formation of aggregation-prone state)  and the rate of irreversible 
aggregation.17 However, using Arrhenius equation to fit protein stability data can be very 
difficult18 because there are potentially multiple degradation pathways involved. Therefore, long-
term stability is required for protein biologics to achieve regulatory approval.15 Protein  
aggregates can have a detrimental effect by inducing an unwanted immune reaction in patients 
treated with the products. Because of this reason, extensive characterization using multifaceted 
analytical techniques and clinical studies are required to achieve marketing approval of a 
biosimilar product.15 
Forced degradation studies include a set of analytical tests applied to a protein molecule 
to examine the physicochemical mechanism of degradation. On the other hand, the accelerated 
stability study measures the rate of a given degradation process over time at a different 
temperature in a specific formulation conditions. Examining the effect of storage time and 
excipients on the accelerated and long-term stabilities of biologic drug products is an important 
part of formulation development and comparability evaluation.19 Protein drug products may 
encounter many environmental stresses during expression, purification, processing, storage, and 
shipment. Therefore, forced degradation and accelerated stability studies are required to 
examine the degradation profile of a biologic drug by applying various stress conditions, such as 
elevated temperature, freeze-thaw, agitation, oxidation environment, light, and the presence of 
different interfaces and pH changes.19 The design and outcome of successfully forced 
degradation and accelerated stability studies depend on the analytical techniques employed to 
identify and characterize the degradants generated.19 
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Forced degradation studies play a critical role in the development of biological drug 
products. For instance, forced degradation is used in the selection of candidate molecule, 
characterization, formulation development, stability indicating assay development, and 
comparability studies. The robustness of a protein formulation against environmental stress 
factors is essential since biologic products are exposed to various types of stress during 
production, fill-finish, shipment, storage and final administration.4, 20 Examples of these stress 
factors are elevated temperature, freeze-thawing, and light exposure. Forced degradation (or 
stress testing)  is a general term, which includes all forms of stress to drug substances or drug 
product that exceeds the condition used for stability testing. On the other hand, stability testing 
refers to studies performed to examine the stability of a formulation according to the general 
requirement; in particular, international conference on harmonization (ICH) guidelines Q5C 
(specific for biotech products).21 In accelerated testing, stability testing was conducted at 
elevated temperature under the quiescent condition, according to ICH Q5C.19, 21 
Forced degradation studies are an integral part of the development of therapeutic 
proteins. The purpose of forced degradation studies may vary depending on the phase of the 
therapeutic drug development.19 In general, according to ICH Q5C,21 the first purpose of the 
forced degradation studies is to examine how accidental exposure to conditions other than those 
proposed is harmful to the product. The second purpose is to assess the stability indicating 
analytical methods. In addition, the accelerated stability may provide useful data for establishing 
shelf-life.22,23 The data generated during an accelerated stability study can provide product 
stability information for future product development. An example would be initial assessment of 
proposed production changes, which includes changes in formulation or scale-up. Furthermore, 
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the data can be used in developing and validating of analytical methods for stability studies. In 
addition, the stability study can be used to generate information that will help to uncover the 
degradation profile of the drug substance or drug product.19 Forced degradation studies go hand-
in-hand with the analytical characterization techniques, since the result of these studies depend 
not only on the stress applied but also on the analytical methods used to evaluate them. Hence, 
selected analytical methods that are sensitive in detecting and quantifying the degradation 
products formed are necessary. Multiple degradation products can be generated during forced 
degradation.24-25 Therefore, a combination of complementary methods is required to cover the 
degradation products.26-29 
Upon changes in the manufacturing processes of the marketed products or during 
product development phases, such as scale-up, manufacturing site change, and cell-line change, 
the potential effect of the changes on the product quality needs to be examined. Typically, such 
comparability exercise includes characterization of the product and product-related impurities. 
Thus, the stability profiles of the pre- and post-change products are compared by studying at the 
real time and accelerated storage conditions. If significant differences are obtained during 
analysis of potential impact on the efficacy or safety of the drug product, further studies may be 
necessary, including clinical and non-clinical studies. The comparability evaluation is performed 
case-by-case, depending on the product, its mechanism of action, and type of change made 
during production processes. Therefore, accelerated and stress stability studies are usually 
applied to determine the degradation profile and establish a head-to-head comparison of pre-
change and post-change products.19 
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Unlike the stability testing, which is well-regulated and established in the guidelines (i.e., 
CHQ1A and ICHQ5C), there are no standard procedures for forced degradation biologic products. 
The guidelines provide a rough concept on forced degradation studies, but detailed information 
on how and to which extent these studies should be conducted are not given.30 However, the 
condition for photostability test is outlined in the ICH guidelines QIB.25 Biologic products can be 
exposed to a temperature higher than the recommended storage temperature during 
production, shipment, storage, and final administration. Elevated temperature is the most 
common method to apply stress and generate degraded therapeutic proteins, which are 
developed to be stored under non-refrigerated conditions (2-8°C). When the temperature 
increases, proteins may undergo conformational changes, such as unfolding and partial 
unfolding. These physical changes may lead to further degradation reactions, such as aggregation 
and denaturation. Starting from the onset temperature of unfolding (Tonset) towards the melting 
point (Tm) of the protein, gradual destabilization of the native protein becomes a more visible 
state, which leads to irreversible aggregation.30-32 In addition, diffusion becomes faster at a 
higher temperature, resulting in a more energetic collision, as well as with reactive chemicals, 
thereby favoring both physical and chemical degradation. Chemical reactions may be apparent 
in the unfolded state. An example would be if buried amino acids are exposed for the chemical 
reactions in solution.19  
In particular cases, the Tm value has been used to predict the stability of liquid 
formulations at the planned storage conditions. This was demonstrated by some examples in the 
literature, which suggest a correlation between the measured Tm values and storage stability. 
This correlation eventually allowed to select more robust formulation for these cases.33-38 
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However, Tm measurements can not replace stability assessment under real time and 
temperature conditions. For instance, if the dominant degradation processes or the rate limiting 
step is not related to the (potential) unfolding of the protein, then Tm can not be used as a 
predictive tool for the storage stability.38 In other studies, it has been shown that the extent of 
refolding upon lowering the temperature below the Tm value can be used to predict the stability 
of proteins.53 The specific temperature for thermal stress testing needs to be chosen depending 
on the thermal behavior of the protein. An example would be a drug product for storage at 2-
8°C; accelerated stability assessment is generally conducted at 25°C, as outlined in ICHQ1A.39 In 
addition, the effect of heat is recommended to be tested in increments of 10°C the selected 
accelerated testing temperature. The best approach is that during thermal stress testing, it is a 
good idea to stay below Tonset and at least 10-20°C below the Tm. Studies performed at the Tm 
value can not be used for stability evaluation because the protein will be predominantly unfolded 
under these conditions, and the degradation product may not hold relevant information to  the 
“real-life’’ storage conditions.19 Therefore, the prediction of real-time aggregation rates and shelf 
life from accelerated data may become feasible only if aggregate formation under accelerate  and 
real-time temperature are qualitatively controlled by the same physicochemical factors.19 
A typical example of these conditions is the formation of a conformationally altered 
intermediate or a chemical modification that triggers aggregation.40 Thus, it is critical to 
understand the degradation mechanism at high temperature and compare it to that occurring at 
the storage condition (2-8°C). The evaluation of degradation kinetics can also aid in comparing 
degradation pathways for  the pre-change and post-change products in comparability studies. 
Besides high temperature, for several proteins it has been described that the freeze-thawing may 
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trigger the formation of a larger aggregation with characteristics of a higher degree of native-like 
protein structure.41-44 One should be very cautious in extrapolating the outcome of thermal stress 
studies to real-life storage conditions, because the conditions during forced degradation studies 
generally differ from the real-life storage conditions. Therefore, forced degradation studies 
cannot substitute the stability test under real-time and real temperature conditions. Besides 
selection of  stress conditions, analytical characterization of degradation products is an integral 
part of the forced degradation studies.19 
In this study, well-defined homogeneous IgG1 Fc glycoforms (i.e., HM-Fc, Man5-Fc, 
GlcNAc-Fc, and N297Q-Fc) were studied after incubating at 40˚C, 4˚C, and -80˚C for two, four, 
and twelve weeks. The samples were characterized head-to-head using bio-layer interferometry 
which includes the following: An Fc-immobilized format and a receptor-immobilized format. In 
addition, mass spectrometry was used to monitor chemical modifications during the storage. The 
data collected includes binding affinities, binding response, potency assay (concentration 
measurement) and intact protein mass. To our best knowledge, the impact of storage 
temperature on the functional activity of IgG1 Fc glycoforms with the concept of biosimilar 
comparability has not been addressed in prior studies. Hence, we examined the effect of storage 
temperature on the functional activity of IgG1 Fc glycoforms as a model system for biosimilar 
comparability analysis. 
4.2 Materials and Methods  
4.2.1 Materials  
Yeast nitrogen base (YNB) was used for expression purchased from Sunrise Biosciences. 
BactoTM Tryptone and Yeast Extract were obtained from Becton Dickinson and Company (Franklin 
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Lakes, N.J.). Antifoam 204 utilized in the fermenter was obtained from Sigma-Aldrich (St. Louis, 
MO.). Certified ACS grade crystalline sucrose was obtained from Fisher Scientific (Pittsburg, PA.). 
B. thetaiotaomicron -1,2-mannosidase (BT3990, B.t. -1,2-mannosidase) was expressed  in-
house.45-48 Endoglycosidase H was purchased from New England Biolabs (Ipswich, MA). The 
protein G resin was prepared by conjugating protein G (recombinantly expressed in E. coli)49 with 
Sepharose® CL-4B (Sigma-Aldrich, St Louis, MO)  using divinyl sulfone as a coupling reagent.50 All 
other general chemicals were obtained from Sigma-Aldrich and Fisher Scientific unless otherwise 
noted. 
4.2.2 Preparation of Fc Glycoforms 
 HM-Fc was expressed using a glycosylation-deficient strain of P. pastoris by following the 
same protocol as described in our previous work.51  A large quantity of HM-Fc was expressed 
using a fermenter for the physical and chemical stability studies as well as for the storage stability 
studies. Fermenter media used for expression of HM-Fc was fermentation basal salts medium 
(BSM) and PTM1 trace salts. The non-glycosylated mutant N297Q-IgG1 Fc (N297Q-Fc) was 
designed using site-directed mutagenesis as described in our previous work51 and expressed in a 
spinner flask containing 1 L of Buffered Glycerol-complex Media (BMGY) and 0.00004% biotin. 
After maximum cell growth, the protein expression was induced by methanol feeding for about 
72 hrs. Next, the cell pellets were harvested, and the Fc protein was purified from the 
supernatant using protein G in a similar protocol as described in chapter two. Both N297Q-Fc and 
HM-Fc were purified using HIC and dialyzed in the storage buffer, which was a 20 mM histidine 
buffer pH 6.0, containing 10% sucrose for further analysis. Man5-Fc and GlcNAc-Fc were 
produced using an in-vitro enzymatic reaction using HM-Fc as a precursor. Man5-Fc was 
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generated by treating HM-Fc with B.t. α-1,2-mannosidase (BT3990),51 while GlcNAc-Fc was 
produced by digesting of HM-Fc with endoglycosidase H. All of the Fc glycoforms were initially 
dialyzed in 20 mM Histidine buffer pH 6.0, 10% sucrose and stored at -80˚C for further analysis. 
For this study, the Fc glycoforms were extensively dialyzed in 20 mM citrate-phosphate buffer pH 
6.0, containing 150 mM NaCl.  Next, samples of 2 mL were sealed in vials and incubated at -80˚C, 
4˚C, and 40˚C, and samples were collected at two, four, and twelve weeks as shown in Table 1.  
After the incubation periods, the samples were stored at -80˚C for further study. 
4.2.3 Liquid Chromatography-Mass Spectrometry (LC-MS) 
 Samples at a concentration of 0.2 mg/mL were first reduced with 10 mM dithiothreitol 
(DTT); 30 µL was injected into the mobile phase of the liquid chromatography (LC). ESI spectra of 
the stressed samples were collected on an Agilent 6520 Quadrupole Time-of-Flight (Q-TOF) 
system. The same procedure was used for conducting the experiment and data analysis as 
described in our previous work.51 Furthermore, the percentages of chemical modification were 
estimated based on the peak intensities using Agilent MassHunter Qualitative Analysis Software. 
Intact protein mass of the samples stored at -80˚C were used as a reference to identify potential 
chemical modifications of the incubated Fc glycoforms.  
4.2.4 Binding Assays 
4.2.4.1 Fc-Immobilized Assay 
 The interactions of the stressed IgG1 Fc glycoforms with the Fc receptor (FcRIIIa) were 
performed with biolayer interferometry (a Blitz instrument Fortebio, Menlo Park, CA). In this 
immobilization technique, protein G biosensor tips were used to measure the interaction. The 
binding of stressed IgG1 Fc glycoforms with FcRIIIa was conducted as described below. Briefly, 
the protein G biosensor was hydrated for about 10 min with PBS buffer (150 mM NaCl, 50 mM 
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sodium phosphate pH 7.4) to remove the coating on the surface of the biosensor. This step was 
followed by incubation of the biosensor for 30 min with PBS kinetic buffer (PBS buffer containing 
1 mg/mL casein as a blocking agent) to block non-specific interactions. For kinetic measurement, 
an initial baseline (30 sec) was performed with PBS kinetics buffer followed by loading (120 sec) 
of the Fc glycoforms (0.8 µM) onto the biosensor. After loading, a new baseline (30 sec) was 
established, followed by the association (180 sec) and dissociation (360 sec) of FcRIIIa to 
measure the kinetics. To determine the KD value, a range of concentrations of the receptor (50-
800 nM) were tested for interaction with the Fc glycoforms (eg., HM-Fc and Man5-Fc). For 
GlcNAc-Fc, the concentration range of the receptor was 200 nM to 1600 nM prepared in a two-
fold serial dilution. To examine the kinetics of interaction in the dissociation phase, the biosensor 
was dipped into an analyte-free PBS kinetic buffer. The dissociation was monitored for 360 sec 
until the signal eventually returning close to the baseline. The data for the binding of the stressed 
samples with the receptor was collected in triplicated and globally fitted to a 1:1 using the first-
order rate equation binding model in Blitz® Pro software.  
4.2.4.2 Receptor-Immobilized Assay 
 The interactions of the different stressed samples of Fc glycoforms with the immobilized 
receptor were examined with biolayer interferometry (Blitz instrument Fortebio, Menlo Park, 
CA). In this immobilization technique, streptavidin (SA) biosensor tips were used to measure the 
interactions. Before the binding experiment, the glycoforms were dialyzed in PBS buffer to 
remove the storage buffer (20 mM citrate-phosphate buffer, 150 mM NaCl, pH 6.0) and to adjust 




4.2.5 Binding Response Measurements 
 The response of the stressed IgG1 Fc glycoforms with the FcRIIIa was examined with 
biolayer interferometry using a Blitz instrument (Fortebio, Menlo Park, CA). In this experiment, 
protein G biosensor tips were used for each of the samples, including their references for 
generating the sensorgrams. The response experiment was conducted as follows. Briefly, the 
protein G biosensor tip was hydrated for about 10 min in PBS buffer (150 mM NaCl, 50 mM 
sodium phosphate pH 7.4) to remove sucrose coating from the surface. This step was followed 
by incubation for 30 min with PBS kinetic buffer (PBS buffer containing 1 mg/mL casein as a 
blocking agent) to block any non-specific interaction during binding. For response measurement, 
an initial baseline (30 sec) was performed with PBS kinetics buffer, followed by loading (120 sec) 
of the IgG1 Fc glycoforms onto the biosensor. The concentration of Fc glycoform during loading 
was 0.8 µM. In the next step, a new baseline (30 sec) was performed, followed by the association 
(180 sec) and dissociation (360 sec) of the receptor. The concentration of the receptor during the 
association was kept at 0.8 µM. The dissociation phase was monitored by dipping the biosensor 
in analyte-free PBS buffer for 360 sec To calculate the binding responses, the curves were 
reference subtracted and exported into Microsoft Excel. The last five points at the end of the 
association phases were averaged from triplicate measurements for each Fc glycoform.  
4.2.6 Concentration Measurements 
 A standard curve was generated before running a quantitative assay on the stability 
samples.  The standard curve with a known concentration of a reference sample was developed 
for each Fc glycoform. The samples were in a formulation buffer (20 mM citrate-phosphate, 150 
mM NaCl-pH 6.0). Protein G biosensors were used to develop the standard curve and measure 
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the concentration of the stressed Fc glycoform. The protein G biosensor was pre-rehydrated with 
the formulation buffer for about 15 min. Next, the “Create a standard curve module” was 
selected in Blitz Pro data analysis software, and 4 µL of each concentration was run for 30 sec 
with shaker enabled. A reference containing a formulation buffer was used to subtract 
background response. After collecting the data, the software calculated binding rates and 
generated a standard curve fitted by a linear model. To determine the concentration, a 4 µL of 
the stressed Fc glycoforms was used, and “quantitate sample module” was selected. After 
acquiring the data, unknown concentrations of the stressed Fc glycoforms were automatically 





4.3 Results  
4.3.1 Chemical Modification of IgG1 Fc Glycoforms at Low and Elevated Temperatures 
Initial characterizations were conducted using mass spectrometry to identify any chemical 
modifications that occurred after incubating the four Fc-glycoforms (Figure 1 in Chapter 2) at -
80°C, 4°C, and 40°C for two, four, and twelve weeks. First, the samples stored at -80°C were 
examined for any chemical modifications and utilized as controls to compare with the samples 
incubated at 4°C and 40°C. For the HM-Fc, the intact protein mass showed the Fc monomer with 
high mannose glycoforms containing between Man8GlcNAc2 to Man12GlcNAc2 residues. As shown 
in Figure 1, the major peak of the HM-Fc was attributed to the Man8GlcNAc2 glycoform, followed 
by decreasing intensity of the peaks as follows: Man9GlcNAc2, Man10GlcNAc2, and Man11GlcNAc2. 
The control HM-Fc stored at -80°C showed no chemical modifications as shown in the intact 
protein mass (Figure 1) as well as the percentage of chemical modification (Table 2). As shown in 
Figure 1A, HM-Fc stored at -80°C showed a peak of +16 Da, presumably oxidation. The estimated 
percentage of the oxidation was 8.7%, and the percentage of chemical modification was 
calculated from the peak intensities of the intact protein mass. This level of oxidation was 
comparable to the sample before incubation, indicating the chemical modification occurred 
during protein production. Besides oxidation, no other chemical modifications were observed, 
suggesting the HM-Fc was stable when stored at -80°C. The HM-Fc glycoforms incubated for two 
weeks at 4°C showed an estimated level of oxidation about 8.7%, and this extent of chemical 
modification was comparable to the control sample stored at -80°C. Thus, this data demonstrated 
the HM-Fc samples remained stable for two weeks at 4°C with no further chemical degradation 
as shown in Figure 1 and Table 2. However, samples of HM-Fc stored at 4°C for four weeks 
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showed a slight increase in the level of oxidation (9.8%). This data demonstrated a slow increase 
in oxidation during storage at 4°C. Further storage of HM-Fc for twelve weeks at 4°C resulted in 
a significant increase in oxidation, which was estimated at about 11.6%. Therefore, this sample 
showed approximately a 3% increase in oxidation level compared to the control sample stored 
at -80°C. Overall, a slight increase in oxidation was observed in samples of HM-Fc incubated at 
4°C for four and twelve weeks.  
The HM-Fc samples stored at the elevated temperature (40°C) for two, four and twelve 
weeks were examined using mass spectrometry. For instance, the HM-Fc stored at 40°C for two 
weeks showed a significant oxidation levels, which were estimated to be about 13.4%. An 
increase of 4.7% compared to the control samples stored at -80°C. This data illustrated the effect 
of elevated storage temperature on the extent of chemical modification of the Fc glycoforms. 
Obviously, higher temperature storage resulted in significant chemical modifications as 
expected. Similarly, samples stored at 40°C for four weeks showed 14.1% oxidation, suggesting a 
slight increase in the chemical modification. However, after an extended storage time (i.e., 
twelve weeks), a significant oxidation was observed, which was estimated at about 28.6%. This 
major degradation of the HM-Fc compared to the similar sample stored at 4°C for twelve weeks 
again, which showed the instability of this glycoform at elevated temperature. Moreover, about 
20% increase in oxidation was observed compared to the control samples frozen at -80°C. This 
trend of increasing chemical modification with incubation period was more apparent for samples 
stored at 40°C compared to the same samples stored at 4°C. 
For the Man5-Fc, the intact protein mass showed the Fc monomer containing five 
mannose residues. As shown in Figure 1B, the main peak of Man5-Fc was attributed to the 
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Man5GlcNAc2 and showed a predominantly single peak at 26280 Da, consistent with our previous 
work.51 Like the HM-Fc, the Man5-Fc samples stored at -80°C showed 9.5% oxidation, which was 
an initial oxidation level generated during protein production. This percentage of oxidation was 
not surprising because HM-Fc was used as a precursor to produce Man5-Fc. Hence, any chemical 
modification that originated from the HM-Fc was expected to appear in the Man5-Fc glycoform. 
Samples of Man5-Fc stored for two weeks at 4°C showed significant modifications compared to 
the same sample of HM-Fc, indicating the impact of glycosylation on the chemical degradation. 
The percentage of chemical modification remained unchanged for Man5-Fc stored at 4°C for four 
weeks. However, a slight increase in chemical modification was observed for the samples stored 
at the same temperature for twelve weeks as shown in Figure 1B and Table 2. 
 The chemical modification of the Man5-Fc glycoform at an elevated temperature was 
similar to the HM-Fc glycoform. For instance, samples stored at 40°C showed an estimated 13.5% 
oxidation and slightly increased during incubation for four weeks at 40°C, which was estimated 
to be 13.7%. However, storage of Man5-Fc at 40°C for twelve weeks resulted in a significant 
oxidation, which was estimated to be 26.1%. The pattern and the level of chemical modification 
observed in both HM-Fc and Man5-Fc glycoforms were similar as shown in Figures 1A, B, C, and 
Table 2. In general, the increase in peak intensity of the oxidized product was more apparent at 
40°C compared to 4°C incubation for both Man-Fc and HM-Fc glycoforms.  
For the GlcNAc-Fc, the intact protein mass showed the Fc monomer containing a single 
N-Acetylglucosamine residue as shown in Figure 1C. The GlcNAc-Fc glycoform showed a single 
peak at 25267 Da, and this glycosylation profile was consistent with our previously reported 
work.51 Characterization of GlcNAc-Fc samples stored at -80°C showed an estimated oxidation 
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level of 8.0%, which was similar to the control Man5-Fc and HM-Fc glycoforms. Since HM-Fc was 
used as a precursor to generate GlcNAc-Fc, any chemical modification that existed in the HM-Fc 
samples was expected to appear in the intact mass of GlcNAc-Fc glycoform. The chemical 
modifications of GlcNAc-Fc at 4°C were 8.0%, 8.1%, and 8.1% for two, four and twelve weeks, 
respectively. Therefore, GlcNAc-Fc incubated at 4°C showed no significant chemical modification 
compared to the same reference sample stored at -80°C. This was a unique stability profile 
compared to the HM-Fc and Man5-Fc glycoforms samples studied at the same storage period 
and temperature. However, for GlcNAc-Fc samples incubated at 40°C, a significant chemical 
degradation was noticed. The oxidation levels at 40°C were 10.3%, 14.4%, and 27.2% for two, 
four, and twelve weeks, respectively. This pattern of chemical degradation was similar to the HM-
Fc and Man5-Fc glycoforms incubated at the same temperature as well as the same incubation 
time. 
The non-glycosylated N297Q-Fc showed a single peak for the Fc monomer, consistent 
with its non-glycosylated state as shown in Figure 1D. The asparagine residue at the 297-position 
was mutated to glutamine to prevent glycosylation during biosynthesis. The N297Q-Fc samples 
stored at -80°C showed an estimated percentage of modification at about 7.1%, calculated based 
on the peak intensities. Compared to other glycoforms studied in this work, the initial oxidation 
level was relatively lower. Samples of N297Q-Fc stored at 4°C for two weeks showed a 10.2% 
oxidation level, higher than any of the other glycoforms tested (HM-Fc, Man5-Fc, and GlcNAc-
Fc). The degradation of N297Q-Fc incubated at 4°C for four and twelve weeks were 10.7% and 
11.1%, respectively. This data demonstrated rapid deterioration in the first two weeks, but 
remained stable over the period of four to twelve weeks. The chemical modifications of N297Q-
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Fc incubated at 40°C for two, four, and twelve weeks were 12.5%, 15.3%, and 30.1%, respectively. 
This increasing trend of chemical modification with N297Q-Fc was higher compared to the other 
glycoforms examined in this study. 
4.3.2 Concentrations of IgG1 Fc Glycoforms Incubated at Low and Elevated 
Temperatures  
The concentration of the Fc glycoform was examined using protein G biosensors as shown 
in Figures 2 as well as the raw values in Table 3. First, a well-characterized reference standard 
was employed for each glycoform to develop a standard curve. The concentration of the Fc 
glycoform was then measured. The HM-Fc showed a slightly lower concentration when stored at 
-80°C which was about 170 µg/mL. The original concentration of the Fc glycoforms studied in this 
work was 200 µg/mL. Furthermore, the concentration of the HM-Fc was decreased to 152 µg/mL 
during incubation at 4°C for four weeks. Similarly, the concentration of HM-Fc further decreased 
to 148 µg/mL during the incubation period of twelve weeks at 4°C. On the other hand, the 
concentration of HM-Fc stored at 40°C for two weeks was 147 µg/mL, indicating a significant 
decrease in concentration compared to the same samples and duration of period when stored at 
4°C (163 µg/mL). A further decrease in concentration was noticed during the incubation period 
of four and twelve weeks, which were 146 µg/mL and 139 µg/mL, respectively. This data 
illustrated the differences in concentration between the three storage conditions, in which higher 
concentration was noticed at -80°C, followed by 4°C and 40°C incubation temperatures. 
Moreover, the trend of decreasing concentration profile of the HM-Fc was faster at 40°C than at 
4°C storage condition. The concentrations of HM-Fc were similar during the two-week incubation 
at -80°C and 4°C as shown in Table 3.  
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For Man5-Fc, the concentration of the samples stored at -80°C was 167 µg/mL. Similarly, 
the concentration of the samples stored at 4°C for two, four, and twelve weeks were 175 µg/mL, 
166 µg/mL, and 168 µg/mL, respectively. This data showed that the concentration remained 
stable throughout the storage time. This stability trend of concentration was visible from the 
concentration curve in Figure 2A as well as the concentration data in Table 3. Furthermore, the 
data highlighted the physical stability of Man5-Fc at a lower temperature, which was comparable 
to the control sample stored at -80°C. However, samples of Man5-Fc stored at 40°C showed a 
significant decrease in concentration as shown in Figure 2B. The measured concentrations at 40°C 
for two, four, and twelve weeks were 158 µg/mL, 152 µg/mL, and 143 µg/mL, respectively. This 
data demonstrated a clear difference in stability between the samples stored at low and elevated 
temperatures. 
Next, the concentration of the GlcNAc-Fc at the three storage conditions was examined. 
For instance, the concentration measured for samples stored at -80°C was 167 µg/mL. Similarly, 
the concentration of the GlcNAc-Fc stored at 4°C for two weeks was 163 µg/mL, suggesting a 
slight decrease in concentration. Furthermore, the concentrations of GlcNAc-Fc incubated at 4°C 
for two and four weeks were 149 µg/mL and 132 µg/mL, respectively. This data showed a 
significant decrease in the concentration of GlcNAc-Fc at 4°C during the extended period of 
incubation. The concentration of GlcNAc-Fc stored at 40°C showed a relatively lower trend in 
decreasing concentration profile compared to the lower temperature storage conditions (i.e., 
4°C). The concentrations of GlcNAc-Fc incubated at 40°C were 166 µg/mL, 151 µg/mL, and 146 
µg/mL, for storage periods of two, four, and twelve weeks (Table 3 and Figure 2B). This decrease 
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in concentration was apparent from the reduction in concentration curve profile as shown in 
Figure 2B.  
A similar concentration measurement was conducted for the non-glycosylated N297Q-Fc, 
and the concentration of the samples stored at -80°C was 133 µg/mL. Thus, N297Q-Fc showed 
the lowest concentration at -80°C, presumably due to aggregation and precipitation. The 
concentration of N297Q-Fc  incubated for two, four, and twelve weeks at 4°C was 134 µg/mL, 
134 µg/mL, and 123 µg/mL, respectively. This data demonstrated that there was no significant 
change in concentration when stored at the low temperature after the initial drop in 
concentration. This was presumably due to the significant decrease in the concentration of 
N297Q-Fc (the protein was diluted) and, consequently, no further aggregation was possible.  The 
concentration of the sample incubated at 40°C for two weeks was 123 µg/mL. This concentration 
was the lowest compared to the other glycoforms stored at the same temperature and 
incubation time. The concentrations of the N297Q-Fc samples incubated at 40°C for four and 
twelve weeks were 118 µg/mL and 115 µg/mL, respectively. Overall, this result indicated the 
reduction in the concentration profile of N297Q-Fc was higher compared to the other glycoforms. 
Moreover, significant differences between the two storage conditions (4°C and 40°C) were 
observed as shown in the major reduction in concentration at 40°C compared to the 4°C storage 
condition. Overall, a higher concentration decrease was observed for samples stored at 40oC 
compared to the same samples stored at 4°C and -80°C. N297Q-Fc showed the lowest 





4.3.3 Binding Interaction of Stressed IgG1 Fc Glycoforms with FcRIIIa  
4.3.3.1 Fc-immobilized Format 
 The binding interaction of the Fc glycoforms with the FcRIIIa was examined using the Fc-
immobilized format. This binding interaction was performed for samples stored at 4°C, 40°C, and 
-80°C incubated for two, four, and twelve weeks. The Fc glycoforms stored at -80°C were used as 
a reference for measuring any change in KD values of the samples stored at 4°C and 40°C. The 
interaction was first evaluated using the Fc-immobilized format, in which the glycoforms were 
immobilized onto the protein G biosensor, and the receptor was kept in solution. The kon, koff, 
and KD values for this format were shown in Table 4 and illustrated in Figure 3. The associations 
(kon) and dissociations (koff) were evaluated and used to calculate the equilibrium dissociation 
constant (KD) values. The HM-Fc KD value stored at -80°C was 29.8±1.8 nM, which was consistent 
with values for non-stressed samples. No significant increase in KD value was observed for HM-
Fc samples incubated at 4°C for two weeks (31.0±1.7 nM). The HM-Fc sample stored at 4°C for 
four weeks showed further decrease in KD value, suggesting that there was a reduction in 
functional activity. Similarly, for samples stored at 4°C for twelve weeks, the KD value was 
37.0±1.1 nM, indicating a further deterioration of the sample upon incubation. Overall, a trend 
of decreasing functional activity of HM-Fc was observed at 4°C after two, four, and twelve weeks 
of storage. 
The binding interaction for samples of HM-Fc stored at 40°C was also examined, using the 
Fc-immobilized format. The KD values for HM-Fc stored at 40°C for two, four, and twelve weeks 
were 31.7±1.5 nM, 37.1±1.8 nM, and 37.0±1.1 nM, respectively as shown in Table 4A. In 
comparison to the 4°C storage condition, the 40°C incubation showed a significant reduction in 
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binding affinities, demonstrating deterioration of the sample at the elevated temperature. This 
difference in binding affinities between the low and elevated temperatures was more apparent 
at twelve weeks of storage period as shown in Table 4 and Figure 3.  
Likewise, the KD values of Man5-Fc were evaluated after incubation at -80°C, 4°C, and 
40°C for two, four, and twelve weeks. No significant change in binding affinities was observed for 
the samples incubated at 4°C, and the value is comparable to the samples stored -80°C. However, 
the KD values of the samples stored at 40°C for two, four, and twelve weeks were 40.9±0.8 nM, 
43.8±1.9 nM, and 52.8±2.5 nM, respectively as shown in Table 4B and illustrated in Figure 3. 
Therefore, Man5-Fc showed a significant decrease in binding affinities at the elevated 
temperature (increase in KD values). This data indicated the effect of temperature as evidenced 
by the decreasing trend in binding affinities. 
The interaction of GlcNAc-Fc with the FcRIIIa was also evaluated after the samples were 
incubated at 4°C and 40°C for two, four, and twelve weeks. The samples stored at -80°C were 
used as a reference to evaluate any decrease in binding affinities for the samples stored at 
elevated and low temperatures. A slight increase in KD values (decrease in binding affinities) was 
observed for samples incubated at 4°C as shown in Table 4C. The KD values of the samples stored 
at 4°C for two, four, and twelve weeks were 1111±166 nM, 1333±181 nM, and 1675±45 nM, 
respectively as shown in Figure 3. Similarly, samples of HM-Fc stored at 40°C showed reduced 
binding affinities with the lowest being 2236±596 nM after twelve weeks of storage. The increase 
in KD value was almost two-fold compared to the sample stored at -80°C as well as the samples 
stored at 4°C for two weeks. Thus, the result highlighted the effect of temperature in binding 
affinities and the kinetic binding as shown in Table 4C and Figures 3 and 4. 
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4.3.3.2 Receptor-immobilized Format 
 The change in KD values of the stressed samples after prolonged storage at the elevated 
and low temperatures was evaluated using the receptor-immobilized format. In addition, the 
result was compared with the Fc-immobilized format for further analysis. The samples incubated 
at 4°C and 40°C for twelve weeks were examined using the receptor immobilized format. The 
twelve weeks’ samples were selected because that change in KD values was more apparent after 
an extended storage time. Also, samples stored at -80°C were used as a reference to assess the 
change in binding affinities of the samples stored at the low and elevated temperatures.  
The KD value for HM-Fc stored at 4°C for twelve weeks was 65.2±2.0 nM. This KD value 
was significantly higher compared to the value measured using the Fc-immobilized format. Thus, 
this result demonstrated the difference between the two immobilization techniques regarding 
their sensitivity in detecting a change in binding affinities upon stress conditions. Likewise, the 
HM-Fc stored at 40°C for twelve weeks was also evaluated, and the KD value was 136.3±9.2 nM. 
Again, this data demonstrated that the functional activity of HM-Fc significantly decreased 
compared to the same sample incubated at 4°C. Moreover, the receptor-immobilized format 
demonstrated significant differences between the two incubation conditions compared to the 
differences observed when using the Fc-immobilized format. Comparatively, the sample stored 
at 4°C for twelve weeks showed a decrease in koff values. The decreased koff was presumably due 
to the presence of a weak binding component in the sample. For HM-Fc, the koff measured after 
incubation at 40°C and 4°C was similar. However, the kon value after incubation at 40°C decreased 
significantly, suggesting an inactive component present in the sample. The kinetic data were 
shown in Table 5 and illustrated in Figures 5 and 6. 
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Like HM-Fc, samples of Man5-Fc stored at 4°C and 40°C for twelve weeks were evaluated 
using the receptor-immobilized format. First, the samples stored at -80°C were evaluated, and 
the KD value was 34.3±1.9 nM, which was consistent with our previous work reported for the 
same non-stressed samples.51 The KD value for Man5-Fc stored at 4°C for twelve weeks was 
65.2±1.9 nM. This increase in KD value was attributed to the faster dissociation rate. Moreover, 
the koff value measured was significantly faster compared to the same sample stored at -80°C. 
Furthermore, the kon values of the samples stored at 4°C and -80°C were similar (2.1±0.0)x105 M-
1s-1 and (2.4±0.0)105  M-1s-1, respectively. Again, this data suggested a significant proportion of 
the protein was partially active. For samples of Man5-Fc stored at 40°C for twelve weeks, the KD 
value was 121.9±7.1 nM. Thus, a significant decrease in KD value was observed, which was 
attributed to the increase in koff rate and a reduction in the association rate as shown in Table 5. 
The koff values of the samples incubated at 4°C and 40°C for twelve weeks were similar, whereas 
significant differences in kon values were observed as shown in Table 5 and Figures 5 and 6.  
Similarly, samples of GlcNAc-Fc stored at 4°C, 40°C, and -80°C for twelve weeks were 
examined using the receptor-immobilized format. The KD value for the GlcNAc-Fc stored at -80°C 
was 988.8±21.8 nM, which was consistent with our previous work for the non-stressed samples.51 
The data suggested the samples stored at -80°C were stable with no change in KD values expected. 
However, GlcNAc-Fc stored at 4°C for twelve weeks showed a significantly lower binding affinity 
(8779.3±143.4 nM) compared to the same sample stored at -80°C. Again, this decrease in KD value 
was attributed to the increase in koff value and a reduction in the association rate, in which both 
contributed to the lower binding affinity. One difference observed with the GlcNAc-Fc compared 
to the other glycoforms was that the kon value at 4°C was significantly lower compared to the kon 
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value of the same sample stored at -80°C. The GlcNAc-Fc stored at 40°C for twelve weeks showed 
a significantly lower KD value, again attributed to the decrease in association and increase in 
dissociation rates. 
4.3.4 Binding Responses of Stressed IgG1 Fc Glycoforms 
The binding response of the Fc glycoforms with FcRIIIa was also evaluated using the Fc-
immobilized format. HM-Fc samples stored at -80°C showed a higher response compared the 
same samples stored at 4°C and 40°C (Figures 7 and 8A , Table 6). Also, the samples stored at 4°C 
for two, four, and twelve weeks showed similar binding responses.  However, samples of HM-Fc 
stored at 40°C showed a significant decrease in binding response compared to the same samples 
stored at -80°C. Moreover, differences in response were observed for samples incubated at 40°C, 
in which the trend in response was as follows: two weeks> four weeks> twelve weeks. 
Representative response binding curves were given in Figure 8A, and the raw values were shown 
in Table 6. For ease of comparison, the response values were further illustrated in Figure 7. In 
general, a similar pattern was observed for HM-Fc, Man5-Fc, and GlcNAc-Fc. Furthermore, 
differences in response were more apparent when the samples stored at -80°C, 4°C, and 40°C for 
twelve weeks were compared. This data illustrates the need to monitor the stability for an 





4.4 Discussion  
During manufacturing, shipping, and storage, antibodies are subjected to various 
degradation pathways, which can potentially affect their potency.14 In one study, it has been 
demonstrated that chemical degradation in the antigen binding site decreased the binding 
affinity.4 However, the effect of physical and chemical degradations of the Fc fragment on the 
functional activity as well as binding affinity to Fc receptors is less known.  
The mass spectrometry data demonstrate a significant chemical modification at 40°C 
compared to the samples incubated at 4°C and -80°C. This could be either due to the physical 
degradation that accelerates the chemical degradation or the impact of temperature on the rate 
of chemical deterioration. Nevertheless, the difference in chemical degradation between the 
storage conditions was apparent as shown in Table 2 and Figure 1. Samples were tested for 
chemical modification using intact protein mass spectrometry under reducing conditions. A 
significant chemical modification (+16), presumably due to oxidation was observed for samples 
stored at 40˚C and showed a trend with the incubation time (twelve weeks>four weeks>two 
weeks). This trend in chemical modification was observed in all glycoforms tested as shown in 
Figure 1 and Table 2. Samples stored at -80˚C and 4˚C showed a modest change in the chemical 
modification, indicating a stable storage temperature. Moreover, the data showed the Fc 
glycoforms were more stable when stored at -80˚C and 4˚C than at 40˚C. Unlike the elevated 
temperature, no significant chemical modification (+16) was observed for samples stored at 4˚C. 
Several reports demonstrated deamidation of asparagine residue and oxidation of 
methionine sulfoxide after prolonged storage at an elevated temperature. IgG1 contains two 
conserved Met residues: Met 252 and Met 428 (EU numbering).52 Methionine oxidation can be 
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induced by oxidizing agents, such as Ter-butyl hydro-peroxide, H2O2, UV, and an elevated 
temperature. In one study, Met oxidation was found to affect binding to protein A, protein G, 
and FcRn; however, binding to FcRIIIa was not affected.53 Oxidation has been shown in samples 
stored at an elevated temperature, whereas a sample kept at a low-temperature aggregation 
was found to be the major degradation pathway. Another study reported the oxidation of 
tryptophan and methionine during storage at a high temperature.4 These samples incubated at 
low and elevated temperatures were examined for chemical modification using peptide 
mapping. Minor oxidation of Met and deamidation of asparagine was observed.54  
The concentration of the samples was measured using BLI by binding with the protein G 
on the surface of the biosensors. The concentration decreased more rapidly in samples incubated 
at 40˚C. The concentration corresponds to the rate of binding of the Fc glycoforms to the protein 
G biosensors. A significant drop in concentration was observed for N297Q-Fc, presumably due to 
aggregation and precipitation as shown in Figures 2A and 2B. Samples stored at 4˚C showed a 
modest change in concentration, except N297Q-Fc in which a significant decrease was observed, 
presumably due to aggregation and precipitation. As shown in Figures 2A and 2B, a significant 
decrease in concentration was observed, indicating the presence of degraded protein generated 
during stress. For instance, HM-Fc stored at 40°C for twelve weeks showed about a 30% decrease 
in concentration, presumably due to the inactive protein present in the sample (i.e., protein 
unable to bind protein G). Similarly, HM-Fc stored at 4°C for twelve weeks showed a 26% 
decrease in concentration, likely due to the presence of inactive protein (Table 2). Therefore, the 
decrease in concentration measurement agreed to the reduction in binding affinities measured 
in the samples incubated at 4°C and 40°C for twelve weeks. Furthermore, these samples showed 
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similar levels of inactive protein, resulting in a similar decrease in the association rates as shown 
in Table 5.  
In this study, a reduction in binding affinities, which corresponded with the storage times, 
was observed for samples incubated at 40˚C and 4˚C. A decrease in association rate and an 
increase in dissociation rate was noted for the Fc-glycoforms incubated at 40˚C tested as shown 
in Figure 3 and Table 4. Samples stored at 4˚C for two, four, and twelve weeks showed modest 
changes in binding affinities when tested using the Fc-immobilized format. This data 
demonstrated the Fc glycoforms remained relatively stable at the low-temperature incubation, 
which agreed with the binding responses and chemical modifications examined. A trend of 
decreasing binding affinities was observed for all glycoforms tested, except N297Q-Fc in which 
no binding was observed.  
In addition to the Fc-immobilized format, the glycoforms were examined using the 
receptor-immobilized format to assess the binding affinities as well as to compare the two 
immobilization formats. Differences in equilibrium dissociation constants were noticed between 
the Fc glycoforms incubated at 4˚C and 40˚C for twelve weeks, as shown in Figure 6 and Table 5. 
The HM-Fc samples incubated at 4˚C showed a minor decrease in association rate compared to 
the control sample stored at -80˚C. This data indicated the absence of inactive protein during the 
twelve weeks of incubation period at 4˚C. However, the dissociation phase showed a significant 
increase, presumably due to the presence of a partially active protein in the sample. Therefore, 
the HM-Fc data suggested a substantial amount of partially active protein, but a minor inactive 
protein in the sample generated during the incubation period of twelve weeks at 4˚C. Likewise, 
samples of HM-Fc incubated at 40˚C for twelve weeks showed a significantly lower association 
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rate compared to the same samples stored at -80˚C and 4˚C. This significant decrease in 
association rate was presumably due to the presence of a large amount of inactive protein 
present in the sample generated during incubation at 40˚C.  
A significant increase in dissociation rate was noted, presumably due to the presence of 
a substantial amount of partially active protein in the sample. Thus, the data of the HM-Fc 
samples incubated at 40˚C for twelve weeks indicated a substantial presence amount of inactive 
and a partially active protein generated during twelve weeks of incubation. Moreover, both 
samples incubated at 4˚C and 40˚C showed a similar increase in the dissociation rate, which was 
attributed to the comparable amount of a partially active protein in the samples. However, a 
major decrease in association rate was observed only in the samples incubated at 40˚C, indicating 
a significant amount of inactive protein was present in this sample compared to the same 
samples incubated at 4˚C. Furthermore, this data demonstrated that the differences in the 
binding kinetics between the samples incubated at low and elevated temperatures were 
attributed to the differences in the type of degradation products generated during storage. These 
degraded products could be due to chemical modifications, aggregates, or conformational. A 
similar binding profile was observed for Man5-Fc compared to HM-Fc incubated at a low and 
elevated temperature for twelve weeks. This similarity is not surprising because Man5-Fc and 
HM-Fc have similar glycosylation profiles, binding activity, and physical stability.  
Similarly, GlcNAc-Fc samples incubated for twelve weeks at 4˚C, 40˚C, and -80˚C were 
examined using the receptor-immobilized format. A significant decrease in association rates was 
observed for both the samples incubated at 4˚C and 40˚C for twelve weeks. This data suggested 
the comparable amount of inactive protein present in both storage conditions. Moreover, the 
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data indicated GlcNAc-Fc was unstable at 4˚C and 40˚C incubation, presumably due to its 
truncated N-linked glycan at Asn297. Therefore, this work demonstrated the application of stress 
conditions to differentiate glycoforms based on their stability attributed to their difference in 
glycosylation size and state. The instability ultimately resulted in the significant loss of functional 
activity for the samples containing shorter or no glycans. In other words, this data demonstrated 
that the effect of glycosylation not only modulates the binding affinity to FcRIIIa but also affects 
stability and, consequently, affects the activity.  
Like the receptor-immobilized format, the Fc-immobilized format showed a decrease in 
association rate and an increase in dissociation rate after twelve weeks of the incubation period. 
However, the difference in binding kinetics (kon, koff, and KD) between the low and elevated 
incubation temperature were more apparent when measured using the receptor-immobilized 
format. Also, lower binding affinities were observed when the receptor-immobilized format was 
utilized. Nevertheless, both methods demonstrated differences in binding affinities for all the 
samples examined, which could be helpful in a biosimilar assessment. Therefore, these 
glycoforms were found to be a useful model for biosimilar comparability analysis.  
The impact of physically and chemically degraded products generated during the 
incubation at a low and elevated temperature on the binding affinities cannot be easily assigned. 
However, the differences in KD values observed between the two immobilization formats for the 
stress samples in this study can be deconvoluted using the mixtures of glycoforms examined in 
chapter 3. These mixtures contain N297Q-Fc (inactive) and GlcNAc-Fc (partially active) combined 
with HM-Fc in different proportions. In the mixture study, using the receptor-immobilized 
format, a decrease in association rate was observed that was proportional to the amount of 
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N297Q-Fc present in the mix. However, no change in dissociation rate was observed. Also, using 
the Fc-immobilized format, a decrease in dissociation rate was noted due to the presence of a 
weak binding component (i.e., GlcNAc-Fc). Therefore, N297Q-Fc and GlcNAc-Fc can potentially 
mimic the inactive and partially active proteins present in the stressed samples of the Fc 
glycoforms generated during storage. In this study, the differences in KD, kon , and koff between 
the samples incubated at low and elevated temperatures were similar to the differences 
observed between the mix1  (a mixture of N297Q-Fc and HM-Fc) and Mix2 (a mix of GlcNAc-Fc 
and HM-Fc) studied in chapter 3.  
For all of the stressed samples incubated for twelve weeks, a decrease in association rate 
and an increase in dissociation rate was observed when the receptor-immobilized format was 
utilized. The reduction in association rate was an indication of an inactive protein (i.e., unable to 
bind to a receptor) present in the sample (i.e., unable to bind receptor). However, an increase in 
the dissociation rate was likely due to the presence of the partially inactive component (i.e., 
weakly binding to a receptor) present in the sample (i.e., binds to receptor weakly). Moreover, in 
the mixture of HM-Fc and GlcNAc-Fc, we observed displacement of the weak binding GlcNAc-Fc 
by HM-Fc during the association phase. Thus, the dissociation phase behaved more like HM-Fc. 
Overall, no significant change in dissociation rate was noted in the mixture containing HM-Fc and 
GlcNAc when compared to the 100% HM-Fc. However, for the incubated samples, we have seen 
major changes in dissociation rate, presumably due to the presence of a partially active protein. 
In order for this partially active protein to exert contribution in the dissociation phase, it needs 
to have a higher binding affinity than GlcNAc-Fc to withstand displacement by HM-Fc. The 
presence of this partially active protein was similar to the samples of HM-Fc incubated at 4°C and 
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40°C, as shown in their similar dissociation rates. However, the amount of inactive protein was 
higher in the samples incubated at 40°C, as demonstrated by the significant drop in association 
phase. This data was also in agreement with the concentration measured using Bio-Layer 
Interferometry (BLI) as shown in Table 2. 
A significant difference in binding response between samples incubated at 40˚C was 
observed in which the samples stored for two weeks showed the highest binding responses 
followed by the samples stored at four weeks and twelve weeks. Therefore, the binding 
responses showed a decreasing trend with increasing incubation times, indicating a loss of 
functional activity. This reduction in binding responses could be due to the chemical or physical 
degradation of the samples incubated at 40˚C for extended storage time. Moreover, this 
decrease in binding response with an increase in storage time at the elevated temperature was 
observed in all glycoforms, except N297Q-Fc in which no binding with FcRIIIa was observed.  
Samples stored at 4˚C showed no significant change in responses, indicating the samples 
remained relatively stable (native state) during the incubation time. The loading level of HM-Fc 
to protein G was examined and found to be the same regardless of the incubation time. 
Moreover, no significant difference in the loading level of Fc to protein G was observed between 
two, four, and twelve weeks, in all the samples tested. Thus, the difference in binding responses 
indicates that there was a protein loaded onto the protein G that binds weakly with FcRIIIa 
(partially active). Therefore, the Fc-immobilized format successfully differentiated the samples 
stored at low and elevated temperatures. This binding response measurement can be utilized to 




In general, the samples incubated at 4°C showed a similar response, suggesting the 
protein remained relatively stable during the incubation period. However, the samples stored at 
40°C showed a decrease in binding response, in which a higher response was observed in the 
samples stored for two weeks and the lowest response in the samples stored for twelve weeks. 
Furthermore, the difference in response (i.e., measured using Fc immobilized format) was more 
visible when the samples incubated at 4°C, 40°C, and 80°C were compared at twelve weeks of 
storage (Figures 8A, 8B, and 8C). In addition, the data demonstrated the use of stress (40°C) to 
observe differences in response, which was not visible at low temperatures (4°C and -80°C). For 
instance, HM-Fc incubated at 4°C showed a decrease in response compared to the same samples 
incubated at 40°C for twelve weeks. The estimated decrease in response of HM-Fc incubated at 
4°C for twelve weeks was 28.3% compared to the same samples stored at -80°C. Similarly, the 
samples of HM-Fc incubated at 40°C for twelve weeks showed a 52.4 % decrease in response 
compared to the control samples of HM-Fc stored at -80°C. A further decrease in response at an 
elevated temperature illustrated the instability of HM-Fc, presumably due to chemical and 
physical degradations. Man5-Fc showed a similar binding response profile to HM-Fc at the low 
and elevated temperatures. Compared to the GlcNAc-Fc stored at -80°C, the GlcNAc-Fc samples 
stored at 4°C and 40°C for twelve weeks showed 36.0% and 73.14% decrease in binding response, 
respectively. This higher percentage of decrease in binding response of the GlcNAc-Fc compared 
to HM-Fc and Man5-Fc was presumably due to the differences in the glycosylation state. In other 
words, GlcNAc-Fc contained a more truncated glycan (single N-Acetylglucosamine), potentially 
leading to aggregation and further physical degradation. 
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Overall the data highlights the use of longer incubation time to compare samples 
incubated at low and high temperatures to observe apparent differences, which were not 
possible to differentiate at a lower temperature and shorter incubation time. This stress 
condition and techniques developed in this study can be applied when comparing the originator 
with its biosimilar product, in the biosimilar comparability analysis. 
4.5 Conclusion 
The functional activities of homogeneous glycoforms were characterized after incubating 
at elevated and low temperatures. The data indicated samples stored at the elevated 
temperature showed a significant decrease in binding affinities. Additionally, a reduction in 
binding response to receptor (i.e., measured using the Fc immobilized format) was observed for 
the samples stored at the elevated temperature. Samples stored at -80˚C and 4˚C showed a 
moderate change in binding affinities as well as binding response to FcRIIIa. Mass spectrometry 
characterization indicated significant chemical modification for samples incubated at the 
elevated temperature, presumably due to oxidation, while samples stored at a low temperature 
showed a moderate change in the chemical modification. Concentration measurement using BLI 
for all glycoforms demonstrated a decreasing trend when stored at low and elevated 
temperatures. N297Q-Fc showed the lowest concentration, presumably due to precipitation and 
aggregation during storage. When the two immobilization formats were compared (Fc-
immobilized vs. receptor-immobilized), a significant difference in binding affinities was observed. 
This was due to the differences in the mechanism of binding between the two formats as 
described in chapter 3. Moreover, the data collected showed significant differences between the 
two formats in detecting a change in binding affinities attributed to the stress condition. The low 
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and elevated temperatures generated physical and chemical degradation products after 
incubation of the samples for twelve weeks, which ultimately resulted in lower binding affinities 
to FcRIIIa. More studies are required in the future to understand further if the decrease in 
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Figure 1. Intact protein ESI-MS analysis of tested IgG1 Fc glycoforms under 
reducing conditions. Samples were incubated at -80˚C, 4˚C, and 40˚C for two, 
four and twelve weeks. Figure 1A, 1B, 1C, and 1D are for HM-Fc, Man5-Fc, 
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Figure 2. The concentration of IgG1 Fc glycoforms measured using Bio-Layer Interferometry (BLI). 
Protein G biosensors were used to determine the concentration of samples incubated for two, 
four, and twelve weeks at -80˚C, 4˚C, and 40˚C. Figure 1A and Figure 2A and 2B represent for the 





















Figure 3. Bar graphs show KD values for samples of IgG1 Fc incubated at low 
and elevated temperatures for two, four, and twelve weeks. The KD values 







  Figure 4. Bar graphs show the kon, and koff values for IgG1 Fc 








Figure 5. The bar graph show KD values for samples of IgG1 Fc incubated at -80˚C, 4˚C, 









Figure 6. Bar graphs of the kon and koff values for samples of IgG1 Fc 








Figure 7. The binding responses of IgG1 Fc glycoform to FcRIIIa measured the Fc-
immobilized format. The samples were incubated at -80˚C, 4˚C, and 40˚C for two, four, 









Figure 8. Representative binding response curves measured using the Fc-immobilized 






























HM-Fc 2W 4˚C 
HM-Fc 4W 4˚C 
HM-Fc 12W 4˚C 
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HM-Fc 4W 40˚C 
Figure 9. Representative fitting binding curves for the interaction of IgG1 Fc with FcRIIIa 
measured using the Fc-immobilized format. Figure 9A, 9B, and 9C represent for HM-Fc, 


























Figure 10. Representative fitted binding curves for the interaction of IgG1 Fc with 
FcRIIIa. Samples were incubated for twelve weeks at -80˚C, 4˚C, and 40˚C. The binding 








IgG1 Fc glycoforms Buffer condition  Time in 
weeks  
Sample 1  Sample 2 
 HM-Fc  Citrate-phosphate pH 6.0 
buffer with, 150 mM NaCl 
0 - 80°C - 80°C 
2 4°C 40°C 
4 4°C 40°C 
12 4°C 40°C 
Man5-Fc Citrate-phosphate pH 6.0 
buffer with, 150 mM NaCl 
0 - 80°C - 80°C 
2 4°C 40°C 
4 4°C 40°C 
12 4°C 40°C 
GlcNAc-Fc  Citrate-phosphate pH 6.0 
buffer with, 150 mM NaCl 
0 - 80°C - 80°C 
2 4°C 40°C 
4 4°C 40°C 
12 4°C 40°C 
N297Q-Fc  Citrate-phosphate pH 6.0 
buffer with, 150 mM NaCl 
0 - 80°C - 80°C 
2 4°C 40°C 
4 4°C 40°C 
12 4°C 40°C 
Table 1. Samples of IgG1 Fc incubated at low and elevated temperatures and the buffer 









Percentages of oxidation 
HM-Fc  Man5-Fc  GlcNAc-Fc  N297Q-Fc  
T0    -80˚C 8.7   9.5  8.0  7.1 
2 WK / 4˚C 8.7 12.1 8.1  10.2 
4 WK / 4˚C 9.8 12.9 8.1 10.7 
12 WK/ 4˚C 11.6  13.7 8.8 11.1 
2 WK / 40˚C  13.4  13.5 10.4  12.5 
4 WK / 40˚C 14.1 13.7 14.4 15.4 













Incubation time and 
temperature 
Concentration in µg/mL 
HM-Fc  Man5-Fc  GlcNAc-Fc  N297Q-Fc  
T0 -80˚C 167±6   167±3  167±2   133±1 
2 WK / 4˚C  163±3 175±2  163±1  134±2 
4 WK / 4˚C 152±2 166±2 149±4 134±2 
12 WK/ 4˚C 148±4  168±6  132±4 123 ±1 
2 WK / 40˚C  147±2  158±1 166±4  115±3 
4 WK / 40˚C 146±4 152±1 151±1 118±1 























 (1/Ms) Avg.   kon (1/Ms)x10
5
 koff (1/s) Avg.  koff (1/s)X10-3    KD (nM)   Avg.  KD (nM) 
T0 -80 ˚C 1.891e5 1.8±0.0 4.379e-3 5.4±0.3 30.4 29.8±1.8 
1.807e5 5.384e-3 29.80 
1.786e5 5.143e-3 28.79 
2 WK / 4 ˚C 1.437e5 1.5±0.1 4.695e-3 4.7±0.1 31.95  
31.0±1.7 1.601e5 4.848e-3 30.28 
1.557e5 4.725e-3 30.34 
4WK / 4 ˚C 1.606e5 1.5±0.1 5.501e-3 5.2±0.3 34.25  
35.0±4.2 1.551e5 5.344e-3 34.46 
1.329e5 4.821e-3 36.28 
12WK/ 4 ˚C 1.513e5 1.5±0.0 5.646e-3 5.6±0.1 37.29 37.7 ±1.1 
1.487e5 5.501e-3 36.99 
1.436e5 5.608e-3 39.05 
2 WK / 40 ˚C 1.266e5 1.3±0.1 4.035e-3 4.2±0.1 31.88 31.7±1.5 
1.35e5 4.25e-3 31.49 
1.348e5 4.25e-3 31.53 
4WK / 40˚C 1.359e5 1.3±0.1 4.968e-3 4.9±0.1 36.57 37.1±1.8 
1.33e5 4.925e-3 37.02 
1.254e5 4.686e-3 37.37 
12 WK/ 40˚C 1.395e5 1.4±0.0 6.589e-3 6.6±0.3 47.23 47.3±0.2 
1.349e5 6.277e-3 46.52 
1.418e5 6.854e-3 48.34 
Table 4. The kon , koff, and KD values for samples of IgG1 Fc incubated at -80˚C, 4˚C, and 40˚C 
for two, four and twelve weeks. The measurement was performed using the Fc-immobilized 















 (1/Ms) Avg. kon (1/Ms)x10
5
 koff (1/s) Avg. koff (1/s)X10
-3
 KD (nM)   Avg.  KD (nM) 
T0 -80 ˚C 2.15e5 2.1±0.1 6.94e-3 6.9±0.4 32.76 31.9±2.8 
2.32e5 7.207e-3 31.07 
2.015e5 6.46e-3 32.05 
2 WK / 4 ˚C 1.794e5 1.9±0.1 6.149e-3 6.4±0.2 34.27 34.3±1.5 
1.905e5 6.530e-3 34.28 
1.873e5 6.472e-3 34.56 
4WK / 4 ˚C 1.732e5 1.7±0.0 6.068e-3 6.1±0.0 35.04 34.9±2.3 
1.756e5 6.099e-3 34.74 
1.732e5 6.042e-3 34.89 
12 WK/ 4 ˚C 1.627e5 1.7±0.0 6.232e-3 6.3±0.1 38.31 38.0±1.3 
1.659e5 6.333e-3 38.18 
1.734e5 6.467e-3 37.3 
2 WK / 40 ˚C 1.546e5 1.6±0.0 6.442e-3 6.4±0.0 41.66 40.9±0.8 
1.6e5 6.441e-3 40.27 
1.573e5 6.397e-3 40.66 
4WK / 40˚C 1.547e5 1.6±0.0 6.973e-3 7.1±0.2 45.07 43.8±1.9 
1.63e5 7.384e-3 45.31 
1.526e5 7.006e-3 45.90 
12 WK/ 40˚C 1.821e5 1.8±0.1 9.478e-3 9.7±0.3 52.05 52.8±2.5 
1.788e5 9.465e-3 52.94 














 (1/Ms)  Avg. kon (1/Ms)x10
5
 koff (1/s)  Avg. koff (1/s)X10
-3
    KD (nM)   Avg.  KD (nM) 
T0 -80 ˚C 9.471e4 1.1±0.1 1.028e-1 114.0± 10.0 1086 1046±147 
1.153e5 1.222e-2 1060 
1.168e5 1.166e-1 997.9 
2 WK / 4 ˚C 1.106e5 0.9±0.1 1.223e-2 110.23±11.0 1105 1111±166 
9.842e4 1.082e-1 1099 
8.82e4 1.002e-1 1131 
4WK / 4 ˚C 7.813e4 0.8±0.1 1.049e-1 112.1±12.1 1342 1333±181 
8.194e4 1.059e-1 1292 
9.191e4 1.256e-1 1367 
12WK/ 4 ˚C 5.807e4 0.6±0.0 0.9559e-1 97.9±2.0 1646 1675±45 
5.949e4 0.9986e-1 1679 
5.787e4 0.9825e-1 1698 
2 WK / 40 ˚C 1.365e5 1.1±0.2 1.658e-1 150.7±15.0 1215 1218±162 
1.216e5 1.511e-1 1243 
1.147e5 1.352e-1 1178 
4WK / 40˚C 0.7926e5 0.8±0.3 1.148e-1 122.0±6.0 1449 1479±89 
0.8444e5 1.25e-1 1480 
0.8394e5 1.255e-1 1495 
12WK/ 40˚C 0.7098e5 0.7±0.1 1.554e-1 155.2±27.0 2189 2236±596 
0.8281e5 1.815e-1 2192 


































65.2 ± 2.0 2.43E+05 1.55E-02 63.62 
2.36E+05 1.52E-02 64.27 





14.0 ± 0.7 
137.8 
136.3 ± 9.2 1.00E+05 1.28E-02 126.6 










27.8 ± 2.8 2.85E+05 7.80E-03 27.37 






15.6 ± 0.1 
65.65 
65.2± 1.9 2.43E+05 1.55E-02 63.62 








121.9± 7.1 1.25E+05 1.49E-02 118.8 









34.3 ± 0.6 2.14E+05 7.38E-03 34.37 








8770.3 ± 143.4 2.66E+04 2.29E-01 859.6 








18746.0± 931.8 1.26E+04 2.52E-01 19970 
1.38E+04 2.51E-01 18200 










988.8 ± 21.8 1.91E+05 1.83E-01 9577 
1.85E+05 1.89E-01 1018 
Table 5. The kon , koff, and KD values for samples of IgG1 Fc incubated at -80˚C, 4˚C, and 40˚C 







Incubation time and 
temperature 
Binding Responses   
HM- Fc Man5-Fc  GlcNAc-Fc  
T0 -80˚C 
0.729± 0.01 0.710± 0.018 0.417± 0.010 
2 WK / 4˚C 
0.523±0.009 0.529±0.006 0.286±0.011 
4 WK/ 4˚C 
0.509±0.002 0.512±0.004 0.268±0.004 
12 WK/ 4˚C 
0.522±0.005 0.508±0.007 0.266±0.001 
2 WK / 40˚C 
0.495±0.002 0.472±0.004 0.177±0.007 
4 WK / 40˚C 
0.459±0.001 0.444±0.003 0.134±0.005 
12 WK/ 40˚C 
0.347±0.003 0.338±0.001 0.112±0.002 
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5.1 Summary  
The exact chemical structure of small-molecule drugs and their purities can be well-
defined. This provides an opportunity for generic manufacturers to avoid costly clinical trials if 
they can demonstrate that their generic product is “bioequivalent” in pharmacokinetics 
compared with the brand product. However, unlike small-molecule drugs, protein molecules are 
complex, containing a mixture of different species generated by posttranslational modifications. 
For instance, glycosylation is a posttranslational modification, which significantly contributes to 
the heterogeneity of the protein molecule produced. The majority of protein heterogeneity is 
attributed to the variably complete glycosylation as well as chemical modifications and 
differences in physical conformations. In addition, the complexities of bioprocess make the exact 
replication of the originator molecule a daunting task. Moreover, glycosylation, charge variants, 
and even the three-dimensional structure can be significantly altered and ultimately can affect 
the safety and efficacy profiles of these products. Thus, biosimilar molecules are not simple 
generic molecules and cannot be identical to the originator. Although there are differences in 
posttranslational modifications, biosimilar products are anticipated to have the same quality, 
safety, purity, potency, and efficacy.1  
The complex and heterogeneous nature of glycosylation that ultimately produces a 
mixture of variably complete glycoforms makes it difficult to precisely account for the 
contribution of individual glycans to the overall functional activity and stability of therapeutic 
mAbs. Hence, it is necessary to utilize in-vitro enzymatic reactions to produce well-defined 
homogeneous glycoforms to be used as a model for biosimilar comparability analysis. One way 
to produce homogenous glycosylated IgG1 Fc glycoforms is to utilize glycoengineered P.pastoris 
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followed by enzymatic reactions.2  Well-defined homogeneous IgG1 Fc glycoforms, which include 
HM-Fc, Man5-Fc, GlcNAc-Fc, and N297Q-Fc, were prepared to be used as a model for a 
biosimilarity study. These glycoforms were produced by utilizing several techniques, such as site-
directed mutagenesis, expression in glycoengineered P. pastoris, in-vitro enzymatic reaction, and 
purification techniques.2-3  
The ability of therapeutic monoclonal antibodies to induce ADCC greatly depends on their 
binding affinity to activating receptors, such as FcRIIIa and FcRI.4 As a result, efforts to analyze 
and enhance Fc interactions with FcRs have become an integral part of the biotherapeutic 
development process. FcRIIIa is the only activating receptor expressed on natural killer cells 
related to ADCC. This receptor is implicated in inducing ADCC and patients with high-affinity 
polymorphic variants to show a higher response to treatment.5 Binding kinetics of therapeutic 
mAbs with FcRIIIa can be used as a surrogate measure for biological activity if the correlation 
with another bioassay is established.6   
Two parallel assay methods were developed to precisely evaluate the binding kinetics of 
IgG1 Fc glycoforms to FcRIIIa using a bio-layer interferometry (BLI) technique. In addition, these 
glycoforms were incubated at low and elevated temperatures to evaluate the change in binding 
affinities after prolonged storage time.  Furthermore, these homogeneous glycoforms were 
mixed to model change in glycosylation typically encountered during biosimilar development.  
In the second chapter, four homogenous IgG1 Fc glycoforms were produced using 
expression in P. pastoris, site-directed mutagenesis, and in-vitro enzymatic reaction. The four 
glycoforms were then utilized as a model for biosimilar comparability analysis. Initial 
characterization was performed using mass spectrometry, SEC, SDS-PAGE, and cIEF. Then, these 
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glycoforms were used to develop binding assays using BLI. The data demonstrated that the two 
assays have similar sensitivity to the change in glycoform. In the first method, the Fc was 
immobilized, and the receptor was kept in solution, while in the second format, the receptor was 
immobilized and the Fc was maintained in solution. The two formats were complementary to 
each other and showed similar KD values for these well-defined Fc-glycoforms. The receptor 
(FcRIIIa) was selectively biotinylated and immobilized onto the streptavidin biosensors. In the 
Fc-immobilized format, the Fc was immobilized, and no modification was required. 
In general, the results demonstrated that the two methods provide similar kon, koff, and 
KD values and can be used as parallel binding assay methods during comparability and 
biosimilarity studies.  Moreover, the same sensitivity to the change in glycosylation was observed 
using both immobilization techniques. Overall, high binding affinities were obtained for HM-Fc 
and Man5-Fc, and relatively lower binding affinity for GlcNAc-Fc. No binding affinity was observed 
for N297Q-Fc at the highest concentration tested, indicating the loss of potency upon the 
removal of the glycans. 
One advantage of using Protein G biosensor tips (Fc-immobilized) is that the loading of 
the Fc can be conducted with a variety of formulation conditions without adjusting the buffer as 
well as the pH. However, this format is not sensitive to the concentration of IgG1 Fc glycoforms 
in the samples. Because of this, it may be difficult to detect a change in potency during chemical 
and physical modifications. An advantage of using an immobilized FcRIIIa binding format is that 
a binding affinity test can be performed directly in solutions of IgG1 Fc glycoforms. Therefore, 
this format is potentially sensitive to changes in potency caused by chemical and physical 
degradations. A disadvantage of this format is that buffer conditions used in the formulation 
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must be compatible with receptor binding measurements. In addition, high concentrations of 
sugars and polysorbates can have a detrimental effect on the kinetics and thermodynamics of 
binding measurements. 
In the third chapter, four homogeneous IgG1 Fc glycoforms were produced, which include 
HM-Fc, Man5-Fc, GlcNAc-Fc, and N297Q-Fc. These glycoforms were mixed to make well-defined 
mixtures with evident as well as subtle differences in functional and physical characterizations. 
The mixtures of glycoforms were prepared by mixing HM-Fc with defined proportions of GlcNAc-
Fc, Man5-Fc, and N297Q-Fc. The mixtures with subtle differences contained 90%HM:10X in which 
X represents N297Q-Fc, Man5-Fc, or GlcNAc-Fc. These samples were prepared to model minor 
shifts in glycoform composition encountered during process and cell-line changes in a biosimilar 
development process. The second set of mixtures contained 50%HM mixed with 50% of each of 
the three glycoforms. Again, these mixtures were designed to model major changes in glycoform 
composition encountered during biosimilar and comparability assessments. The third set of the 
mixtures contained a 25% mixture of each glycoform aimed at modeling a complex mixture of 
glycoforms. These four control glycoforms have a broad range of physicochemical and functional 
quality attributes. This makes them suitable candidates to make the mixture of glycoforms and 
to be utilized as a model for biosimilar comparability analysis. The mixture of glycoforms was 
tested using the Fc-immobilized and receptor-immobilized formats to evaluate their binding 
affinities.  
In general, differences in sensitivity between the two assays platforms were observed. 
These differences in kon, koff, and KD values depend on the type of mixture, percentage of 
composition of the mixture, and the assay method used. Binding response measurements using 
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the Fc-immobilized technique were found to be very sensitive in detecting a change in the type 
of mixtures as well as compositions of the mixtures of glycoforms. Overall, the data highlighted 
the need to carefully examine binding assay results since the selected immobilization technique 
could have a substantial effect on the binding assay results. This is important in biosimilarity 
assessments because the glycoform composition can change with the expression condition, cell-
line, and manufacturing sites.  
The main advantage of the Fc-immobilized format was the capacity to measure accurately 
the sample containing a mixture of high and low binding components typically observed in 
monoclonal antibodies, such as a mixture of fucosylated and non-fucosylated glycoforms. 
However, if the sample contains a mixture of inactive and active proteins, then this format will 
not be able to detect it. On the other hand, the receptor-immobilized format is not sensitive if 
the sample contains a mixture of the high and low-affinity components. This is because the high-
affinity glycoform will displace the low-affinity glycoform, and the resulting KD values will be 
greater than anticipated. However, an advantage of this format will be if the sample contains a 
mixture of active and inactive protein, then this method will provide accurate KD value that 
represents the mixture. Overall the concept developed in this study can provide valuable 
information for the development of glycosylated biosimilar products. 
In the fourth chapter, the main goal of the study was to examine the binding kinetics of 
incubated IgG1 Fc glycoforms at the low and elevated temperatures for twelve weeks. First, the 
project was designed to assess differences between Fc-immobilized and receptor-immobilized 
formats in detecting a change in binding affinities of the stressed samples. This study was also 
designed to understand the correlation between the physicochemical stability and functional 
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activity using these glycoforms as a model for biosimilar comparability analysis. Finally, the study 
was designed to understand the behavior of the glycoforms incubated at low and elevated 
temperatures with regard to the change in binding affinities to the Fc receptors.  
In this project, four IgG1 Fc glycoforms were incubated at 4oC, 40oC, and -80oC for two, 
four, and twelve weeks. This study performed at low and elevated temperatures can be used in 
comparability assessments to compare pre-change and post-change. Likewise, the differences in 
functional and physical characteristics, which were not obvious at low-temperature, can be 
differentiated at an elevated temperature. The differences in functional activity between the 
glycoforms could be due to the differences in impurity profiles and glycosylation at Asn297.  
Additionally, the samples were characterized using the Fc-immobilized and receptor-immobilized 
formats to examine any differences between the two assay methods. First, the samples were 
examined using the Fc-immobilized format, and lower binding affinities were observed for the 
glycoforms incubated at the elevated temperature compared to the same samples incubated at 
a lower temperature. A trend of decreasing binding affinities was also noted with increasing 
incubation period. For samples incubated at -80oC, no change in binding affinities was observed 
throughout the incubation period. Furthermore, the decrease in binding affinities was larger at 
40oC compared to 4oC when the measurement was performed using the Fc-immobilized format. 
In addition to the Fc-immobilized format, the samples of HM-Fc, Man5-Fc, and GlcNAc-Fc 
were examined using the receptor-immobilized format to examine the differences between the 
two assay formats. A substantial decrease in binding affinities was observed for the samples 
incubated at the low and elevated temperatures compared to the same samples measured using 
the Fc-immobilized format. In addition, a trend of decreasing binding affinities with incubation 
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time for the samples incubated at low and elevated temperatures was observed. A change in 
binding affinities was observed for samples incubated at -80oC. Overall, the data highlighted 
differences between the two immobilization techniques in detecting a change in binding affinities 
after prolonged incubation at the low and elevated temperatures. These glycoforms proved to 
be useful models for biosimilar comparability analysis. The data indicated the samples incubated 
at the elevated temperature showed a substantial decrease in binding affinities to FcRIIIa 
compared to the same samples incubated at the low temperature. In general, the receptor-
immobilized format was a better method of choice for analysis of stressed samples and in 
detecting a change in potency during incubation for a prolonged time. One advantage of the Fc-
immobilized format was that the sample binding affinity could be determined without measuring 
the concentration of the samples after incubation at low and elevated temperatures. Therefore, 
this method provides ease of measurement from a technical point of view. However, during 
loading the protein G may selectively bind the native protein, leaving the partially unfolded and 
aggregated forms. Consequently, this selectivity leads to a greater binding affinity than expected. 
In other words, this method may provide a good estimation of reduction in potency during 
accelerated stability study. Overall, the sensitivity of this approach for the stressed samples is 
relatively lower compared to the receptor-immobilized format. Nevertheless, both methods 
provide valuable information about the change in potency and are found to be useful in 







5.2 Conclusion and Future Work 
The patents of the top-selling originator biologics are expiring soon, and the next-
generation of biosimilar candidates will be monoclonal antibody therapeutics. These biologics 
are structurally complex and heterogeneous attributed to the Fc glycans. In addition, a biosimilar 
sponsor can never exactly replicate the originator manufacturing processes, and it is well known 
that the process defines the structural and functional aspects of the product. Therefore, the need 
to have sensitive and robust analytical methods to demonstrate the similarity of a biosimilar 
candidate with the originator is urgently needed.           
The methods and concepts developed in this work can be applied to other complex 
glycoforms, such as galactosylated, fucosylated, sialylated, and complex biantennary glycans, to 
explore the differences in binding affinities. In addition, a correlation between the binding assays 
and in-vivo biological activity tests should be established. This correlation will help to evaluate 
the biological significance of the differences in KD values observed between the control 
glycoforms as well as the mixture of glycoforms. Similarly, to examine the significance of the 
difference in binding affinities observed between the samples incubated at low and elevated 
temperatures, a correlation with in-vitro cell-based assays and in-vivo biological activity should 
be established 
Finally, the functional characterization methods, as well as the binding responses 
measurement developed in this work, can be used in comparability and biosimilar assessments 
of glycosylated mAb therapeutics. The application of these methods should be further explored 
by comparing different batches of a mAb therapeutic and correlate the binding assay with a 
295 
 
change in glycosylation profile. Likewise, the application of the methods should be further 
explored by comparing a biosimilar with a reference product, then correlate the binding assay 
results with the glycosylation profile (e.g., fucosylation). In conclusion, the concepts and methods 
developed in this work are useful in biosimilar comparability analysis and process development 
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